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Abstract
Congenital rubella infection is a significant cause of birth defects worldwide. In the 
UK, vaccination programmes, introduced initially in 1970, have been successful in 
preventing congenital rubella cases and interrupting virus circulation. Previous 
studies have shown that women with a non-British background are more likely to be 
susceptible to rubella in pregnancy. London, with a large migrant population and 
suboptimal vaccination uptake is at particular risk of outbreaks.
This thesis presents results of a rubella serosurvey in pregnant women in the North 
Thames area, using 18882 newborn dried blood spot samples to estimate maternally 
derived rubella IgG antibody level as a proxy for maternal levels, and investigate 
maternal age, Strategic Health Authority of residence and country of birth as risk 
factors for rubella seronegative status. Data on maternal country of birth was 
available through linkage to birth registration data, and latent class mixture models 
were used to identify samples which were seronegative for rubella IgG. Results of a 
study to validate two commercial enzyme-linked immunosorbent assays for use on 
dried blood spot sample are also presented.
Overall, 2.7% of pregnant women were estimated to be rubella seronegative (95% 
Cl 2.4% to 3.0%). Non-UK bom women were significantly more likely to be 
seronegative to rubella; for women bom in South Asia, Sub-Saharan Africa and the 
Americas the adjusted odds ratios of rubella seronegative status were 4.96, 4.19 and 
3.42 (95% Cl 3.76 to 6.52, 3.11 to 5.64 and 2.13 to 5.52 respectively). Women aged 
less than 20 years were significantly more likely to be seronegative than women in 
their thirties (adjusted odds ratio 2.53, 95% Cl 1.72 to 3.72). Application of latent
3
class mixture regression models to estimate the independent effect of maternal 
characteristics on rubella antibody level is also demonstrated. These results 
highlight the continued risk to migrant women of rubella infection in pregnancy.
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1. Rubella infection and congenital rubella
1.1 Rubella virus
Rubella infection is caused by the rubella virus, a single-stranded RNA virus of the 
Rubivirus genus in the Togaviridae family. It consists of a lipid envelope, in which 
two viral glycoproteins, El and E2, and a nucleocapsid containing the positive- 
strand RNA molecule and a capsid protein, are contained1^ . Rubella virus is 
transmitted by aerosol and humans are the only known host3. Two German 
physicians first described cases of rubella infection in the mid 18th century, and 
referred to the infection as “rotheln”. Hence the alternative name for rubella is 
German measles3*5. The virus was first isolated in a laboratory setting in 19626. 
There are two genotypes of rubella virus, based on analyses of the viral El gene. 
Genotype I has been detected in samples from Europe, North America and Japan, 
whereas genotype II has been isolated in samples from China and India. No samples 
from Africa have been genotyped. However, the significance of the difference 
between the strains is not clear, since they differ by 7-10% at nucleotide level but 
only 1-3% at the protein level1;2;?.
1.2 Symptoms and diagnosis of post-natal rubella infection
The virus first infects cells in the upper respiratory tract, where it replicates in 
lymphoid tissue and spreads through the lymphatic system, subsequently leading to 
systemic infection involving several organs, including the placenta. The incubation 
period, i.e. the time between infection and the first appearance of symptoms, is
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estimated to be between 14 and 21 days3:4;8 and the infectious period 11 to 12 days. 
The latent period, that is the period between infection and the host becoming 
infectious, is around seven to 14 days3*. Infected persons are therefore infectious 
before the onset of symptoms.
If acquired post-natally, rubella is generally a very mild disease, particularly in 
children. Estimates of the proportion of subclinical cases vary from 10% to 87.5%4. 
Therefore, rubella infections tend to go undiagnosed and hence are underreported. 
The rash is normally the first and only symptom in children, lasting for about three 
to four days9. Complications of infection in children are rare4. The disease tends to 
be more severe in adults, with lymphadenopathy, malaise and low-grade fever 
normally being present before rash onset These symptoms usually subside after one 
to five days. Arthralgia and arthritis, which often appear after the rash disappears, 
are common complications in adults, particularly in post-pubertal women. 
Frequencies o f around 70% have been reported for this group4;5:9. Arthritic 
symptoms rarely last for more than a few days, but have been known to last for up 
to one month4*. These symptoms of rubella infection are also common to other viral 
infections such as measles, parvovirus B19, and human herpes vims type 63. Due to 
the number of differential diagnoses, serological confirmation of infection is always 
required (see section 1.3 below).
Severe complications in postnatal rubella cases are rare. Transient 
thrombocytopenia has been reported in one case out of every 3000 to 35003,4.
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Postinfectious encephalitis has been reported in one out of every 5000 to 10000 
cases, with symptoms, including headaches, dizziness and seizures, persisting 
between one week to one month10. Guillain-Barrd syndrome, myocarditis and optic 
neuritis are other rare complications which have been associated with rubella 
infection4.
13  Diagnosis of post-natally acquired rubella
As mentioned above, rubella is often difficult to diagnose clinically and is most 
reliably diagnosed through serological testing. Accurate diagnosis is of particular 
importance for women who present with, or have had exposure to rash illness in 
pregnancy11 because of the risk to the fetus (see section 1.4 below). The 
recommended method is based on laboratory detection of serum immunoglobulin M 
(IgM) antibody detection using enzyme-linked immunosorbent assays (ELISAs)12. 
However, the accuracy of diagnosis is highly reliant on the timing of the samples in 
relation to the onset of rash. IgM antibody levels increase sharply after the onset of 
symptoms, peak at around 14 to 20 days after symptoms but are undetectable 50-70 
days after onset of symptoms4. The most reliable diagnosis can be achieved through 
serum collected between 3 to 10 days after appearance of rash12. If no IgM is 
detected in the first sample, a further sample should be collected and tested a few 
days later to confirm results. A diagnosis can also be confirmed by testing for 
rubella IgG antibody levels in two samples, one collected shortly after the onset of 
rash and the other during recovery to detect seroconversion, since rubella IgG 
antibody titres are detectable at around one to two weeks after rash onset, peak at
23
around two to three weeks after rash onset and then stabilise at a level which is 
unique for each person. IgG antibody levels following natural infection normally 
persist throughout life4. A chart showing the relative levels of IgG and IgM as a 
function of time after infection is shown in Figure 1.1.
IgG detectable by ELISA
Infection
0nMt ol •YmP*om* Days after onset of symptoms
Source: Adapted from Cooper and Alford4 and Best and Enders12.
Figure 1.1. Relative rubella IgG and IgM levels after onset of rubella symptoms
1.4 C on gen ita l rubella
It was not until the 1940s that an Australian ophthalmologist, Norman MacAllister 
Gregg, First recognised the teratogenic effects of rubella following a rubella 
epidemic in which he observed a large number of children bom with ophthalmic 
defects4. Rubella infection of the placenta, and subsequently of the fetus, occurs 
during maternal viraemia. Fetal rubella infection induces cellular damage and 
disrupts the division of cells4; fetuses and infants affected by congenital rubella
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therefore have a lower number of cells than children not affected3. The virus also 
harms the endothelium of small blood vessels, which disrupts normal 
organogenesis4113, hence the sequelae of congenital rubella are more severe if 
maternal rubella infection occurs during the first trimester. Since fetal immune 
responses improve during the second trimester and cross-placental transfer of 
rubella-specific IgG antibody occurs, the fetus is able to mount a more efficient 
immune response to the virus at a later stage of gestation9.
1.4.1 Symptoms and morbidities of congenital rubella
The consequences of maternal rubella infection vary widely in severity: it may lead 
to miscarriage or stillbirth, or there may be no symptoms at birth with complications 
developing only later in life. A summary of the possible outcomes of maternal 
rubella infection is depicted in Figure 1.2. The most important predictor of outcome 
is timing of infection during pregnancy.
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Normal Intent
infaction
Detects apparent at birth
No placental infaction
Infection of pregnant woman
Detecta appear in later childhood, 
adoteMence or adulthood
Adapted from Cooper and Alford* and Banatvala*.
Figure 1.2. Possible outcomes of maternal and fetal rubella infection.
Congenital rubella may affect any organ in the body, as is illustrated by the range of 
the most common defects associated with congenital rubella, listed in Table 1.1.
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Defect/condition Time when recognised Permanent?
Sensorineural hearing loss Early infancy to later childhood Yes
Cardiovascular defects
Persistent ductus arteriosus Early infancy Yes
Pulmonary artery stenosis Early infancy Yes
Ocular defects
Cataracts (unilateral or bilateral) Early infancy Yes
Retinopathy Early infancy Yes
Intrauterine growth retardation In utero/early infancy No (but could
have long term
consequences)
Hepatosplenomegaly Early infancy No
Bone lesions Early infancy No
Diabetes mdlitus Later life Yes
Brain defects
Microcephaly Early infancy Yes
Encephalitis Early infancy No
Thyroid disorders—I .  1 ..— ------- ^  - . 9  ,  ^  .— — TTT7— 7 T ~ ... Later life YesAdapted from Banatvala9 and Cooper and Alford4
Table 1.1. Commonly observed symptoms of congenital rubella.
By far the most common defect associated with congenital rubella infection is 
sensorineural hearing loss (SNHL), which may be bilateral or unilateral, and either 
present at birth, or develop in later childhood1* 15. SNHL, congenital eye defects and 
congenital heart disease comprise the classic triad of defects leading clinicians to 
suspect congenital rubella infection. However, these are only present in a minority 
of children diagnosed with congenital rubella14. Hospital-based studies tend to 
report a higher proportion of children affected by congenital rubella with combined 
and severe symptoms compared to population-based studies15. In a follow-up study 
of 102 congenitally infected children, 15 (14.7%) had deafness as the only defect, 
whereas five (4.9%) had multiple defects16. In contrast, Dudgeon17 reported that 246 
of 300 children (82%) referred to Great Ormond Street Hospital in London with 
congenital rubella had more than one defect. The term congenital rubella syndrome
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(CRS) is used to refer to range of defects caused by congenital rubella, although the 
majority of affected children only have a single defect7;18.
Longer-term outcomes for children with congenital rubella have been reported for 
two cohorts, one bom in New South Wales, Australia between 1939 and 1944 (this 
was the original cases series of affected children studied by Gregg) and another 
bom in the US in 1964-1965 following a worldwide rubella epidemic19. Health 
outcomes of the former group are well described. Fifteen of the 78 children in the 
Australian original cohort died early in life20, and although the cause of death was 
not reported by Gregg, this has subsequently been attributed to the unavailability of 
surgery to correct heart defects in the 1940s. Therefore only children with less 
severe defects in this cohort were followed up19;21. At the age of 50, 40 individuals 
originally studied by Gregg were investigated. All 40 had hearing impairment, 
which was severe in 36 individuals. Twenty three individuals (58%) were 
employed, and only one lived in an institution. A higher mortality rate from cancer 
(at any site) compared to the rate expected for the population in New South Wales, 
was also detected by the age of 50 (standardised mortality ratio 6.0,95% confidence 
interval 1.2 to 17.6). Cancer incidence (also at any site) among these individuals 
was not significantly different to the expected incidence (standardised incidence 
ratio 2.4, 95% confidence interval 0.6 to 6.0)19. At the age of 60, seven of 32 (22%) 
individuals in the Australian group had developed type 2 diabetes. The expected 
age-specific prevalence in Australia is 13.1%, the authors do not state if this 
difference is statistically significant. In addition, seven of 32 subjects had thyroid
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abnormalities21. It has been suggested that autoimmune processes may play a part in 
these late onset conditions4122.
In contrast to the Australian case series, only one report of the longer-term 
outcomes of the American group of children with congenital rubella bom in the 
1960s has been published, and it lacks detail. They generally experience worse 
outcomes than the Australian cohort, since more children with severe defects 
survived due to developments in surgery to treat congenital heart defects21. By the 
1990s, one third of the American group was reported to be living a “normal” life, 
one third was in institutional care and the final third was living at home holding 
down non-competitive occupations if in employment at all. A high prevalence of 
insulin dependent diabetes was also observed for this cohort, with 15% of cohort 
members living with the condition 23.
1.4.2 Diagnosis of congenital rubella
If congenital rubella is suspected, serum samples should be tested for rubella- 
specific IgM3:12. This method is most reliable during the first three months of life12. 
Early diagnosis is of importance, since newborns with congenital rubella infection 
are highly infectious for several months after birth and therefore may need to be 
isolated to prevent spread of infection3. Rubella-specific IgM antibody is not 
detectable after 18 months of life, making late-onset conditions difficult to attribute 
to congenital rubella infection, particularly if only one symptom is present, for 
example SNHL. In addition, rubella-specific IgM antibody testing in children who
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have been vaccinated or exposed to natural infection is likely to be difficult to 
interpret7112. Restrospective testing of newborn screening blood spot cards may be 
useful in children presenting with SNHL as the only defect. This has been used to 
diagnose congenital cytomegalovirus infection (see for example Barbi et al24), 
although this is not routine practice (see chapter 4).
1.43 Risks of congenital infection
The risk of fetal damage is highest during the first trimester of pregnancy since 
organogenesis occurs during this period, and the fetal immune system has not 
developed sufficiently to resist infection at this stage of pregnancy. By the end of 
the first trimester, organogenesis is completed and fetal immune responses 
improved. Consequently rubella-associated defects are usually not found in children 
infected in utero after the first trimester3;4. Enders et al25 reported no evidence of 
rubella infection (as determined by IgM antibody testing) occurring before the last 
menstrual period (LMP) or up to 11 days following it among 38 pregnancies.
In early studies, the reported risk of congenital defects following maternal rubella 
infection varied between 5 and 50% although these estimates were inaccurate due to 
the inability to serologically diagnose rubella infection. Miller and colleagues 
followed up all women with serologically confirmed rubella infection during 
pregnancy reported to Public Health Laboratories in England and Wales 1976-78 
(when a rubella outbreak occurred)16. Children were also followed until two years 
of age to ascertain the prevalence of rubella associated defects. Table 1.2
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summarises the outcomes by the week of pregnancy during which infection 
occurred.
Week of 
pregnancy*
Number of 
infants tested
% infected Number of 
infected babies 
followed up (%)
% of followed 
babies with 
defects
Overall risk 
of defects
<11 10 90% 9 (90%) 100% 90%
11-12 6 67% 4 (67%) 50% 34%
13-14 18 67% 12 (67%) 17% 11%
15-16 36 47% 14 (39%) 50% 24%
17-18 33 39% 10 (30%) 0% 0%
>18 155 25% (23-26 
weeks) to 
100% (>36 
weeks)
53 (34%) 0% 0%
* Defined as the difference between the LMP and onset of rash.
Adapted from Miller et al16.
Table 1JL Risks of fetal infection and defects following serologically confirmed symptomatic 
maternal rubella infection by week of pregnancy.
In total, 20 children in this study developed rubella-associated defects, all of whom 
were infected before the 17* week of pregnancy. Of these children, 75% had 
deafness as the only manifestation, whereas 25% also had heart defects. All of those 
with heart defects were infected before the 11th week of pregnancy16. The increase 
in the proportion of infants infected after the 26* week of pregnancy has not been 
explained, but this finding was based on small numbers in the study by Miller et 
al16. None of the eleven children bom to women with confirmed asymptomatic 
rubella infection had serological evidence of congenital infection, however maternal 
reinfections (which tend to be subclinical) and asymptomatic primary infections 
could not be differentiated.
While the risk of fetal infection following maternal reinfection is much lower than 
following primary infection, it is not negligible. For example, Morgan-Capner et
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al26 found evidence of fetal infection in 3 of 42 (7%) infants or products of 
conception of women with serologically confirmed or suspected rubella reinfection, 
the majority of whom were asymptomatic. In all of these cases, the women were 
infected during the first trimester in pregnancy. The risk of fetal infection following 
maternal reinfection during the first 12 weeks of pregnancy was estimated to be 
around 30% using virus detection or IgM testing of products of conception or 
infants of women with serologically confirmed reinfections during pregnancy26. 
Although risks to the fetus following symptomatic maternal reinfection may be 
higher, this could not be properly assessed in the study by Morgan-Capner and 
colleagues, as it is rare26. The risk of congenital infection following asymptomatic 
primary maternal infection in pregnancy is higher than for maternal reinfection. In a 
small case series reported by Cradock-Watson and colleagues27, three of six 
children bom to women with primary asymptomatic rubella infection were infected 
in utero; one of these children had thrombocytopenia and osteopathy.
1.4.4 Burden of disease from congenital rubella
Reliable data on the burden of disease attributable to congenital rubella-associated 
defects in developing countries are scarce, due to the lack of surveillance systems, 
access to health care and laboratory services. Most estimates of congenital rubella 
prevalence at birth in developing countries tend to be derived from epidemic 
situations, and prevalence studies have no or short follow-up periods, which is 
likely to lead to an underestimation of the number of affected children14. In the most 
recent study in which the burden of disease from congenital rubella was estimated,
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Cutts and Vynnycky28 used data from 44 serosurveys from several developing 
countries to model the incidence of congenital rubella. The authors estimated that in 
1996, around 110,000 cases of congenital rubella associated defects occurred 
globally (excluding the European region). However, the range of this estimate was 
large, from around 14,000 to 310,000, reflecting the variability in seroprevalence 
estimates from the serosurveys, and the lack of seroprevalence data for the majority 
of developing countries28.
Prior to the introduction of vaccination in the UK, between 200 and 300 children 
per year, in non-epidemic years, were bom with severe birth defects caused by 
congenital rubella29. In epidemic years, this figure could be ten times as high 18. 
However, this figure is likely to be underestimated since the most common defect, 
SNHL, may not develop until later childhood. As SNHL is often the only defect, it 
may not be attributed to rubella. In a study of children at the Nuffield Hearing and 
Speech Centre, Peckham15 estimated that congenital rubella-associated hearing loss 
accounted for around 15% of cases of SNHL in a non-epidemic year. Likewise, 2% 
of cases of congenital heart disease were associated with congenital rubella in a 
non-epidemic year15.
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Key points
•  Rubella is a mild viral infection, particularly common in children. A sizeable 
proportion of cases are asymptomatic. Rubella is highly teratogenic and can 
cause severe and multiple birth defects, including SNHL, congenital heart 
disease and cataracts if a woman is infected during pregnancy.
•  The risk of birth defects is highest if infection occurs during the first trimester of 
pregnancy. The risk of birth defects is minimal after the 18th week of pregnancy.
•  Congenital rubella was a major public health problem prior to the introduction 
of vaccination, with over 200 children bom annually in the UK with severe 
congenital rubella-associated defects. In countries without vaccination 
programmes, congenital rubella is a major disease burden: it is estimated that 
around 100 000 children worldwide are bom each year with congenital rubella 
defects.
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2. The epidemiology of rubella in England and worldwide
2.1 Seasonality, average age at infection and force of infection
Rubella displayed both epidemic and endemic behaviour in developed countries 
prior to the introduction of vaccination30^ 1. Infections follow a seasonal pattern, 
increasing annually in spring and summer, with low-level transmission throughout 
autumn and winter leading to endemicity in mainland populations, although not in 
island populations and remote communities where populations may be too small to 
maintain continuous transmission4;14;28;32. In the UK, data from the Royal College of 
General Practitioners (RCGP) and diagnostic laboratories (the only sources of data 
on reported cases of rubella infection prior to the introduction of vaccination) show 
that minor rubella epidemics occurred every three to five years18. The inter­
epidemic period varied by country31; in the US for example, the inter-epidemic 
period has been reported as six to nine years30.
In non-immunised populations, rubella is predominantly a childhood disease. The 
basic reproduction rate (/?<?), ie. the average number of secondary infections 
produced by one infected individual in a completely susceptible population8:33:34, 
has been estimated as seven to eight for rubella, compared with 15 to 17 for measles 
and pertussis and five to six for polio33. In the UK before the introduction of 
vaccination, 50% of cases occurred in the 5 to 14 year age group, with an average 
age at infection at around 10 to 11 years18:35. This was relatively high compared to
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communities in for example rural Gambia36 and Addis Ababa, Ethiopia37, implying 
a lower force of infection in the UK8. The force of infection, that is the per capita 
rate of acquisition of infection, is determined by factors such as population density 
and crowding, climate, population mixing, and birth rates38. It is the main 
determinant of the proportion of women who have been exposed to the virus and 
developed immunity prior to reaching reproductive age in the absence of 
vaccination programmes, and hence the incidence of congenital rubella in 
unvaccinated populations. The force of infection can be estimated from 
seroprevalence data by age obtained through a serosurvey (or case notification data 
if case notifications are deemed to be reliable and not biased by age8). The relatively 
low force of infection and consequently higher age at infection in the UK left 
approximately 18% of women susceptible to rubella as they entered childbearing 
age groups35;38. This proportion was shown to be similar in serosurveys conducted 
in other mainland industrialised countries in the 1960s39;4°. Cutts et al28 estimated 
the proportion of women with antibodies to rubella by age 13 (assumed to be the 
lowest age at childbearing in the majority of countries), from 44 rubella serosurveys 
carried out in developing countries between the 1960s and 1990s, prior to the 
introduction of vaccination. A selection of these data is presented in Figure 2.1.
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Figure 2.1 Estimated proportion of 13-year old women seropositive to rubella ( with 95% 
confidence intervals) in selected settings.
The World Health Organisation (WHO) suggest that in populations where more 
than 20% of women of reproductive age are susceptible to rubella, the risk of 
congenital rubella should be considered high41. Plotkin13 summarises the different 
patterns of rubella transmission in unvaccinated populations into three main groups:
1) Low force of infection: Low incidence of rubella infection until school age. 
15% to 20% of women are susceptible by the time childbearing age is 
reached. This pattern was typical of Europe and North America prior to the 
introduction of vaccination.
2) Intermittent epidemics: Low prevalence of rubella immunity between 
epidemics. Around 50% of women of are susceptible by the time 
childbearing age is reached. Large rubella outbreaks occur periodically as a
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result of virus re-introduction. This pattern is common in remote areas of 
developing countries and in island nations.
3) High force of infection: High incidence of infection in early childhood and 
low proportions of women are non-immune as they reach childbearing ages. 
This pattern is common in densely populated areas of developing countries.
It follows that the incidence of rubella in pregnant women and subsequently 
congenital rubella is likely to be negligible in countries with a high force of 
infection, since the vast majority of pregnant women are immune, and far higher in 
countries with lower forces of infection, where a significant proportion of adult 
women will be susceptible to rubella8.
The epidemiology of rubella infection has changed radically as a result of the 
introduction of vaccination programmes in many countries since the 1960s, the aims 
of which are to prevent congenital rubella-associated defects in children.
2.2 Rubella vaccines
A worldwide rubella epidemic occurred in 1962 to 1964, resulting in a large number 
of children being bom with rubella associated defects. In the United States alone, 
around 12.5 million rubella cases were reported and 20,000 children were bom with 
defects as a result of maternal rubella infection. The cost of the epidemic was 
estimated at over $220,000 per child affected4131:42. It led to greater understanding of
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the natural history and the development of diagnostic methods, and also spurred on 
the development of a rubella vaccine, following isolation of the virus in 196243.
Initially, focus was on the development of an inactivated virus vaccine. However, 
this was an unsuccessful strategy, since the vaccines developed were not antigenic. 
Inactivated rubella vaccines have only recently been shown to be antigenic in 
mouse models. There was greater success in developing a live attenuated vaccine 
and several vaccine strains, HPV-77, Cendehill and RA 27/3 were developed in the 
late 1960s42. The latter, attenuated in human diploid cells42;44, is the vaccine most 
widely used in Europe and the Americas, including in the UK where it was licensed 
for use and introduced in 197031;45. The licensure of the Cendehill and HPV-77 
vaccines was subsequently withdrawn, due to questionable efficacy and concerns 
about side-effects31:42.
The RA 27/3 is available either as single antigen vaccine, or combined with measles 
(MR), measles and mumps (MMR), or with measles, mumps and varicella antigens 
(MMRV)4;3,:42. Rubella vaccine can be given intranasally or subcutaneously, 
however the RA 27/3 strain has been shown to be more effective in preventing 
reinfection if given subcutaneously46*7. The RA27/3 strain was used in the 
monovalent schoolgirl vaccine in the UK offered until 1996, and is currently offered 
as part of MMR vaccine. The MMR vaccines currently used in the UK are MMR II 
(Merck, Sharpe and Dome) and Priorix (Glaxo Smith Kline)45.
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2.2.1 Rubella vaccine efficacy
The efficacy of the different rubella vaccine strains has been evaluated using 
various study designs. Last48 defines vaccine efficacy as “the percentage reduction 
in cases among vaccinated individuals’*. However, early studies of vaccine efficacy 
conducted in the 1970s used seroconversion as the main outcome and 
haemagglutination-inhibition (HAI) techniques to measure rubella antibody titres in 
vaccinees. Seroconversion following one vaccine dose of the RA 27/3 strain was 
estimated at around 95 to 100% in individuals over 11 months old4:31:42;49. This was 
a higher seroconversion rate than seen with the HPV-77 and the Cendehill 
strains46149. Individuals immunised using the RA27/3 strain have also been shown to 
experience less waning of antibody titres compared to individuals vaccinated with 
the HPV-77 strain49. The various strains o f rubella virus are not different in terms of 
their protein composition and do not produce different serologic reactions. The 
differences in immunogenicity are therefore not thought to be due to the small 
differences between the different virus strains, but are more likely a result of 
alterations in the virus during attenuation in the different cell cultures114.
Rubella vaccine efficacy has also been evaluated in outbreak settings, and by 
challenging vaccinees intranasally or subcutaneously with vaccine. During an 
outbreak in Italy, approximately 10% of girls showed serological, but not clinical, 
evidence of reinfection five years after receiving the RA 27/3 rubella vaccine50;51, 
whereas in an outbreak in a children’s home in Massachusetts, 50% of children 
vaccinated with the Cendehill vaccine around six months previously showed
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serological signs of reinfection, but were asymptomatic52. Greaves et al53 estimated 
rubella vaccine efficacy to be 90% (95% confidence interval 71% to 96%) during an 
outbreak in an American high school in 1980. However, a clinical case definition 
was used, without serological testing, and the type of rubella vaccine was not 
specified.
In experimental challenge studies, Fogel et al47 demonstrated that 7% of adolescent 
volunteers who had received RA27/3 vaccine subcutaneously exhibited evidence of 
reinfection (as defined by an increase of antibody titres) one year after vaccination, 
compared to 68% of the group who had received Cendehill and 47% of those who 
had received HPV-77 vaccine. Similarly, Grillner et al54 found only 10% of women 
experienced reinfection, again evidenced by a significant increase in antibody titres, 
two years after subcutaneous vaccination of RA27/3 vaccine compared to 24% and 
53% of women who had received HPV-77 and Cendehill vaccines respectively. 
However, Chang et al52 points out that experimental challenge studies in 
populations where rubella virus is still circulating may overestimate efficacy and 
vaccine-induced antibody persistence since contact with wild vims will lead to a 
boosting of antibody levels which is not related to the effect of the vaccine.
2.2.2 Duration of vaccine-induced protection against rubella infection
The duration of rubella antibody persistence after vaccination is therefore of 
particular importance in countries where rubella wild vims has stopped circulating 
as a result of the introduction of a vaccination programme. Although there have
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been several studies of rubella antibody persistence in vaccinated subjects, many 
have only short follow-up periods or are based on relatively small sample sizes. For 
example, in an early study, Banatvala et alss followed up 123 female medical 
students vaccinated with one of four rubella virus strains (Cendehill, HPV-77, 
RA27/3 or a strain licensed for use in Japan, To-336). Six to 16 years after 
vaccination, only 6.5% of the women had no detectable antibody using single radial 
haemolysis (SRH), andl5.4% had antibody levels less than 15 International Units 
per ml (IU/ml), indicating low antibody levels requiring revaccination. When the 
subjects were challenged with RA27/3 rubella virus intranasally, even subjects with 
low antibody levels were protected from viraemia. The exact follow-up period was 
not specified. In addition, the results for the experimental study are stratified by 
follow-up period and type of vaccine, leaving only a small number of subjects in 
each group. Several authors have observed that reinfection after experimental 
challenge is more common among vaccinated individuals than in those who have 
experienced natural infection, whichever vaccine strain is used31;49;55;56.
Early studies in countries such as the UK may also be misleading since there was 
significant circulation of rubella vims in the population prior to the introduction of 
the MMR vaccine in 1988 (see section 2.3.1), thus providing natural “boosting” of 
rubella immunity. This effect has been demonstrated by Christenson and Bcjttiger57 
in Sweden, which had a similar vaccination programme to that of the UK in the 
1970s, with rubella vaccination only offered to 12-year old schoolgirls. The authors 
found that women with vaccine induced immunity who had also been exposed to
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wild virus had significantly higher antibody titres than vaccinated women who had 
not been exposed to natural infection 16 years after initial vaccination57. In a 
population-based study in Holland, De Haas and colleagues58 found that antibody 
levels in cohorts which had been offered vaccination were lower than in cohorts 
which had experienced natural infection.
Perhaps the most relevant and comprehensive study is that by Davidkin et al59 in 
which 354 children in Finland were followed for up to 20 years, with serum samples 
taken up to 12 times for each individual. They were given rubella vaccine as MMR 
at age 14 to 18 months, with a second dose at six years, and followed up during a 
period in which rubella virus circulation in Finland was minimal. The authors found 
that overall, 93% of individuals who were seronegative before vaccination had 
antibody levels above 4 IU/ml (defined as the cut-off value indicating rubella 
susceptibility) 15 years after their second dose. However, there was significant 
waning of rubella antibody levels. Among children who had received one dose of 
rubella vaccination at age 14 to 18 months and a second at six years, the geometric 
mean antibody level was 67 IU/ml, 28 IU/ml and 22 IU/ml one, eight and 15 years 
after the second MMR dose respectively. The decline was more rapid during the 
first eight years following the second dose and statistically significant QxO.OOl). 
Antibody decline was less marked between eight and 15 years since vaccination, but 
was still statistically significant (p<0.05).
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The same authors have also investigated the effect of age at which rubella 
vaccination is offered60. Among Finnish children who were first vaccinated with 
MMR at 14 to 18 months and with a second dose at six years, the proportion with 
low rubella antibody levels (defined as <15 IU/ml) was 26% 12 years after the first 
vaccination, and 31% 15 years after the first vaccination. For comparison, among 
children who were given MMR at 6 years and 12 to 13 years, only 9% had low 
rubella antibody levels 15 years after their first dose. Consequently, if  MMR 
vaccine is given in early childhood, antibody titres may decline substantially before 
girls enter reproductive age. The effect of the second vaccine dose was also 
investigated in a subset of these children, but was only found to be transient. 
Waning o f antibody levels was found to be most rapid during the first four to five 
years after vaccination.
It is not clear which is the optimal age at which to provide the second MMR dose. 
Its main aim is to prevent primary vaccine failures which are most common with the 
measles component of the vaccine (see for example Johnson et al61 and Jacobsen et 
al62) as well as to provide a further opportunity for vaccination for children who had 
not received the first dose. Pebody et al63, using serological findings from pre­
school children participating in a vaccine trial for acellular pertussis vaccine in 
England, found that only 4.6% of children were seronegative to rubella at the time 
the second MMR dose is given (at age four to six years), however 23% were 
seronegative to measles and 20% to mumps, thus warranting administration of the 
second dose early to prevent measles and mumps outbreaks in young children.
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Similar proportions of children seronegative to measles before the second MMR 
dose have been found in a Swedish study of children who receive a first dose of 
measles vaccine at age 18 months, but the second dose is given at 12 years64. As in 
the Finnish study referred to above60, Pebody et al found that the second dose only 
has a temporary effect on increasing antibody levels for measles and rubella. In 
children who had received a first dose MMR at the age of 18 months and an MR 
dose at age five as part of the measles-rubella catch-up campaign in 1994 (see 
section 2.3.1), rubella antibody levels had declined to pre-second dose vaccination 
levels three years following the booster. The role of the second dose of rubella 
vaccine in reducing the incidence of rubella infection is therefore not clear, and the 
role of the second dose in preventing waning immunity appears limited65.
Despite fairly limited evidence it appears that rubella antibody will wane in highly 
vaccinated populations without circulation of rubella virus, and this may be of 
concern since rubella immunity needs to last throughout the reproductive ages. It 
has therefore been suggested that further doses of rubella vaccines may need to be 
offered to ensure that this is the case60. However, it has also been argued that IgG 
antibody levels may not always be indicative of protection from infection and 
vaccinated individuals with low antibody levels may not be infected if exposed55164. 
For example, Matter et al66 hypothesise that neutralising antibodies may still protect 
these individuals from infection.
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223  Adverse reactions to rubella vaccine
The most common reactions to rubella vaccine are similar to symptoms of rubella 
infection and include fever, rash, joint pain and lymphadenopathy31:42. Many 
countries, including the UK, have a policy of vaccinating unimmunised susceptible 
women identified through antenatal screening programmes, or in targeted 
vaccination campaigns. The association between rubella vaccine and joint pain and 
arthritis in adult women has therefore been of particular concern, and several studies 
have been published in this area. In a retrospective cohort study in Israel, Slater et 
al67 compared the occurrence of joint symptoms in women who received RA27/3 
rubella vaccine post-partum after testing negative for rubella antibody on antenatal 
screening, to women who did not receive a vaccine as they were found to be 
seropositive at screening. No significant difference in the development of joint 
symptoms within four months of the birth of their baby was found between the 
vaccinated and the control group. However, despite a large sample (around 950 
women) complete case ascertainment was unlikely due to the long period between 
vaccination and the survey (up to six or seven years). Another retrospective cohort 
study by Ray et al68 found an increased risk of carpal tunnel syndrome within six 
weeks of receipt of RA27/3 rubella vaccine in previously seronegative women aged 
over 30 years, as compared to unimmunised seropositive women.
Tingle and colleagues69 report results of a controlled trial, in which susceptible 
women were randomised to receive rubella vaccine or a placebo post-partum, 
following a negative antenatal screening test for rubella antibody. Follow-up
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assessments were carried out regular intervals up to one year. The authors 
concluded that rubella vaccine causes acute arthralgia and arthritis; however the 
occurrence of chronic arthritis or arthralgia was only marginally higher in the 
vaccinated group, although of statistical significance (adjusted odds ratio with 
placebo group as baseline 1.58,95% confidence interval 1.01 to 2.45). The HPV-77 
was found to cause the highest incidence of joint symptoms, followed by RA27/3, 
with Cendehill least likely. However, the occurrence of joint symptoms is 
significantly lower following vaccination than natural infection69. Adverse reactions 
are most common in previously seronegative individuals, and much less likely to 
occur in individuals who have already been exposed to the vims either through 
vaccination or natural infection31142.
In the UK, rubella vaccine has been available only as part of MMR since 200370 and 
it is therefore the MMR vaccine which is offered to women post-partum. As with 
the monovalent rubella vaccine, the most common adverse reactions following 
MMR vaccination are similar to mild manifestations of the three infections, 
including rash, fever and general malaise45. MMR has also been found to cause 
febrile convulsions71 and idiopathic thrombocytopenic purpura72, and the latter has 
been linked with the rubella component of the vaccine.
2.2.4 Contraindications to rubella vaccine
Since rubella vaccines contain live attenuated strains of rubella vims, pregnancy is a 
contraindication for rubella vaccine due to the theoretical risks to the fetus of
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exposure to rubella virus. The introduction of the RA27/3 vaccine caused particular 
concern over possible teratogenic effects as the strain is grown in human tissue 
cultures (see section 2.2 above). Therefore, several surveillance systems, in the 
US73, Germany and Sweden74 and the UK75 were set up to estimate the risk to the 
fetus in pregnant women who were inadvertently vaccinated. In none of these 
studies have children been bom with birth defects that can be attributed to vaccine- 
related rubella virus infection in utero. If the results from surveillance data on 
women who were inadvertently vaccinated within 3 months before or during 
pregnancy from the UK, Germany, Sweden and the US are pooled, the maximum 
theoretical risk of defects of rubella-associated defects in the fetus is 0.5%, based on 
the upper limit o f the binomial 95% confidence interval, and 1.3% if only 
vaccination within the first three months of pregnancy is included. This estimate is 
based on nearly 700 live births to women vaccinated shortly before or during early 
pregnancy74. However, evidence of fetal rubella infection (based on positive rubella 
IgM antibody testing) was found in four of 25 live-born infants in the UK whose 
mothers were previously susceptible and were inadvertently vaccinated more than 
one week after conception76. The UK Department of Health recommend that rubella 
vaccine is not given during pregnancy, and that women avoid pregnancy for one 
month after receipt of rubella vaccine76.
Other contraindications relate to individuals with congenital immunodeficiency 
syndromes, those receiving immunosuppressants, or those who are allergic to any
48
ingredient of the vaccine, such as neomycin. However, children with HIV who are 
not severely immunocompromised may still benefit from the vaccine31:45.
22S  Rubella vaccination strategies
Rubella vaccination programmes were introduced in most developed countries 
during the late 1960s or early 1970s, using one of two main strategies to deliver 
rubella immunisation in order to prevent rubella infections in pregnant women and 
hence cases of congenital rubella. One strategy is to selectively vaccinate adolescent 
girls, to offer protection to those who have not been naturally infected. This strategy 
directly prevents infections among pregnant women and hence cases of congenital 
rubella, yet does not interrupt transmission of the virus, which would continue to 
circulate among men and younger children. The selective vaccination policy was 
implemented in several countries during the early 1970s following the licensure of 
rubella vaccine, including the UK, Sweden and Australia77'79.
The alternative policy involves universally vaccinating all young children, before 
they enter school. In the long term, this policy would serve to decrease the size of 
the susceptible population to a degree that rubella virus circulation ceases, thus 
indirectly protecting pregnant women from infection. This universal programme, 
now the most common strategy, was pioneered in the US where it was introduced in 
1969. After the adoption of rubella vaccination in many countries in the early 
1970s, surveillance data on the number of rubella cases and vaccine uptake, and 
results of rubella serosurveys became available. The effectiveness of these two
strategies in preventing cases of rubella and congenital rubella has subsequently 
been extensively contrasted and investigated using mathematical modelling of the 
static and dynamic effects of vaccination on the force of infection and the basic 
reproduction number8.
In one of the first such studies to be published, Knox77 found that universal 
vaccination of boys and girls at a young age can lead to the largest declines in 
incidence of congenital rubella both in the short and long term, however only if 
vaccine efficacy (which Knox defines as including both uptake and efficacy) is 
greater than 70%. If vaccine efficacy approaches 100% in the long term, rubella will 
be eradicated and incidence of congenital rubella will fall to zero after 
approximately 16 years. If vaccine uptake or efficacy is less than this, the incidence 
of congenital rubella may increase in the short term, since the force of infection 
(referred to as attrition of susceptibles by Knox) decreases as a result of vaccination 
of young children, thus leading to an increase in the age at infection (as discussed in 
section 2.1). This is in contrast to the selective policy, which will serve to decrease 
congenital rubella irrespective of vaccine uptake. On the other hand, at 100% 
vaccine efficacy, this policy will take nearly twice as long (around 30 years) to 
eradicate rubella and reduce the incidence of congenital rubella to zero. Similar 
findings were reported by Hethcote80.
However, both Hethcote and Knox have been criticised by Anderson and May81 for 
their lack of use of empirical data in formulating their models and in validating
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them. Anderson and May81 used data from serosurveys and on vaccination uptake 
from the US and the UK to estimate the epidemiological parameters used in the 
models together with more accurate data on infectious and latent periods. Using 
compartmental models, they investigated the effect of introducing universal or 
selective vaccination policies, as a function of the original age at infection, and 
vaccination uptake. They concluded that if the average age of infection is initially 
less than 12 years, as is the case in countries with high forces of infection such as 
the Gambia36 or Ethiopia37, the introduction of vaccination of all boys and girls 
aged one year would lead to a decrease in the force of infection, and a subsequent 
increase in the age at infection, so that the incidence of congenital rubella could 
increase, if  vaccination uptake and efficacy is not sufficiently high. The vaccination 
uptake required to lower the incidence of congenital rubella depends on the initial 
force of infection. In countries with a high force of infection and an average age at 
infection of 3 years, 96% of the yearly cohort of children would need to be 
vaccinated to prevent an increase in the incidence of congenital rubella.
Anderson and May81 also found that a selective vaccination policy will always lead 
to a decrease in the incidence of congenital rubella, although the relative 
effectiveness of universal and selective policies depends on the level of vaccine 
uptake. The universal policy will lead to a greater reduction in the incidence of 
congenital rubella than the selective policy at high levels of uptake. The authors 
estimated that around 84% of the annual birth cohort need to be vaccinated for the 
universal strategy to be more efficient in preventing congenital rubella in countries
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such as the UK and US, where the average age at infection was around nine to ten 
years prior to the introduction of vaccination. Anderson and May’s estimate of the 
proportion required to be vaccinated is therefore higher than that presented by 
Knox77.
Following the publication of Anderson and May’s study Nokes et al published 
seroprevalence data showing that the force of infection for rubella was highest 
among children and adolescents and lower among young children and adults prior 
to the introduction of vaccination of all young children in England. In a subsequent 
model, Anderson and Grenfell82 used more realistic assumptions including 
heterogeneous mixing (assuming homogeneous mixing tends to overestimate the 
proportion required to be vaccinated83), and an age-dependent force of infection to 
model the effect on herd immunity on universal childhood rubella vaccination. The 
authors found that in a UK setting, the introduction of universal vaccination of 60% 
or more of the annual cohort of two year old children and continued vaccination of 
girls at age 10 to 15 years and susceptible women would lead to a decrease in the 
incidence of congenital rubella. The vaccination of all children would delay 
infections until older ages for which the force of infection is lower. If vaccination 
uptake were to decrease below 60% among young children, large outbreaks could 
result, but if the proportion of young children vaccinated remains above 80 to 84% 
in the long term, rubella would eventually be eliminated from the population.
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Using a dynamic model, Anderson and Grenfell82 also found that the introduction of 
a universal vaccination policy would lead to a lengthening of the inter-epidemic 
period. The authors predicted that an outbreak of rubella would occur around 20 to 
22 years after the introduction of a universal vaccination policy, the effects of which 
would be dampened by the vaccination of adult women found to be susceptible. 
This study contributed to the evidence used to justify the introduction of a universal 
childhood vaccination programme in the UK in 1988. It also demonstrated the 
importance of serosurveys to inform modelling and subsequently vaccination 
policy.
An increased age at infection following the introduction of universal childhood 
vaccination predicted by the models of Knox77, Hethcote80, Anderson and May81 
and Anderson and Grenfell82, has been observed in several countries. For example, 
the introduction of universal childhood vaccination in the US in 1969 led to sharp 
decreases in the number of reported cases of rubella, however the age at infection 
increased from around nine to ten years before the introduction of vaccination to 
around 16 years in 1980. The decline in reported congenital rubella cases was less 
sharp than the fall in the rubella cases due to the shift of virus transmission to older 
age groups81184. Similarly, outbreaks in Costa Rica in 199985 and Brazil in 2000- 
200186 spread to pregnant women and led to children being bom with congenital 
rubella defects. Both these outbreaks are thought to be caused by a decrease in the 
force of infection and a subsequent increase in the average age at infection as a
53
result of vaccination campaigns among children, which were not accompanied by 
sufficient supplementary vaccination of susceptible adults.
2.2.6 Use of rubella vaccine worldwide
Consequently, the World Health Organisation (WHO) does not recommend the use 
of rubella vaccine in resource poor countries where rubella susceptibility among 
women of reproductive age has been documented to be low. However, countries 
where congenital rubella is perceived as a public health problem and sufficient 
resources are available, are recommended to implement a selective strategy to 
prevent infection in pregnant women by vaccinating adolescent girls and/or women 
and possibly adult men. Universal strategies should only be implemented in 
countries where high vaccination uptake among children can be achieved and 
maintained in the long term87.
Some form of rubella vaccination programme is now implemented in 123 countries 
worldwide as of 2006, comprising 27% of the global birth cohort (Figure 2.2). This 
is an increase from 65 countries using rubella vaccines in 199588.
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Countries Using Rubella Vaccine in National 
Immunization Schedule, 2006
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Directly from the World Health Organisation84.
Figure 2.2. Countries with national rubella vaccination programmes.
A large number of countries have only recently implemented rubella vaccination 
programmes. Only 51 countries had some form of national rubella vaccination 
programme before 199089. The use of rubella vaccine in national immunisation 
schedules in 2007 also varied by WHO region, as demonstrated in Table 2.1.
WHO Region Number of countries in 
region
Number implemented rubella 
vaccination (%)
Africa 46 2 (4.3%)
Americas 35 34 (97.1%)
Eastern Mediterranean 21 15 (71.4%)
Europe 53 52 (98.1%)
South-East Asia 11 3 (27.3%)
Western Pacific 27
____ :_____ W "
18 (66.7%)
Adapted from the World Health Organisation90.
Table 2.1. Number of countries which have implemented rubella immunisation by WHO 
region 2007.
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In the European region, all countries apart from Tajikistan have incorporated rubella 
vaccine into their national vaccination programmes. Similarly, in the Americas all 
countries apart from Haiti are using rubella vaccine nationally. However, in the 
African region only two countries (Mauritius and the Seychelles) have implemented 
rubella vaccination90, most likely reflecting available resources as well as lower 
susceptibility among pregnant women due to high forces of infection. Neither India 
nor China has implemented rubella immunisation nationally. The most common 
form of administration of rubella vaccine is as part of MR, MMR, or MMRV 
vaccine offered to young children. As of 2007, only one country, Tunisia, is 
selectively vaccinating adolescent girls only. A table of current rubella vaccination 
schedules and year of introduction by country is available in Appendix A.
Data on uptake are not routinely collected by the WHO91, although routine 
monitoring of vaccine coverage at a country level has been recommended. The 
introduction of a vaccination programme does not necessarily indicate high 
uptake92. In several countries, including Greece and Italy, MMR vaccination 
programmes were implemented without a goal for uptake, leading to suboptimal 
coverage and subsequently outbreaks which spread to pregnant women and resulted 
in births of children with congenital rubella defects93*95. In order to eliminate rubella 
circulation, the WHO recommends that rubella vaccination uptake should exceed 
80%87, particularly if rubella is administered together with measles vaccine.
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In many developing countries, MMR vaccine is offered to children through private 
sector clinics. Vynnycky et al96 have estimated that if private sector vaccination 
reaches less than 60% of the population in countries with medium or high forces of 
infection, an increase in the incidence of congenital rubella cases in the population 
as a whole could be expected approximately 10 years following introduction of 
vaccination. It is therefore important to monitor the availability and uptake of 
private sector MMR vaccination and rubella seroepidemiology in order to prevent 
outbreaks in countries where private vaccination provision is widespread in sections 
of the population.
2*2.7 Rubella elimination efforts
Rubella vaccine is currently not under consideration for promotion by the Global 
Alliance for Vaccines and Immunisation (GAVI)97, and most initiatives for rubella 
eradication have been carried forward at a regional level. Following WHO and 
UNICEF initiatives to control measles first implemented in the 1980s, goals for 
elimination of measles are now implemented in three WHO regions, the Americas, 
Eastern Mediterranean and Europe98. Rubella has also been considered a candidate 
infection for elimination, since rubella vaccine can be incorporated with the measles 
vaccine. MMR vaccines also tend to be cheaper than monovalent rubella vaccines, 
due to greater demand92.
There are several reasons why rubella should be considered a candidate disease for 
elimination. First, it has no animal hosts and the only human reservoir, newborns
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infected with congenital rubella, spread virus transiently. Second, the vaccine is 
highly effective (see section 2.2.1)13. In addition, rubella has a basic reproduction 
number lower than measles, which makes it easier to control through vaccination. 
However, congenital rubella is not common in developing societies with high 
rubella virus circulation, and the possible adverse effects of introducing rubella 
vaccination programmes makes introduction of rubella vaccine and consequently 
global eradication more complex.
Despite these issues, two of the more resourced regions of the WHO, Europe and 
the Americas, have set goals for elimination of rubella. In 1998, The WHO 
European region set a goal to eliminate measles by 2007 and to achieve a congenital 
rubella incidence of less than 1/100 000 births by 2010":1°°. This was a revision of 
an earlier 1984 goal of elimination of congenital rubella by the year 2000. To reach 
this goal, the WHO European region has recommended reducing the proportion of 
women of childbearing age susceptible to rubella to less than 5% nationally101. 
Some countries in Europe have already eliminated rubella including Finland, where 
the last congenital rubella case was reported in 1986102.
In 2003, the Pan American Health Organisation (PAHO) set a goal of eliminating 
rubella and congenital rubella syndrome from the Western Hemisphere by 2010103. 
The PAHO strategy was influenced by a US policy to eliminate rubella. In 1989, the 
US Centre for Disease Control and Prevention (CDC) adopted a goal to eliminate 
indigenous rubella transmission and congenital rubella infection by 2000 through
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high uptake of childhood MMR vaccination. This goal had to be revised in 
2000104;105 since there was still evidence of rubella virus circulation by 2000, with 
the vast majority of cases occurring among migrants from Central or South 
America841105. A new goal for elimination by 2010 was thus set.
In 1997 the South and Central American rubella control initiative was begun, with 
vaccination campaigns targeted at adults, particularly women, and the introduction 
of MMR vaccine for children into national vaccination programmes. PAHO also 
encouraged rubella and congenital rubella surveillance and improved diagnostic 
testing. These efforts led to a reduction of reported rubella cases of over 98% in the 
region between 1998 and 2006106. According to Dayan et al104, hemispheric rubella 
control contributed to the US goal of rubella elimination, since the previously 
observed annual peaks in rubella notifications disappeared after 2000. Less than 25 
cases o f rubella are now reported annually in the US. In March 2005, following an 
expert panel meeting in 2004 where evidence to support elimination was reviewed, 
the CDC announced that rubella has been eliminated from the Unitd States107.
2 3  Rubella control in England
23.1 Rubella vaccination strategies in the UK
A selective rubella vaccination campaign was introduced in the UK in 1970, with 
rubella vaccine offered to schoolgirls aged 11 to 13 years. At the time, a selective 
rubella vaccination strategy was considered more suitable than a universal strategy 
since uptake of measles vaccine was below 60% for 24-month old children during
59
the 1970s108. Rubella vaccine was also offered to adult women found to be 
susceptible following antenatal screening, and health care workers35;109:11°. 
Vaccination uptake among schoolgirls was monitored by the Department of 
Health111, and ranged between 78% and 86% among 11 to 13 year old girls between 
1970 and 1988112. This was below the suggested target o f 95%110. There are no 
routine data on the uptake of post-partum vaccination following a negative antenatal 
screening result for rubella antibody. In one study113 of women seeking antenatal 
screening in seven hospitals in the Manchester area between 1983 and 1984, 85% 
(range 69% to 94%) of seronegative women who delivered were vaccinated in 
hospital. However, in a later study covering eight laboratories across England, the 
variability in post-partum vaccination uptake was far greater, with uptake as low as 
5% in one hospital114.
The introduction of a selective vaccination programme led to a downward trend in 
reported congenital rubella cases110 as is illustrated in Figure 2.9 on page 84. 
However since rubella vims was still circulating among children and adolescent and 
adult men, rubella epidemics still occurred, with an inter-epidemic period of around 
4 years18. The selective vaccination programme did have an effect on reported 
rubella seroprevalence among adult women. Using data from more than 8000 left­
over diagnostic serum samples from the Public Health Laboratory Service (PHLS) 
and collected in 1986 to 1987, Morgan-Capner et al115 found that men aged between 
10 and 30 years were significantly more likely to be seronegative compared to 
women of the same age. For example, 21% of 13 to 16 year old boys were
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seronegative compared to only 3% of girls, while only 4% of 17 to 30 year old 
women tested negative for rubella antibody. 11% of men of the same age tested 
negative. Although the selective vaccination programme was successful in lowering 
seronegativity among women, susceptible women were still at considerable risk of 
infection during pregnancy due to continuing virus circulation. A study in 
Manchester in 1983 to 1984 showed that 57 women who had screened negative for 
rubella antibody were infected during pregnancy. This amounted to 2.2% of the 
total number of pregnant women who screened negative in the period113. These 
cases were serologically confirmed after rubella contact or suspected rubella 
infection.
In order to interrupt virus transmission and eventually eliminate congenital rubella, 
universal vaccination against rubella for all young children aged around 12 to 15 
months (the time at which measles vaccine was initially given) was introduced in 
1988, as part of MMR vaccine. For the first three years of the universal programme, 
MMR vaccine was also offered to preschool children aged four to five years, until 
the first cohort who had received the MMR vaccine at age one to two years had 
entered school ages18. Uptake of MMR vaccine reached 89% among children aged 
24 months by November 1990, only two years into the programme. This was 
significantly higher than the 80% uptake for the single antigen measles vaccine 
reached by 1988108. The introduction of MMR vaccine led to further decreases in 
the number of reported cases o f congenital rubella and terminations due to rubella 
infection or contact after 1988 (see page 84 and page 86 respectively). The number
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of clinical rubella cases notified to the Office of Population Censuses and Surveys 
(OPCS) halved between 1989 and 1990, from 24570 to 11482 cases. The universal 
vaccination campaign was also believed to have averted a predicted rubella 
epidemic in 1990, based on the four year inter-epidemic period observed in the UK 
during the 1970s and 1980s18.
The introduction of MMR vaccine particularly served to reduce virus transmission 
among children. Prior to the introduction o f MMR vaccine, the attack rate among 
susceptible pregnant women (i.e. the proportion of susceptible pregnant women 
infected) was higher among parous than nulliparous women. This was a result of 
high rates o f vims transmission among schoolchildren, who then infected their 
pregnant mothers18:110;113. Following the introduction of MMR vaccine, vims 
transmission among children declined to the extent that nulliparous women were 
more likely to be infected during pregnancy than parous women. This is illustrated 
in Figure 2.3, based on data from Miller et al116 from six public health laboratories 
in England which shows serologically confirmed rubella infections in pregnant 
women by parity and year between 1987 and 1993.
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Adapted from Miller et al116
Figure 2 3  Proportion of susceptible pregnant women w ith serologically confirmed rubella 
infection by parity and year 1987-1993.
The introduction of MMR vaccine resulted in minor increases in the number of 
rubella cases reported in 1993. The main group affected were males aged 10 to 25 
years who were too young to have received MMR vaccine, and who for obvious 
reasons would not have received schoolgirl vaccine. However, women of 
reproductive age were also affected and 25 infections in pregnant women were 
confirmed, although the impact on the number of children bom with congenital 
rubella was much smaller than in earlier epidemics (see page 84) since mixing 
between pregnant women and young men was apparently much less than mixing 
between pregnant women and children prior to introduction of MMR vaccine116:117.
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The rubella outbreak in 1993 justified in part a one-off “catch-up” vaccination 
campaign for measles and rubella in November 1994, aimed at reducing the number 
of susceptible adolescent and adult men able to transmit virus to pregnant 
women116. The main justification for this campaign was related to measles however, 
since a measles epidemic had been predicted to occur in the UK in 1995 due to 
significant proportions of schoolchildren still seronegative to measles118. In 
addition, localised measles outbreaks occurring in Scotland, England and Wales 
during 1993 and 1994 provided further incentives108.
All five to 16 year olds in the UK were offered MR vaccine during November 1994. 
Uptake was estimated at 92%117. The catch-up campaign substantially reduced the 
number of children seronegative to rubella, based on serological surveillance data 
from the PHLS network of public health laboratories. The percentage of five to 10 
year olds who were rubella seronegative declined from 17.5% in 1994 to 3.0% in 
1995, with no difference by sex. However sex differences were seen in 11 to 16 
year olds, related to the schoolgirl rubella vaccination programme. In this age 
group, the proportion of girls seronegative to rubella declined from 6.2% to 1.0% 
and the proportion of seronegative boys fell from 24.5% to 6.9%117. The mumps 
component was not included in the catch-up campaign, since there was a shortage 
of mumps vaccine at the time, and it was deemed unlikely that manufacturers would 
be able to produce a sufficient quantity o f trivalent vaccines109:119. The omission of 
mumps from the catch-up campaign did however perpetuate outbreaks, particularly 
in universities in 2004 to 2005, among young adults bom between 1982 and 1986,
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who had not been exposed to wild virus contact due to reduced virus circulation and 
were too old to have received MMR119;12°.
The catch-up campaign did not have an effect on the number of serologically 
confirmed rubella cases, which increased during late 1995 and peaked in 1996. 
These cases occurred in young men who had not qualified for either the MR or the 
schoolgirl programme (97% of cases were over 17 years). The outbreaks mainly 
occurred in higher education institutions, with some spread to the surrounding 
community. Two reports from boarding schools o f rubella infections affecting boys 
aged 13 to 18 years were also recorded117. This outbreak subsequently spread to 
pregnant women, and an increase in the number of reported cases of congenital 
rubella compared to the preceding years was recorded in 1996.
The single-vaccine programme for schoolgirls was discontinued after the measles- 
rubella catch-up campaign due to the low proportion of young women who were 
seronegative to rubella351117. A second dose MMR vaccine was introduced in 1996 
to be offered to four-year old boys and girls. The primary aim of the second dose 
was to prevent measles primary vaccine failures; however it was also predicted that 
even an uptake of over 90% for the primary dose of MMR would not provide 
sufficient protection to ensure herd immunity in the population for either of the 
three diseases, taking vaccine efficacy into account1171121. The second dose 
therefore provided a further opportunity of vaccination for those who had either 
missed the first dose, or received it but not seroconverted.
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23.2 Current data sources on MMR vaccination uptake
Data on childhood vaccination uptake in England have been collected by local 
Health Authorities and collated annually by the Department of Health since the 
1960s109. In the mid 1980s, data collection on the uptake of vaccination was taken 
over by Child Health Records Departments (CHRD) in each District Health 
Authority (DHA), subsequently each Primary Care Trust (PCT). Vaccination data 
collection was also computerised at this stage. General Practitioners (GPs) submit a 
completed form for each vaccination carried out to the CHRD for their respective
10Q *122*12^ *area * ’ . The denominator for the CHRD data is all children registered with a 
GP in the health administrative area (currently PCT in England). It is therefore the 
registered population, and not the resident population which is included as the 
denominator124. This computerised programme is known as Cover of Vaccination 
Evaluated Rapidly (COVER), and is co-ordinated by the Centre for Infections at the 
Health Protection Agency (HPA), formerly the PHLS. Quarterly data on 
vaccination uptake by PCT is produced through this programme1091122, and an 
annual publication is produced by the Department of Health123.
The COVER programme provides timely data on vaccination uptake, and since GPs 
have a financial incentive to report high immunisation uptake, the data are 
considered to be accurate122. Lyratzopolous and colleagues125 validated CHRD 
vaccination records in Bolton between 1991 and 1995 by cross-checking with GP 
records and parental recall assessed by postal questionnaire. They found that of
66
children who were listed on CHRD records as having received only one dose of 
MMR vaccine, 12% had had two doses according to GP records, and among 
children who were listed on the CHRD records as having received no doses of 
MMR, 28.0% had had one dose and 24.6% had had two doses according to GP 
records. There was generally poor agreement between GP records and parental 
recall, with parents generally overestimating receipt of MMR vaccine. The authors 
conclude that the COVER system may slightly underestimate vaccination uptake, 
however this may lead to relatively large differences in susceptibility inferred from 
vaccination coverage125. However, in an area such as London, with high internal 
and international migration, it is also highly likely that vaccination uptake is 
underestimated, since many migrants may not make contact with a GP for some 
time, and are less likely to be immunised if migrating from a country without a 
national vaccination programme122.
Granerod et al126 validated COVER denominator populations against Office for 
National Statistics (ONS) estimated resident populations from two censuses (1991 
and 2001), in order to evaluate the impact of creation of PCTs from the previous 
DHAs in 2002. They found that COVER data underestimated the resident 
population. The main differences in denominator populations in one and five year 
old children were due to the creation of PCTs in 2002, and in two year old children 
to regional boundary changes in 1998. If the resident children missed by COVER 
were unvaccinated, this would significantly overestimate uptake by around 2.7-
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3.5%. On the other hand, if the children missed by COVER were vaccinated, uptake 
estimates would remain largely unchanged126.
In 2005 to 2006, currently the latest year for which COVER data are available, 
estimates of vaccination uptake have not been submitted by nine London PCTs due 
to issues with the computing system, the Child Health Interim Application. This is 
used by the PCTs to collate the data on immunisation which are then passed on to 
the HPA. These problems have also led to vaccination invitations and reminders to 
parents not being sent. Similar problems have been reported with a new computing 
system, RiO127.
233  MMR uptake in England and in London: temporal and 
geographical trends
As discussed in section 2.2.4, modelling studies have shown that in the UK over 
80% vaccine uptake among two year olds is required in the long term to eradicate 
rubella82:128:129. In England, uptake of first-dose MMR was high at over 90% when 
it was first introduced. In 1995 a research group published a study reporting an 
association between measles vaccine and development of bowel disease130, and in 
1998 the same group published an “early report” of a small number of children with 
regressive developmental disorders and intestinal symptoms131. The latter study was 
widely reported in the media, as it was suggested that progressive developmental 
disorders could be caused by the trivalent MMR vaccine, despite this not being 
suggested by the results of the study132. Several large epidemiological studies have
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repudiated this claim and the results have not been replicated in clinical or 
laboratory studies133.
Following media reports of these studies, national uptake fell from 91% of children 
(by their second birthday) in 1994 to 1995 to below 80% in 2003 to 2004. Uptake of 
first-dose MMR vaccine in England by the year of the child’s second and fifth 
birthday, and uptake of both doses by the fifth birthday are shown in Figure 2.4. In 
2006 to 2007, uptake of the first dose had increased to 85% nationally, although this 
excludes data for nine PCTs in London (for reasons described in the previous 
section 2.3.2). The uptake of both doses by the fifth birthday has remained 
relatively stable at around 75%.
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Adapted from NHS Health and Social Care Information Centre' . Note that data collection on uptake of second dose
MMR was begun in 1999.
Figure 2.4. MMR uptake in England by age and dose 1990-2007.
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Vaccine uptake also varies across areas in England. London has very poor uptake of 
first-dose MMR vaccine compared to the rest of the country. Figure 2.5 shows 
uptake of first dose MMR vaccine by Government Office Region in 2004-2005, the 
latest period for which complete data were available.
■  less than 80%
□  80-84.9%
□  85% and above
Note. 1) North West, 2) North East, 3) Yorkshire & Humber, 4) East Midlands, 5) West Midlands, 6) East of England, 7)
Ixmdon, 8) South East, 9) South West
Adapted from NHS Health and Social Care Information Centre134.
Figure 2.5. First dose MMR uptake by Government Office Region, England 2004-2005.
Vaccination uptake also varies within London. Figure 2.6 shows first dose MMR 
uptake in Greater London by PCT. The vast majority of PCTs in London had a first 
dose MMR uptake below 85% in 2004 to 2005, with the exception of Kingston, 
Harrow and Waltham Forest PCTs. The lowest first dose MMR uptake in London in
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2004 to 2005 were found in Kensington and Chelsea PCT (marked number 4 in the 
Map in Figure 2.6), where only 50% of two-year olds had received a dose of MMR 
vaccine. Lambeth, Lewisham, Southwark and Camden PCTs also had exceptionally 
low MMR vaccination uptake, with 54%, 56%, 60% and 63% respectively of two- 
year old children having received a dose of MMR vaccine.
■  <65%
■  65-74%
■  75-84% 
m >=85%
Note: 1) Iambeth 2) Southwark 3) Lewisham, 4) Kensington & Chelsea, 5) Camden, 6) Harrow. 7) Kingston, 8) Waltham 
Forest
Adapted from NHS Health and Social Care Information Centre134
Figure 2.6. First dose MMR uptake by child’s second birthday by PCT, London 2004-2005.
Uptake of pertussis, and diphtheria, tetanus and polio vaccine (DTP) is also lower in 
London than in other regions123134. In addition, London has lower recorded vaccine 
uptake than other metropolitan cities in other countries, such as New York135 and 
Amsterdam136, although some of these differences may be accounted for by 
different methods of measuring vaccination uptake by country122.
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As in the rest of England, first dose MMR uptake has declined in London since the 
late 1990s, as can be seen in Figure 2.7, showing first dose MMR vaccination 
uptake in London between 1999 and 2007.
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Adapted from NHS Health and Social Care Information Centre13.
Figure 2.7. First dose MMR vaccine uptake by child’s 2nd birthday, London 1999-2007.
In London, vaccination uptake has been below the level required to maintain herd 
immunity for measles, mumps and rubella for many years and the risk of a measles 
outbreak is now deemed high, as measles is the most infectious of the three 
diseases33. In the winter of 2001/2002, a measles outbreak occurred in south 
London, which subsequently spread to other areas of the capital. A total of 129 
measles cases, confirmed by diagnostic testing of oral fluid specimens, were
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reported between December 2001 and May 2002. In this particular outbreak, cases 
occurred disproportionately in affluent areas o f south London137.
This measles outbreak prompted a catch-up campaign in the winter of 2004/2005 
targeted at primary school age children who had not received a dose of MMR 
vaccine. A full report of the uptake of MMR vaccine has not been published, 
although some results are quoted in a London Assembly report127. It is estimated 
that 44,000 children were vaccinated in the campaign, which would lead to 
increases of 2% to 3% percent in the uptake of the first MMR dose, and six to 12% 
for the second dose127. The catch-up campaign failed to prevent another measles 
outbreak, this time in North and East London in the spring and summer of 2007. 
This outbreak was centred primarily in traveller communities in South East London, 
and secondly in Jewish communities in North and East London, but subsequently 
spread to the wider community, including unimmunised children138.
Following substantial media interest in the study by Wakefield et al131, some parents 
opted to have their children vaccinated with single antigen vaccines. Uptake of 
single antigen vaccines is not monitored through the COVER system; however 
Sonnenberg et al139 estimated that a maximum 5.6% and 4.0% of children would 
have received single antigen measles and mumps vaccine respectively, based on the 
number of requests for importation of single antigen vaccines through the 
Medicines and Healthcare products Regulatory Authority. It was not possible to 
evaluate the maximum contribution of single antigen rubella vaccine, since it was
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widely available in the UK until at least 2003, when MMR was recommended for 
post-partum vaccination of rubella susceptible women.
23.4 Socio-demographic factors affecting vaccine uptake
There are no recent studies in which the low immunisation uptake in London is 
specifically explored, however several studies have looked at the association 
between socio-economic, attitudinal and demographic factors influencing 
vaccination uptake in the UK, which are relevant to this issue. A full discussion of 
the factors affecting vaccination uptake is beyond the scope of this thesis; however 
a summary of studies into the effect of socio-economic status and ethnicity on 
vaccine uptake, in particular MMR, is presented here. Since routine data on 
vaccination uptake is presented at PCT level, many of these studies are ecological, 
exploring PCT level uptake in relation to area level measures, such as deprivation 
indices, which may not apply in determining vaccination uptake at an individual 
level.
Socio-economic factors
Association between area level indicators of deprivation and vaccination uptake has 
been investigated by Li and Taylor140. In their study of MMR uptake in the North 
East and North West Thames Regional Health Authorities (RHAs), children living 
in highly deprived inner city wards were less likely to have received MMR vaccine 
than children living in suburban areas or wards with low deprivation. The authors 
suggest that this is a result of high mobility of families in poor inner city areas,
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making them less likely to be traced by GPs for immunisations. As also reported by 
Peckham et al141, Li and Taylor found that children of a higher birth order and those 
living in one parent families were less likely to be immunised. In an ecological 
study examining vaccination uptake in London by DHA, Sharland et al142 also 
reported lone parenthood as a risk factor for low vaccination uptake, although 
higher unemployment rates were associated with higher vaccination uptake. The 
authors speculate that unemployed parents would have more time to attend 
vaccination clinics or GP appointments.
The relationship between vaccination uptake and deprivation, at least at a ward or 
area level, has changed since 1998 after the widespread media reporting of alleged 
links between MMR vaccine and autism (see above). In another ecological study, 
Middleton and Baker137 found that although MMR uptake in deprived health 
authorities in England was lower than in affluent areas throughout the period 1991 
to 2001, the gap in uptake had declined since 1998. This was due to faster declines 
in more affluent areas than in deprived areas. Similarly, Wright and Polack143, 
investigating factors independently associated with MMR vaccine found that 
predictors of uptake had changed since 1998. MMR vaccination uptake by DHA in 
England in 1997 to 1998 was positively and independently associated with lower 
deprivation (as measured by Townsend deprivation score), and a lower proportion 
of households in professional and managerial occupations, whereas in 2003 to 2004, 
higher MMR uptake was independently predicted by lower population densities and 
a higher proportion of the active population with no qualifications. Friedrichs et
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al144 also found, using an immunisation and child health database in Scotland, that 
children in deprived post code sectors received MMR vaccination at older ages, 
whereas in more affluent areas, children were vaccinated at a younger age or not at 
all.
The observed relationship between low vaccine uptake and deprivation could 
therefore partly be due to the effects of living in a poor area, which is likely to have 
worse provision of immunisation services. For example, following the new General 
Medical Services (GMS) contract, which was implemented by the government in 
2004 and allowed GPs to choose which services they provide, including 
immunisations, the highest proportion of GMS services opting out of providing 
immunisations was found in the most deprived fifth of PCTs in England145. Since 
2004,10%  of London GPs have opted out o f providing immunisation services 127.
Individual level studies into the effect of socio-economic indicators and MMR 
uptake are rarer. Pearce et al146 found in a study of over 14500 children enrolled in 
the UK Millennium Cohort Study that non-receipt of MMR vaccine was 
significantly and independently associated with lone parenthood, higher birth order, 
a maternal age below 20 or over 34 years, maternal self- or unemployment and a 
high level of maternal education (A level or above). Receipt of single antigen 
measles, mumps or rubella vaccine on the other hand was associated with higher 
maternal age and education level, maternal unemployment and a higher household 
income. Children of mothers with Pakistani, Bangladeshi, Indian or black ethnic
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background were less likely to have received a single antigen vaccine. For the 
majority (67%) of children who had not received MMR vaccine, the parents or 
carers had made a conscious decision not to vaccinate their child. These findings 
were similar to those reported by Samad et al147 for non-receipt of routine childhood 
immunisation in the first year of life.
Ethnicity
Several groups have also studied vaccination uptake among different ethnic groups,
although few studies have investigated ethnic group as a determinant of MMR 
1uptake. Baker et al considered immunisations during the first two years of life 
among children bom in 1980 in Yorkshire RHA. They found that children from an 
Indian ethnic background had the highest uptake for all recommended vaccines, 
whereas children from a mixed ethnic background had the lowest uptake overall. 
Although this study highlights differences in uptake by ethnic group, it is not clear 
if these differences were statistically significant, and socio-economic factors were 
not controlled for.
Likewise, Olusana et al149 found that children bom between 1988 and 1991 to 
African mothers living in City and Hackney did not have vaccination uptake rates, 
including for MMR, significantly different to children from other ethnic 
backgrounds. However this study did not differentiate between the other ethnic 
groups and also did not control for socio-economic factors.
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Bhopal et al1S0 found that Sikh children had significantly higher uptake of measles 
vaccine than non-Sikh children, whereas Hindu and Muslim children did not have 
measles vaccine uptake rates significantly different from children from non-Asian 
ethnic groups. Uptake of three doses o f pertussis vaccine was shown to be higher 
among Muslim and Sikh groups, leading the authors to conclude that language 
difficulties may “protect” certain ethnic groups from adverse publicity about 
vaccines (a widely publicised report in the 1970s linked the whole-cell pertussis 
vaccine with permanent brain damage, led to significant declines in pertussis 
vaccine uptake)45. However, this study assigned ethnicity (Asian, non-Asian, Sikh 
etc) on the basis o f last name, and did not differentiate between non-Asian ethnic 
groups.
Hawker et al151 found similar results in Birmingham following the adverse MMR 
publicity after 1998. The authors also show that children from a Black Caribbean 
background had consistently lower uptake than children from either the Asian or the 
White ethnic groups. Low vaccination uptake among Black Caribbean children aged 
nine months has also been observed by Samad et al152.
235  Antenatal screening programme for rubella antibodies
In addition to vaccination of young children, rubella control in the UK also includes 
an antenatal screening programme. All pregnant women in the UK are offered 
screening for rubella antibodies during their first antenatal visit153;154. The aim of 
this programme is to protect future pregnancies of susceptible women, by offering
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post-partum rubella vaccination. The Department of Health recommends the use of 
an enzyme-linked immunosorbent assay (ELISA) or single radial haemolysis (SRH) 
test for detection of rubella IgG antibody153.
Data on uptake of antenatal screening for infections (HIV, hepatitis B and syphilis) 
and rubella antibody, as well as the proportion who screen positive are collected on 
a regular basis from maternity units and laboratories by antenatal screening 
coordinators on behalf of the regional epidemiology units o f the HPA. However, 
since only aggregated data on antenatal screening are requested, such as the size of 
the booked antenatal population, uptake of screening, the proportion testing positive 
to each of the conditions or screen negative for rubella antibody, the number of 
rubella antibody negative tests cannot be broken down by maternal characteristics, 
only by maternity unit155;156.
Reports from the antenatal surveillance programme are published by the HPA 
regional epidemiology units. In London, the surveillance system for infectious 
diseases in pregnancy was set up in 2000. The latest published data for the London 
region Antenatal Screening Surveillance programme156 for the period 2000 to 2004, 
demonstrate that around 95% of women take up antenatal screening for rubella 
antibody. This proportion was stable throughout the period156. In 2004, 40 per 1000 
pregnant women in London were found to have low or undetectable antibody 
through the antenatal screening programme, with the prevalence varying between 
30 to 40 per 1000 pregnant women through the period 156. However, Anderson et
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al155 demonstrate that the proportion of women who screen negative varies by
maternity unit. Figure 2.8 is a Figure from their paper showing the proportion of 
pregnant women who screened negative for rubella antibody in 2002. For example, 
0.03% women were found to have low antibody levels at the Royal Free Hospital 
compared to 14.3% of women at Newham Hospital, most likely reflecting 
differences by ethnic group and migration history in their antenatal population (see 
section 2.4.3 below for a discussion of ethnicity as a risk factor for rubella 
susceptibility in pregnancy). The number of women screened in each maternity unit 
was not provided by the authors.
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Figure 2.8. Rubella susceptibility rate in pregnant women by London maternity unit 2002.
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These results should be treated with some caution. First, the assay used to test for 
rubella antibody is likely to vary by laboratory as well as the definition of a screen 
negative test result. Second, the methods used to measure rubella antibody levels 
are not presented in the literature. It is therefore difficult to assess comparability of 
the proportion of women screening negative for rubella antibody across antenatal 
units. Second, although over 90% of maternity units submitted data to the antenatal 
infection surveillance programme, some data items were incomplete. Third, 
denominators are calculated differently depending on whether the data were 
reported by an antenatal unit or a laboratory (i.e. either all antenatal bookings or all 
women screened for rubella antibody respectively), further diminishing 
comparability across maternity units155;156.
There are no routine data on the proportion of women who are offered post-partum 
vaccination, and in turn, how many women are vaccinated. Unpublished data from 
East Anglia showed that of 76 screen negative women for whom data on 
vaccinations were available, only 22 (28.9%) had a record of post-partum rubella 
vaccination157. Data from St George’s hospital in South London showed that 
although 85% of women received post-partum vaccination, the most common 
reason for not receiving vaccine was that antenatal screening results were 
incorrectly recorded in the hospital records. In addition, other opportunities for 
vaccination, such as when women seek abortion, are missed158.
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2.4 Current epidemiology of rubella and congenital rubella in 
England
2.4.1 Surveillance of rubella and congenital rubella cases
Data on rubella or congenital rubella in the UK before 1970, when the schoolgirl 
vaccination programme was introduced, are scarce apart from rubella case 
notifications collated by the RCGP. Rubella became a notifiable disease in the UK 
in 1988. Suspected cases are reported by the clinician to a local government 
representative, who then reports the cases to the ONS (previously OPCS), weekly. 
Since late 1994, the HPA offers confirmatory testing for rubella using oral fluid 
samples. These samples are collected between one and six weeks after the onset of 
symptoms. Prior to this date, regional PHLS and NHS laboratories reported 
serologically confirmed cases to the PHLS109. The number of reported rubella cases 
and the proportion of these tested and subsequently confirmed can be found in 
Table 2.2.
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Year Uncorrected notified 
cases
Number
tested
% tested Number
confirmed
%
confirmed
1995 6196 2847 45.9% 468 16.4%
1996 9253 4217 45.6% 1295 30.7%
1997 3409 2021 59.3% 36 1.8%
1998 3208 2211 68.9% 28 1.3%
1999 1961 1347 68.7% 49 3.6%
2000 1719 1179 68.6% 9 0.8%
2001 1524 1065 69.9% 7 0.7%
2002 1720 1423 82.7% 14 1.0%
2003 1418 1030 72.6% 3 0.3%
2004 1334 1131 84.8% 2 0.2%
2005 1183 847 71.6% 3 0.4%
2006 1234 948 76.8% 3 0.3%
2007* 1100 909 82.6% 9 1.0%
‘Provisional figures.
Data adapted from Health Protection Agency159.
Table 2J2. Number of notified rubella cases, the proportion tested for rubella antibodies, and 
the number and percentage of cases confirmed of those tested.
As mentioned in section 2.3.1 above, there was a small rubella epidemic in 1996, 
mainly in young men who were too old to receive MMR. This can be detected in 
Table 2.2. Since then, the number of suspected cases of rubella reported has 
declined, whereas the proportion of suspected cases that have confirmatory testing 
has increased. The small proportion of tested samples which are subsequently 
confirmed testifies to the low positive predictive value of a clinical diagnosis when 
an infection is rare109.
In 1971, the National Congenital Rubella Surveillance Programme (NCRSP) was 
established, in order to monitor the effect of the schoolgirl vaccination programme 
on lowering the incidence of births affected by congenital rubella29:35. The NCRSP 
covers England, Scotland and Wales. Initially, reporting was passive, using 
laboratory reporting systems, and reports from paediatricians and audiologists.
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Since 1990, cases have been notified by paediatricians to the NCRSP through the 
British Paediatric Surveillance Unit which uses active surveillance160. After initial 
notification, a form is sent to the reporting clinician for further details about the 
case, including date of birth, country of birth of the mother, and likely country 
where the mother was infected. The NCRSP has been shown to be sensitive enough 
to detect smaller outbreaks, such as the 1996 outbreak, as well as a congenital 
rubella case epidemiologically linked to an outbreak in Greece161. Figure 2.9 shows 
the number of cases of congenital rubella reported to the national programme 
between 1971 and 2005.
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Figure 2.9. Number of congenital rubella cases reported to NCRSP 1971-2007.
Since the introduction of schoolgirl vaccine, the general trend in reports is 
downward, however, the three to five year epidemic cycle is still evident until the
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late 1980s, when MMR vaccine was introduced and rubella circulation was 
interrupted in the British population18. The 1996 outbreak, resulting in a small 
increase in reported congenital rubella cases, is also evident in the data.
Fifty five cases of congenital rubella have been reported to the surveillance 
programme between 1990 and 2007 (NCRSP unpublished data). The majority of 
children reported to the programme since the introduction of MMR vaccine have 
severe and multiple rubella associated defects1435. This is most likely a result of 
clinicians only considering congenital rubella as a cause for defects when more than 
one symptom is present; if the only symptom is SNHL, congenital rubella is less 
likely to be considered the potential cause. It is therefore likely that reports to the 
NCRSP underestimate the true incidence of congenital rubella, particularly since 
some children may be asymptomatic at birth and develop deafness in later 
childhood (see section 1.4.1)14;162.
Reports to the NCRSP are also supplemented by the number of terminations of 
pregnancy (TOP) following rubella infection, contact or vaccination, which is 
monitored in England and Wales by the ONS35;163. The number of terminations 
where rubella infection, vaccination or contact was stated as the main reason for 
termination by year is shown in Figure 2.10.
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Figure 2.10. Number of rubella-associated terminations, England and Wales 1971 - 2001.
Similar to the pattern of reported congenital rubella cases, the number of 
terminations due to rubella infection or contact demonstrates a generally downward 
trend, however before the late 1980s, a pattern of recurring epidemics is obvious. 
The ONS stopped publishing these statistics in 2001, as the number of rubella 
associated terminations is so low14.
2.4.2 SurveUlance of rubella susceptibility in the population
Although confirmed rubella diagnoses and surveillance of congenital rubella 
provide an indication of the level of virus circulation in the population, the WHO 
recommend that these surveillance systems are supplemented by regular 
serosurveys of the population in order to monitor the proportion who are 
seronegative to rubella, overall and by age164. The HPA uses residual samples from
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confirmatory testing for other infections to test for antibodies to rubella, in order to 
monitor rubella seronegative status in the population by age, sex and area, and to 
evaluate the effect o f vaccination campaigns on herd immunity in the 
population10*11*11* 117.
Results from the latest such serosurvey were reported by Vyse et al165. The samples 
used were collected in 2000, and the authors show that among females, the 
proportion seronegative to rubella was highest among one to four, five to nine and 
15 to 19 year olds, with approximately 8%, 7% and 5% seronegative respectively. 
The highest proportions of seronegative males could be found in the age groups one 
to four, and 30 to 34 years, among whom around 25% and 15% were seronegative 
respectively. Exact point estimates of the proportion of individuals seronegative to 
rubella were not given in this study.
2.43 Congenital rubella in children of migrant women
Although cases of congenital rubella are now rare in the UK (see Figure 2.9), 
children bom to women who have migrated to the UK are overrepresented among 
cases of congenital rubella. Between 1990 and 2007, 55 congenital rubella cases 
were reported to the NCRSP. Twenty-one of these children were bom to UK-bom 
women who acquired the infection in the UK, 18 had mothers who were non-UK 
bom but infected in the UK, and the remaining 16 had mothers who had acquired 
infections abroad (NCRSP unpublished data). Between 1991 and 1996, 26% of non- 
UK bom mothers had acquired their infection abroad before moving to the UK.
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These imported infections were acquired in Asia, or in Europe166 (and NCRSP 
unpublished data). There were no cases reported in 1997 or 1998. Between 1999 
and 2007,13 cases were reported to the programme; 11 of the affected children had 
mothers who were bom abroad, exclusively in South Asia and sub-Saharan Africa. 
Three of the non-UK bom women had acquired their infection in the UK whereas 
all the UK-bom mothers had acquired their infections in the UK (NCRSP 
unpublished data). One of these cases was reported from Scotland, but linked to a 
major rubella outbreak in Greece, which peaked in early 1999. This outbreak led to 
subsequent outbreaks in at least four UK universities that all involved Greek 
students. As a result, one baby, bom to a UK-bom woman who had received 
schoolgirl vaccination and had protective antibody levels in pregnancy three years 
earlier, was bom with rubella associated defects. Maternal reinfection with rubella 
was later confirmed161. These findings have highlighted rubella as a significant risk 
in migrant populations and in returning travellers162:167;168.
Women bom outside the UK and women from minority ethnic groups living in the 
UK have been found to be at higher risk of being susceptible to rubella than white 
or British-born women. In a study of 1964 women screened for rubella antibody at 
Charing Cross Hospital in London, carried out before the introduction of MMR 
vaccination, Peckham et al169 observed that 25.8% of Chinese and 16.5% of Indian 
and Pakistani women screened negative compared to 9% of White women. These 
differences were statistically significant. Likewise, in a study by Miller et al170, 
using antenatal screening data from Leeds, Luton and Manchester, women from
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south Asia were found to be more likely than non-Asian women to screen negative 
for rubella antibody, however more detailed ethnic groups were not specified. 
Nulliparous women were also found to be at increased risk. Following these studies, 
awareness and immunisation campaigns were launched to promote immunisation in 
south Asian communities throughout Britain. However, when Miller and colleagues 
updated their 1987 study three years later, women of a south Asian ethnic 
background remained at increased risk of screening negative to rubella antibody in 
pregnancy. In addition, south Asian women were also more likely to be diagnosed 
with rubella in pregnancy171.
The most recent study investigating the increased risk of rubella susceptibility of 
women of a non-White ethnic group was carried out using data from the St Mary’s 
Maternity Information System covering antenatal screening data from North West 
London over four years, 1996 to 1999172. Women from South Asia and Africa were 
far more likely to be susceptible than British women (Figure 2.11). Nulliparous 
women were also found to be more likely to be susceptible than parous women, 
since parous women are more likely to have received post-partum vaccination if  
they screen negative to rubella antibody during their first pregnancy. However, it is 
not known how ethnic background was established. In addition, estimates of rubella 
susceptibility were obtained from antenatal screening and it is not clear which 
laboratory methods were used to determine antibody levels or the assay cut-off 
value used to determine susceptibility.
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Figure 2.11. Rubella susceptibility in pregnancy by ethnic group and parity.
Clearly, women from a non-British background are more likely to be susceptible to 
rubella in pregnancy if they are bom in a country without a vaccination programme 
leaving them unexposed to rubella as they enter reproductive age. Devi et al158 
found that many immigrant women who are susceptible have had previous contacts 
with health services in the UK, including obstetric and gynaecology services, but 
were not offered rubella antibody testing prior to becoming pregnant. Language 
difficulties may also complicate communication with some immigrant women over 
the risks of rubella in pregnancy.
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Key points
•  In unvaccinated populations the main determinant of the proportion of women 
of reproductive age susceptible to rubella, and hence the incidence of congenital 
rubella, is the force of infection. This is in turn determined by birth rates, 
environmental and social factors.
•  The epidemiology of rubella has changed since the development of a vaccine in 
the late 1960s. In the UK, rubella vaccine was introduced for schoolgirls in 
1970. In 1988, measles-mumps-rubella (MMR) vaccine was introduced. This 
was offered to all preschool children, in an effort to eradicate the three diseases. 
A second MMR dose was introduced in 1996. As a result of successful 
immunisation, cases of congenital rubella are now rare in the UK, with only 13 
reported cases since 1999.
•  MMR uptake varies between English regions. London has the lowest MMR 
uptake in England, and the proportion of children receiving MMR vaccine has 
remained below the level required to maintain herd immunity to rubella for 
many years.
•  The majority of children with congenital rubella reported since the early 1990s 
have mothers who were bom outside the UK. Non-UK bom women are also 
more likely to be susceptible to rubella than women bom in the UK.
•  All pregnant women in the UK are offered screening for rubella antibody, and 
women who screen negative should be offered post-partum vaccination. Since 
data from the antenatal screening programme is not disaggregated by maternal
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characteristics, such as age and ethnic group, risk factors for maternal rubella 
susceptibility cannot currently be monitored in this way.
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3. Demographic context: patterns of international 
migration to the UK and London
As outlined in chapter 2, rubella susceptibility is more common among women bom 
outside than in the UK, and as a result the majority of children bom with congenital 
rubella since the introduction of MMR vaccine in 1988 have mothers who were 
bom abroad. Demographic change through international migration to the UK could 
therefore have an impact on the epidemiology of rubella in the UK, in particular 
susceptibility among pregnant women. This chapter outlines major trends and 
patterns of international migration to the UK since the 1990s relevant to the 
prevalence of susceptibility to rubella.
3.1 UK data sources on international migration
International migration is normally measured in terms of flows, i.e. the number of 
people crossing a national border, and stocks, which is the number of resident 
migrants. The UK, unlike many other European countries, does not have a 
centralised population register which can be used to estimate both stocks and flows 
of international and internal migrants. Instead, estimates of international migration 
to and from the UK rely on data sources which were primarily developed for other 
purposes, including control of immigration and measurement of unemployment173.
Rows of international migrants are measured primarily by the International 
Passenger Survey (IPS), and Home Office Control of Immigration Statistics. The
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IPS is a voluntary survey which is carried out at principal air and seaports in the 
UK. It is the only source of data on international migration flows which takes 
account of both immigrants and emigrants, and is used to estimate total international 
migration and the number of migrants by country of origin/destination, age, sex, 
occupational status and citizenship173.
The IPS does not only measure migration; the majority of respondents are travellers 
who only intend to stay in the UK for a limited time. A migrant to the UK is defined 
as a person who states that he/she has resided abroad for more than a year and 
intends to stay in the UK for more than 12 months. The sub-sample of migrants in 
the IPS is relatively small. In 2006 for example, total international migration 
estimates and estimates of migrants by country of origin/destination, age etc, was 
based on a sample of 3794 individuals. The total response rate for the 2006 EPS was 
89%174. The small sample on which all estimates of international migration are 
based therefore generates large standard errors, and in particular the estimated 
number of migrants by region of origin or destination should be interpreted with
173caution .
Since the IPS records only people’s intentions, figures are adjusted before 
publication to take account of the number of people intending to stay for a year or 
more, but who stay for a shorter period, and the number of asylum seekers who 
often stay for longer than a year even if an initial claim is rejected175.
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Data on the number of people entering the United Kingdom and who are subject to 
border control are collated and published by the Home Office176, including work 
permit holders and dependants, refugees, asylum seekers and dependants and 
individuals with student visas. These data therefore exclude British citizens and 
European Union (EU) citizens; however they are often used to provide a picture of 
more long-term migration to the UK. The data available are highly dependent on the 
current legal framework for accepting and deporting migrants173.
The size of the international migrant stock in the UK is primarily estimated using 
the decennial Census, through which data on place of birth are collected. However, 
nationality, year of entry into the UK for non-UK nationals, and country of previous 
residence are not available from either the 1991 or 2001 censuses. The most recent 
migrants can be identified since place of residence one year ago is collected. Since 
the census is conducted only every ten years, the Labour Force Survey (LFS), a 
quarterly survey of around 60000 households across England, Scotland and 
Wales177, has also been used to estimate stocks of international migrants and in 
particular their economic activity. However, it is not possible to measure emigration 
using the LFS, and the size of the sample o f migrants is limited.
3.2 Pattern of international migration to the United Kingdom
The following two sections provide a summary of migration to the UK since the late 
1990s using data from the IPS (section 3.2.1), and data on the geographic settlement
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patterns of the migrant population in England and in London, using data from the 
2001 Census (section 3.2.2).
3.2.1 International m igration flow s to the UK
Data from the IPS shows that both immigration and emigration to and from the UK 
has increased since the mid-1990s, however immigration has increased at a faster 
rate. As Figure 3.1 shows, the UK experienced net migration of 185,000 people in 
2005174.
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Figure 3.1. Total international migration to the UK 1996-2005.
Figure 3.2 displays the number of immigrants to the UK by citizenship between 
1996 and 2005. The largest increase in migrant flows has been in the group “other
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non-UK” nationals, which includes nationals of the eight EU accession countries 
until 2004, thus perpetuating a decrease in this group in 2004 and 2005.
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Adapted from Office for National Statistics174.
Figure 3.2. Estimated number of migrants to the UK by country of birth, 1996-2006.
Nearly half of international migrants to England settle in London and the South 
East, as demonstrated in Figure 3.3 below, showing the proportion of migrants by 
region of destination within England.
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Figure 33. Distribution of international migrants to England by Government Office Region of 
destination 2006
The proportion of international migrants settling in London has varied between 
1996 and 2005 between 50.8% and 37.5%, although the differences by year may not 
be statistically significant. These data provide a general trend but exact figures 
should be interpreted with caution as discussed in section 3.1.
3.2.2 Stock o f international m igrants in England and London: 2001 
Census data
Data from the 2001 Census provide the most reliable picture of settlement pattern of 
migrants to the UK by region. However, the UK has a long history of international 
migration, and it is not possible to obtain date of entry to the UK for international 
migrants from the Census. Of all the regions in England, London has the highest 
proportion of its population bom abroad, as shown in Figure 3.4. Although this 
pattern of settlement of the non-UK bom population is mainly an effect of historical
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migration, this confirms the general trend demonstrated in Figure 3.3. In England 
and Wales, the proportion bom abroad was 8.9% in 2001.
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Figure 3.4. Percentage of people born abroad by Governement Office Region, 2001
The proportion of the population bom abroad is also highly variable within London. 
As shown in Figure 3.5, the boroughs with the highest proportions of non-UK bom 
individuals are in North West and Central London. Brent (marked 2 on the map in 
Figure 3.5) has the highest proportion of non-UK bom residents; nearly half the 
population (46.5%) at the time of the 2001 Census were bom abroad. In Kensington 
and Chelsea (marked 1) and Westminster (marked 3), 44.5% and 44.1% 
respectively of residents were bom abroad. Havering, Bexley, and Bromley, all 
boroughs in east or south east London, have the lowest proportions of residents bom 
abroad, with 5.6%, 8.1% and 10.0% respectively178.
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Note: 1) Kensington and Chelsea, 2) Brent, 3) Westminster, 4) Bexley, 5) Havering 6) Bromley 
Adapted from Office for National Statistics17*179
Figure 3.5. Percentage of people born outside UK by London Borough, 2001
The pattern shown in Figure 3.5 also varies according to the region of birth of the 
non-UK bom population. Figures 3.6 to 3.8 show the proportion of the population 
bom in Europe, Sub-Saharan Africa and South Asia by borough in 2001.
Note: 1) Kensington and Chelsea, 2) Westminster, 3) Haringey, 4) Havering, 5) Bexley 6) Barking and Dagenham 
Adapted from Office for National Statisics17*179
Figure 3.6. Percentage of people born in Europe by London Borough, 2001
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Note: 1) Brent, 2) Southwark, 3) Harrow, 4) Havering 5) Bromley 6) Bexley 
Adapted from Office for National Statisics178-179
Figure 3.7. Percentage of people born in Sub-Saharan Africa by London Borough, 2001
□ <5%
■ 5-9.9%
■ >=10%
□ <5%
□ 5-9.9%
■ 10-14.9%
■ >=15%
Note: 1) Tower Hamlets, 2) Newham, 3) Brent, 4) Havering, 5) Bromley 6) Bexley
,17*;179Adapted from Office for National Statisics'
Figure 3.8. Percentage of people born in South Asia by London Borough, 2001
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The population bom in Europe is relatively spread out across London, particularly 
across west London, and concentrated in Central London. Kensington and Chelsea, 
Westminster and Haringey have the largest proportions of European bom residents, 
with 16.8%, 14.9% and 12.6% of its population bom in Europe respectively. 
Havering, Bexley and Barking and Dagenham had the lowest proportions of its 
population bom in Europe with 2.3%, 2.4% and 3.2% respectively.
Brent, Harrow and Southwark had the highest proportion of their residents bom in 
Sub-Saharan Africa, with 11.2%, 11.1% and 10.9% bom in Sub-Saharan Africa 
respectively. Again, the boroughs of Havering, Bromley and Bexley had the lowest 
proportions of residents bom in Sub-Saharan Africa, with 0.9%, 1.8% and 2.0% 
respectively.
The two London boroughs with the highest proportion of residents bom in South 
Asia are located in East London: in Tower Hamlets and Newham 19.3% and 15.7% 
respectively of the population are bom in South Asia. Havering, Bexley and 
Bromley in South East London have the lowest proportions, with only 0.8%, 1.6% 
and 1.4% of the population bom in South Asia respectively.
The UK has experienced substantial net migration since the mid 1990s, and 
although the overall proportion of migrants in England and Wales was low in 2001, 
London, and in particular certain London Boroughs have sizeable proportions of 
residents bom in countries where vaccination programmes against rubella are not in
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place. Since London is an area with low MMR uptake, migration from countries 
without rubella vaccination programmes may place these migrants at heightened 
risk if an outbreak occurs.
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Key findings
•  Since the mid-1990s, net international migration to the UK has increased. A 
sizeable proportion of migrants were bom in countries without rubella 
vaccination programmes.
•  The main destination for migrants arriving in the UK is London. One fifth of 
London’s population were bom abroad in the 2001 Census, compared to less 
than 10% of the population of England and Wales as a whole.
•  Boroughs in inner London have a higher proportion of residents bom outside the 
UK than boroughs in outer London.
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4. Serosurveys
4.1 Brief description of antibodies and immunological memory
The rationale of serological surveys, or serosurveys, is to estimate current 
prevalence of or past exposure to, infections by measuring immunological markers, 
most often antibodies, in bodily fluids180. The mechanism of antibody production is 
highly complex, and only a basic description will be presented here. The 
mammalian immune system is commonly divided into the innate and the adaptive 
immune system. The former constitutes the “first line of defence” against 
pathogens, with the skin, mucosal membranes and cellular detection and destruction 
pathogens as major components, whereas the latter is activated if a pathogen 
penetrates the defences offered by the innate system181.
The adaptive immune system consists o f cells known as lymphocytes. These can in 
turn be subdivided into T-cell and B-cell lymphocytes, which are activated through 
contact with specific pathogens. When activated, B-cell lymphocytes differentiate 
into plasma cells which produce antibodies, or immunoglobulins (Ig)181. Antibodies 
are found in blood and tissues and forms the humoral immune system, whereas T- 
lymphocytes form the cell-mediated immune system181;182. The biological markers 
of the cellular immune system are generally more difficult to detect using laboratory 
assays, whereas antibodies can be readily detected using a variety of assays and 
therefore have widespread use for diagnostic and seroepidemiological purposes180.
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The main functions of antibodies are to react with pathogens, or antigens, by 
preventing them from attaching to receptors on epithelial cells (known as 
neutralisation), aiding the uptake and destruction of pathogens by phagocytes 
through coating (opsonisation), and stimulating further immune responses by the 
activation of complement cascades182. The adaptive immune response is slower to 
react at a first exposure to a given pathogen, however once antibodies for a 
particular infection have been developed, the response to, and clearance of 
subsequent invasion of an antigen is much more rapid so that it can be eradicated 
from the body before generalised infection occurs182. In some cases, including for 
rubella, immunity can be retained throughout life181.
Antibodies are divided into five classes, IgG, IgM, IgE, IgD, and IgA, which have 
different functions. IgG class antibodies account for around 75% of the total 
antibody count. Specific IgG antibodies are produced in response to each invading 
pathogen. IgG antibodies circulate in the blood stream and concentrations increase 
more slowly during the course o f acute infection, but infection-specific IgG remains 
in tissues and blood for months or years. IgG antibodies in turn have four 
subclasses, IgGl to IgG4; the function of IgG2 and IgG4 is neutralisation, whereas 
IgGl and IgG3 are multifunctional, and are involved in opsonisation, neutralisation 
and complement activation1811182.
Serosurveys exploit the body’s production of specific antibodies, in particular IgG 
antibodies in response to invasion by an infectious agent, which can be detected in
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the blood stream for months or even years following infection180. Low or 
undetectable IgG antibody levels tend to signify susceptibility or lower levels of 
immunity to a particular infection, however a particular level of antibody providing 
protection against infection may be difficult to specify (as discussed in section 4.5 
below).
4.2. Laboratory methods for rubella IgG antibody detection
IgG antibodies, including those against rubella infection, can be measured by a 
variety of antibody detection techniques. Originally, the neutralisation technique 
was used to measure rubella antibodies, but it is slow and highly labour intensive, 
although still used for verifying immunity if IgG antibody levels are low12. The 
haemagglutination inhibition (HI) technique was previously widely used to detect 
rubella IgG antibodies; however it is labour intensive and only gives results 
expressed as titres. The HI technique, as well as other qualitative techniques 
including latex agglutination and single radial haemolysis (SRH) have now largely 
been superceded by quantitative methods, of which the most commonly used is the 
enzyme linked immunosorbent assay (ELISA), which is less time and labour 
intensive4112.
ELISAs provide a quantitative result, where low or undetectable rubella antibody 
levels often indicate no previous exposure to the disease4112. ELISA technology 
relies on the binding of antibody in a patient serum sample to the walls of a well in 
a test plate coated with a specific antigen. After serum samples have been placed in
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the coated wells and incubated, all wells in the test plate are washed, and anti­
human antibodies labelled with enzymes are added to the wells, which bind to the 
human antibodies. Following further incubation and wash steps, a substrate which 
reacts with the enzymes are added, and the wells are read in a spectrophotometer; 
the depth of colour reflecting the amount of antibody in the sample180:183:184. The 
results of an ELISA are often reported as an optical density (OD) reading, which 
can be adjusted for inter-plate, and possibly inter-batch variation. These adjusted 
plate readings can then be calibrated into standardised results. The international 
standard measurement of rubella IgG antibody level is international units per 
millilitre (RJ/ml)l85.
4.3 Examples of rubella serosurveys
Several rubella serosurveys were carried out in England during the 1970s and early 
1980s to monitor the effect of introducing selective vaccination of schoolgirls on 
virus dynamics and herd immunity. Serosurveys were carried out in Manchester in 
197781 and in South East England in the period 1980 to 8438. In addition, a 
longitudinal serosurvey covering the period between 1969 and 1985 was carried out 
in South Yorkshire186. Since 1986, the HPA conduct regular serosurveys based on 
residual diagnostic serum samples sent in for biochemistry or microbiology testing 
to regional HPA laboratories109^ 10:116;117;165 (see section 2.4.2).
Rubella immunity in pregnant women is of particular interest as it is the main 
determinant of the risk of congenital rubella in a population (see chapter 2).
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Consequently many serosurveys, particularly in developing countries, have focused 
on this population subgroup. The methodology, antibody detection methods and 
definition of rubella immunity vary greatly between studies. Table 4.1 summarises 
the setting, assay methodology, definition of immunity, and data collected on 
possible risk factors, in 37 published reports of rubella serosurveys in pregnant 
women, indexed on Medline+ or EMBASE between January 1990 and January 
2008. The studies are listed by WHO region. Only studies where rubella immunity 
was investigated where included, whereas studies solely examining serological 
diagnosis of acute rubella infection during pregnancy were not.
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Africa
Authors Setting Population and 
sample size
Laboratory
method
Definition of 
seronegative 
population
Overall prevalence 
of seronegativity 
(with 95% Cl if 
presented)
Risk factors for 
which data was 
collected
Rodier et al18/ Cotonou, Benin, 
1993
211 pregnant 
women seeking 
antenatal care
HI (bioM&ieux, 
France)
Manufacturer’s 
recommended cut­
off value (not 
stated)
14.2% Age, parity
Kebede et al188 Addis Abeba, 
Ehtiopia, 1994-1995
846 newly delivered 
women and 1622 
newborns presenting 
at a children’s 
hospital
Single radial 
haemolysis (SRH), 
seronegative 
samples retested 
with ELISA (Dade 
Behring, Milton 
Keynes, UK)
<8.6 IU/ml 5.3% Not stated
Tolfvestam et al189 Massawa, Eritrea 
1995
112 women 
attending free 
antenatal clinic
In-house ELISAs Not stated 7% Not stated
Lawn et aliyo Ashanti Region, 
Ghana, 1997
305 urban women 
attending antenatal 
clinic, and 100 
pregnant women in 
rural areas identified 
through health 
workers
SRH, manufacturer 
not stated. 
Seronegative 
samples retested 
with latex 
agglutination test 
(Abbott 
Laboratories, 
Maidenhead, UK)
<15 IU/ml 7.4% Age, parity, tribe, 
occupation, 
education, 
childhood and 
current residence
Bukbuk et a T 1 Maiduguri, Nigeria 207 women 
attending antenatal 
clinic
ELISA (Flow 
Laboratories, Herts, 
England)
Absorbance at 540 
nm > value of cut­
off control sera
45.9% Age, pregnancy 
outcome, number of 
previous 
pregnancies
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Corcoran and 
Hardie192
Western Cape, 
South Africa, 2001
1200 women tested 
for HIV and syphilis 
infection
ELISA (Dade 
Behring, Germany)
Optical density <0.2 3.5% District of 
residence, age
Barreto et al193 Maputo,
Mozambique, 2002
990 women seeking 
antenatal care at one 
of nine health 
clinics in urban or 
rural areas
ELISA (BIO-RAD, 
Mames la Coquette, 
France)
<10 IU/ml 4.6% Area of residence, 
maternal age, parity, 
abortion history, 
number of still 
births, years of 
schooling. Living in 
hut or not
Americas
Authors Setting Population and 
sample size
Laboratory
method
Definition of 
seronegative 
population
Overall prevalence 
of seronegativity 
(with 95% Cl if 
presented)
Risk factors for 
which data was 
collected
Prabhakar et al1*4 Jamaica, 1986 3267 women tested 
in TORCHES* 
survey
ELISA (Dade 
Behring, Marburg, 
Germany)
Optical density<0.2 
seronegative
31.0% Parish of residence
Dos Santos et al,V5 Salvador, Bahia, 
Brazil 1990-1991
1024 women 
referred seen in 
antenatal clinic
HI (Bio-
Manguinhos, Cruz, 
Brazil)
Not stated 22.6% Age, place of birth, 
education, history of 
miscarriage, blood 
transfusions
Wynter et al196 Urban, rural and 
private urban 
antenatal clinics, 
Jamaica, 1996-1997
389 women seeking 
antenatal care
HI and ELISA 
(Rubazyme)
HI titre <1:8,
Rubazyme
value<1.0
21.3% Type of clinic
Danovaro-Holiday 
et al197
Douglas County, 
Nebraska, US 1998- 
99 (following 
rubella outbreak)
216 pregnant 
women
(predominantly 
Hispanic) screened 
at two antenatal 
clinics
Not stated <6.5 IU/ml 11.1% Country of birth, 
age, education, 
previous births in 
the US
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Libman et al1V8 Montreal, Canada, 262 women tested ELISA (Abbott <10 IU/ml 10.9% Maternal age and
1994 through routine 
antenatal screening
Diagnostics,
Mississauga,
Canada)
country of birth
D&inor et allw Port-au-Prince, 503 women seeking ELISA (Dade <15 IU/ml 4.8% Age, area of
Haiti, 2002 antenatal care at 
hospital
Behring, Marburg, 
Germany)
residence
Haas et al"0 Lejeune, US, 2004 973 women 
presenting for 
antenatal care
ELISA (Wampole 
Laboratories, 
Princeton, US)
<1.1 (units not 
specified)
9.4% Maternal age, parity
Eastern Mediterranean
Authors Setting Population and 
sample size
Laboratory
method
Definition of 
seronegative 
population
Overall prevalence 
of seronegativity 
(with 95% a  if 
presented)
Risk factors for 
which data was 
collected
Rasul et al^1 Karachi, Pakistan, 
1987-1988
2000 women tested 
through routine 
antenatal screening
ELISA (Rubazyme, 
Abbott Laboratories, 
Abbott Park, US)
Not stated 15.8% Age, parity
Bdour^ Amma and As-Salt, 
Jordan (year not 
stated)
439 women 
attending public 
antenatal clinics
ELISA (Biokit, 
Spain)
<10 IU/ml 43.7% Age
Makhseed et a l^ Kuwait, 1995 600 women 
attending antenatal 
clinic
HI Titre <1:8 7.7% Age, parity, 
nationality
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Europe
Authors Setting Population and Laboratory Definition of Overall prevalence Risk factors for
sample size method seronegative of seronegativity which data was
population (with 95% Cl if collected
presented)
m w  _ . . *  f  ’    —
Miller et al110 Six areas of 
England, 1987-1989
117317 women 
tested through 
routine antenatal 
screening
Not stated Not stated 2.4% Parity
Miller et al*” Six areas of 
England, 1985-1991
~100000 women 
tested through 
routine antenatal 
screening
Not stated Not stated 1% (parous) 2% 
(nulliparous) in 
1991
Ethnicity, parity
Gtiner et al205 Ankara, Turkey, 
1990-1993
1351 women seen in 
antenatal clinic
ELISA
(Eurogenetics, N.V.)
<10 IU/ml 
seronegative
17.9% None stated
Miller etal11' Six areas of England 
1994-1995
Women tested 
through routine 
antenatal screening 
(total n not stated)
Not stated Not stated 2.0% (nulliparous), 
1.2% (parous)
Parity
Semerikov et al2”0 Perm, Russia, 1992- 
1996
Pregnant women (not HI (in-house) 
stated how identified or 
samples obtained. Total 
n not stated)
<10 IU/ml 16.5% Not stated
Odland et al'"7 St Petersburg, 
Russia, 1995
182 women attending 
outpatient antenatal 
clinic
Indirect enzyme <10 IU/ml 
immunoassay (Dade 
Behring, Marburg,
Germany)
22.5% Age, number of 
previous deliveries, 
abortion history, 
smoking, 
contraceptive use, 
previous use of 
antibiotics for
urinary tract 
infections
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Authors Setting Population and sample 
size
Laboratory
method
Definition of 
seronegative 
population
Overall prevalence 
of seronegativity 
(with 95% a  if 
presented)
Risk factors for 
which data was 
collected
Tookey et alwi North West Thames, 
UK 1996-1999
137398 women tested 
through antenatal 
screening
Not stated Not stated 2.5% Age, parity, ethnic 
group
Karakoc et a l^ Adana, Turkey, 
1999-2000
100 women seen in 
antenatal clinic
Microparticle EIA
(Abbott
Laboratories)
<10 IU/ml 0% Age
Anderson et al155 London, UK, 2002 109139 women tested 
through routine 
antenatal screening
Not stated Not stated 3.6% Maternity unit 
attended
Knowles et a l^ Dublin, Ireland, 
2002
7872 women tested 
through routine 
antenatal screening
ELISA (Biokit, 
Spain)
<15 IU/ml 5.8% Country of birth, 
age group
Pehlivan et alzlu Malatya province, 
Turkey, 2003-2004
803 pregnant women 
seen in urban and rural 
health centres
ELISA (Trinity 
Biotech, New York 
US)
<0.9 (units not 
specified)
5.6% Age, education, 
occupation, family 
structure, residence, 
income, type of 
health insurance, 
trimester of 
pregnancy
Aksakal et alnl Karagedik province, 
Turkey 1998
467 pregnant women 
with available blood 
samples
ELISA (Trinity 
Biotech, New York 
US)
<6.5 IU/ml 1.7% Age group, 
education, 
occupation, marital 
status, type of social 
insurance
Ocak et alU2 Hatay province, 
Turkey 2004-2006
1652 pregnant women 
receiving antenatal care 
in one of two maternity 
hospital outpatients’ 
clinics
ELISA (Abbott 
Laboratories, Abbott 
Park, US)
<10 IU/ml 5.0% Age
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South-East Asia
Authors Setting Population and 
sample size
Laboratory
method
Definition of 
seronegative 
population
Overall prevalence 
of seronegativity 
(with 95% Cl if 
presented)
Risk factors for 
which data was 
collected
Ashrafunnessa et 
al213
Dhaka, Bangladesh, 
1997-1998
609 women 
attending obstetric 
outpatients’ 
department
ELISA (Platelia, 
Pasteur)
<10 IU/ml 14.1% Maternal age, parity
Weerasekera et al214 Colombo, Sri 
Lanka, 1999-2001
500 women 
attending antenatal 
clinic
ELISA (CARO
Diagnostic,
Germany)
Not stated 18% Age, parity, 
vaccination history, 
previous rubella 
exposure
Palihawadana et 
al215
Kalutara district, Sri 
Lanka
620 women 
attending antenatal 
clinics
ELISA (Pasteur 
Diagnostics, France)
<15 IU/ml 24% Demographic, 
clinical and 
socioeconomic 
variables, including 
age, marital status, 
social class, parity, 
rubella vaccination 
history etc
Gandhoke et al/I0 Delhi and
surroundings, India, 
1988-2002
5317 women tested 
through antenatal 
screening
HI (make not 
specified), and 
ELISA (several 
different 
manufacturers)
Presence of IgG 
antibodies (level not 
stated)
16.9% None
Gupta et al21' Delhi, India, 2003- 
2004
305 women 
attending antenatal 
clinic
ELISA (Biokit, 
Spain)
Not stated 12.8% Maternal age, 
obstetric history
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Western Pacific
Authors Setting Population and 
sample size
Laboratory
method
Definition of 
seronegative 
population
Overall prevalence 
of seronegativity 
(with 95% Cl if 
presented)
Risk factors for 
which data was 
collected
Sekawi et al218 Kuala Lumpur, 
Malaysia, 2001- 
2002
414 women tested 
through routine 
antenatal screening
Enzyme 
immunoassay 
(EIAgen, Italy)
<15 IU/ml 7.7% Maternal age, 
history of rubella 
vaccination for 
subset of women
Tseng et al219 Pintung, Taiwan, 
1999-2002
5007 women 
presenting for 
routine pregnancy 
examination
Microparticle
enzyme
immunoassay
(Abbott
Laboratories, Abbott 
Park, US)
<5 IU/ml 10% (95% Cl 0- 
28.6%) to 37.3% 
(95% Cl 25.7- 
48.9%) depending 
on country of birth
(n=134)
Year of birth, 
country of birth
Table 4.1. Summary of rubella serosurveys in pregnant women indexed on EMBASE or Medline+ between 1990 and 2008.
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Table 4.1 highlights the substantial inter-and intra-country differences in rubella 
seroprevalence. In unvaccinated populations, these differences reflect variations in 
the force of infection, and in very isolated populations, the time since the latest 
epidemic13. For example, 3.5% of pregnant women in Western Cape, South Africa 
were found to be seronegative192, compared to 45.9% in Maiduguri in Nigeria191. 
Data on antenatal rubella seronegative status from developed countries tend to be 
derived from routine antenatal infection screening, whereas in developing 
countries, serosurveys are normally carried out using samples from women 
seeking antenatal care at hospitals or health centres. The WHO41 recommends that 
antenatal clinics are suitable settings to carry out sampling for rubella serosurveys 
if over 90% of women attend. The largest sample sizes were also achieved in 
studies reporting findings from a routine antenatal screening programme, which is 
required to achieve sufficient power for serosurveys in immunised populations 
where the proportion of seronegative women will be lower.
All the identified studies presented in Table 4.1 were carried out using serum 
samples; in many cases, these samples would be collected in antenatal clinics for 
other reasons and thus the left-over sera could be used for rubella antibody testing 
without the need for extra blood sampling. The most common antibody detection 
technique used was the ELISA, used in 25 of 37 studies identified (67.6%), but 
the cut-off value used to define the seronegative population varied between the 
different studies. This reflects the difficulty in defining an antibody level which is 
protective against rubella infection (see section 4.5 below). The WHO41
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recommends using enzyme-immunoassays, such as ELISAs, for serosurveys and a 
cut-off level between 10 and 12 IU/ml for defining the seronegative population. 
Lower cut-off levels are discouraged since some assays have less reliability at 
lower antibody levels.
4.4 The use of alternative samples in serosurveys
As demonstrated in Table 4.1, the majority of serological surveys for rubella are 
carried out using serum samples. This is not surprising as the highest 
concentration of IgG can be found in serum, and most IgG antibody assays are 
consequently optimised for use on these samples. However, serum samples are 
invasive and painful to collect through venepuncture, and require trained staff, 
sterile blood sampling equipment and safe needle disposal220. In large scale 
serological surveys, serum sample collection, processing and handling therefore 
becomes very expensive. Invasive blood sampling may also increase the non­
response rate 220;221. With the development of more sensitive assay methodology, 
it has become possible to use alternative samples to serum.
Oral fluid samples are increasingly used for serological surveys and diagnosis of 
infections222;223. These samples consist of salivary gland secretions and crevicular 
fluid and can be collected by absorptive collection devices. IgM, IgG and IgA 
antibodies are present in crevicular fluid. Oral fluid samples are therefore suitable 
for diagnostic or research purposes, particularly when research is carried out in 
children as collection is painless and non-invasive and samples can be taken and
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dispatched by staff who have minimal training in sample collection221. Oral fluid 
samples are used by the HPA for routine diagnosis of suspected infections of 
measles, mumps and rubella1091222. However, since the concentration of antibodies 
is much lower in oral fluid than in serum, highly sensitive assays, such as 
antibody capture and time-resolved fluorescence assays are required to measure 
antibody levels221^ 1225.
4.4.1 Dried blood spot samples
Dried blood spot samples have been used for serological surveillance and 
diagnosis as an alternative to serum samples. Guthrie and colleagues226 first 
developed a method of collecting and using dried blood spot samples for 
screening newborns for phenylketonuria (PKU), in the early 1960s. Newborn 
screening programmes for PKU were universally implemented in most developed 
countries in the 1960s and 1970s, and as sensitive methods to detect biomarkers 
and DNA on minimal samples have been developed, many more metabolic, 
endocrine and haematological disorders have successively been added to newborn 
screening programmes227. Dried blood spot samples consist of a whole blood 
sample, obtained from finger or heel prick using an automated incision lancet (see 
Figure 4.1), collected onto a filter paper card on which it is dried.
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Note: Tenderfoot (left), Unistix (right)
Figure 4.1 Automated incision lancets for heelprick blood collection in newborns
The specimen discs are then punched out from the cards and diluted in buffer 
solution for analysis. IgG, IgM, IgA and IgE antibodies have been recovered from 
dried blood spots228 234 and viral DNA or RNA can also be recovered, making it 
possible to use these samples in serological surveys and for diagnosis of
infections24’235*236.
There are many advantages to using dried blood spot samples over serum 
samples. Although dried blood spot samples still require skin piercing by heel or 
finger prick, this is likely to be more acceptable than venepuncture, particularly in 
children and in infants. The amount of training required to perform a heel or 
finger prick is also less compared to that required for venepuncture237. In addition, 
the use of needles is avoided, thus reducing the risk of needle stick injuries as well 
as the costs associated with safe disposal of needles and syringes 238. Since the
1 2 1
blood spot sample is dried, it constitutes a low hazard in terms of infection risk; 
HIV, hepatitis C, and Human T-cell Lymphoma/Leukaemia Vims (HTLV) all 
have reduced infectivity in dried blood spots compared to liquid whole blood and 
serum220. Since dried blood spot samples are not considered hazardous substances, 
they are exempt from international regulations concerning transport of hazardous 
material239. Shipping is therefore simplified, in particular since dried blood spot 
samples cannot break or leak during transport. In addition, commercially available 
assays, such as ELISAs, can be relatively easily adopted for use on dried blood 
spot samples220^ 241.
A further advantage to the use of dried blood spot samples in large scale 
serological surveys is the stability of antibodies in dried blood, even under 
unfavourable conditions. Behets and colleagues242 stored dried blood spot samples 
from HIV positive individuals in Kinshasa, Congo, under various conditions 
during a 20-week period under varying conditions: metal container directly 
exposed to the sun, shaded location without air conditioning, refrigerator at 4°C, 
and freezer at -20°C. They reported that specimens with high HIV antibody titres 
remained positive over a six week period when tested by an ELISA, even those 
stored in the metal container. After eight weeks however, low titre specimens 
were no longer positive unless frozen or refrigerated. Similarly, Mendy et al243 
found Hepatitis B surface antigen to be stable in dried blood spots kept at 30 to 
33°C for 28 days. HIV DNA has also been detectable by reverse-transciptase 
polymerase chain reaction (RT-PCR) after storage for 12 weeks at 22°C, and after
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a week at 37°C with 60% humidity, with no difference in DNA yield when 
compared with storage at -20°C244. HIV RNA has been found to be stable in dried 
blood spots at room temperature for over a year245. Dried blood spots therefore 
lend themselves to sample collection for serological surveys and for diagnosis 
even in tropical environments, and do not require a cold chain during 
transportation. Once the blood is dried, the filter paper cards can be sent in normal 
envelopes2381246.
One main motivation for the interest in dried blood spots as a sample for use in 
serosurveys are their use in newborn screening programmes in most developed 
countries. In many countries, including the United Kingdom246, dried blood spot 
specimens from newborn screening are stored for many years. In Denmark247, 
these specimens form a national PKU biobank, which is regularly used for 
research into a multitude of maternal, child, and late-onset conditions.
Newborn screening programmes based on dried blood spots have very high 
uptake, nearing 100% in many countries247, implying that these specimens 
represent a large and unbiased sampling frame for example for allele prevalence 
studies. A full discussion of newborn screening uptake in the UK can be found in 
section 5.2.1 in chapter 5. The newborn screening blood spot sample is the only 
sample collected from such a high proportion of children so early in life. Because 
maternal IgG antibodies are transported across the placenta during pregnancy (see 
section 4.4.2 below), the residual newborn dried blood spot samples have also
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been used for serosurveys in pregnant women, including for IgG antibodies to 
Toxoplasma Gondii248*250 and Parvovirus B19251. Residual newborn dried blood 
spots have only been used in one previous study to estimate maternal rubella 
seroprevalence. Sander and colleagues252 tested 6613 residual newborn dried 
blood spot samples from West Germany in 1984 for rubella IgG antibody using an 
ELISA, and also screened 37000 newborn dried blood spots for rubella IgM to 
detect newborns affected by congenital rubella. The authors report having 
monitored maternal rubella IgG levels in newborn dried blood spots for over five 
years and suggest this as a low cost method of monitoring rubella antibody levels 
in pregnant women.
The prevalence of infections, including hepatitis c253;254, hepatitis B255, and 
HTLV-1 and 2256 has also been examined using newborn dried blood spot 
samples. These samples have also been used for monitoring of maternal HIV 
prevalence, through anonymous surveys in several countries, including Spain257, 
Italy258, Canada259, and the United States, where the programme was first 
piloted260*262. In the United Kingdom, the newborn dried blood spots are used to 
monitor HIV prevalence among pregnant women as part of the unlinked 
anonymous HIV surveillance programme263. It was first piloted in the North East 
Thames area, with the residual samples tested for HIV at the newborn screening 
laboratory at Great Ormond Street Hospital in collaboration with the Institute of 
Child Health264*266. The UK programme now covers seven screening laboratories 
across England and Scotland, and in some areas newborn samples are linked to
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birth registration data, providing information on maternal and paternal country of 
birth265;267. This programme is discussed in more detail in section 5.2.2. Dried 
blood spot samples from newborns have also been used for diagnosis of 
congenital infections, such as cytomegalovirus (CMV) by detection of DNA in 
children with hearing loss or brain damage268'270.
4.4.1.1 Adaption of rubella IgG ELISAs for use on dried blood spot 
samples
Since most IgG ELISAs are optimised for use on serum samples, assay 
methodology requires adjustments in order to be used on dried blood spots, 
although most ELISAs can easily be adapted for use on such samples220. Three 
previous studies to compare rubella IgG concentrations in serum and dried blood 
spots, using paired samples, have been carried out by Helfand and 
colleagues271*272 and Vejtorp and Leerhoy273. In the first study by Helfand et al272, 
120 12 to 15 month old children and healthy adults were enrolled, and serum and 
dried blood spot samples were collected by finger stick. Rubella IgG antibodies 
were measured using a commercial rubella IgG ELISA manufactured by Dade 
Behring (Marburg, Germany). For the second study by the same group271, 273 
paired serum and dried blood spot samples from persons with clinically suspected 
rubella, and 103 healthy blood donors were collected during a rubella outbreak in 
Peru. Samples were tested using a commercially available rubella IgG ELISA 
(Wampole, Cranbury, US). Vejtorp and Leerhoy used an in-house ELISA to test 
47 paired serum and dried blood spot samples from student midwives.
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In these previous studies, agreement between rubella IgG antibody in serum and 
dried blood spot samples was assessed only using the Pearson correlation 
coefficient, which was shown to be high: 0.94 in Helfand et al’s two studies2711272 
(in which rubella IgG levels were expressed as optical density values) and 0.98 in 
Vejtorp and Leerhoy’s study273 (in which rubella IgG levels were expressed as E- 
values, which are similar to optical densities). However, the Pearson correlation 
coefficient is not sufficient as a marker for agreement. It does not take into 
account heteroscedasticity, and may remain unchanged despite for example, a 
change in scale274. Also, confidence intervals for the correlation coefficients were 
not presented in any of these studies.
4.4.2 Placental transfer of antibodies
Newborn samples can be used to monitor maternal antibody levels since maternal 
IgG is transferred across the placenta during pregnancy. Initially, it was thought 
that levels of maternal and newborn IgG concentrations were not significantly 
different275, but in 1966, Kohler and Farr276 demonstrated that total IgG 
concentrations in cord blood were significantly higher than in maternal serum in 
46 mother-baby pairs, a finding which has since been replicated by several 
authors27512771278. This was seen as evidence that maternal IgG is actively 
transported across the placenta during pregnancy.
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That fetal IgG is o f maternal origin has also been shown by various methods 
including Gm typing279. Although fetuses can synthesise small amounts of IgG 
and IgM antibodies after the 12th week of gestation278, this ability is highly 
limited since the fetus is in most cases not exposed to antigens280. In cases of 
intrauterine infection however, the fetus is stimulated to produce its own IgA and 
IgM antibodies 281, and IgM testing of the newborn can therefore be used for 
diagnosis of congenital infections (see chapter 1). A baby bom at term is able to 
produce around 5% of an adult’s IgG level282 and IgG production does not 
increase until a significant time after birth283. Transport of maternal IgG therefore 
provides newborn babies with passive immunity to infections through the neonatal 
period, when they are otherwise highly vulnerable to infection2825284.
Only IgG antibodies are transferred across the placenta. The selective process 
through which proteins are transported across the placenta is based on molecular 
configuration and not size276;285. It is thought that that the Fc section of IgG 
attaches to Fc receptors on the plasmoditrophoblast. IgG molecules are transferred 
through the placental tissue in coated vesicles, providing the IgG proteins with 
protection from lysosomal digestion by placental cells. The total IgG level of the 
newborn is therefore closely dependent on that in the mother2755286. High 
agreement between maternal and fetal or newborn antibody level has been 
demonstrated for antigen-specific IgG antibody. Griffiths et al287 found linear 
correlations between maternal and cord serum IgG levels for measles, rubella, and 
influenza type B in 100 paired serum samples. Cord blood IgG level exceeded
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maternal blood IgG concentrations for herpes simplex virus, measles, rubella, 
respiratory syncytial virus, but not for influenza type B, for which maternal and 
cord blood IgG levels were similar, or for influenza A, for which maternal levels 
were higher.
IgG antibodies have been detected in fetuses aged 13 to 15 weeks278. Total IgG 
antibody level in the fetus increases quadratically with gestational age, and the 
concentration of maternal and fetal total IgG levels are equal at around 35 weeks 
of pregnancy288. Since the rate of transfer of maternal IgG increases throughout 
pregnancy, babies who are bom prematurely have lower levels of IgG than babies 
who are bom at term, making them more vulnerable to infections289. A log-linear 
relationship between fetal total IgG level and gestational age has been described 
277^80 c orre|ation between birth weight and total IgG cord/neonatal serum level 
appears less pronounced281. Yeung et al280 found that 34 babies bom as twins or 
triplets had similar IgG concentrations, even if their twin’s birth weight was 
different.
Babies bom prematurely have also been reported to have lower levels of IgG 
levels to specific infections, including rubella. Linder et al290 found that although 
there was no significant difference in the proportion of full-term (bom after 37 
weeks) and premature (bom before 35 weeks) newborns with detectable rubella 
IgG antibody in cord blood, a significant difference (p <0.001) was found in the 
proportion with detectable antibody among babies bom before and after 30 weeks.
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In addition, it was demonstrated that babies bom prematurely had significantly 
lower rubella IgG geometric mean titres (GMTs) in cord blood than full-term 
newborns, which was attributed to the low IgG antibody levels in the young 
preterm group of newborns (bom before 30 weeks). The correlation coefficients 
for maternal and cord blood IgG concentrations were significantly lower for 
preterm infants than for full-term infants QxO.OOl). Exact p -values were not 
stated in this study.
Leineweber291 demonstrated that maternal and newborn antibody levels were 
highly correlated for rubella, measles, mumps and varicella-zoster IgG in serum 
samples from 135 mother-infant pairs. The samples were taken during the first 
five days of life. However, IgG GMTs were associated with gestational age; an 
association which remained after controlling for maternal age. Preterm infants 
were found to have significantly lower GMTs than infants bom at term. For 
example, 94% of full-term infants bom to rubella IgG positive mothers tested 
positive for rubella antibody (ie had a rubella IgG concentration greater than 15 
IU/ml), whereas 90% of preterm newborns bom to rubella antibody positive 
mothers tested positive ip < 0.05). This difference was statistically significant. 
However, neither Leineweber et al291 or Linder et al290 used regression models or 
controlled for vaccination status of the mother in their analyses. For measles IgG, 
Goncalves and colleagues292 found that the main determinant of cord serum 
measles-specific IgG concentration was maternal vaccination status. Cord 
measles IgG concentrations for newborns of vaccinated mothers were
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significantly lower than for newborns whose mothers had had natural infection (p 
< 0.0001). Gestational age, parity and prevalence of pre-eclampsia only 
contributed to around 1% of the variance in measles IgG concentration.
Goncalves et al293 also tested 231 matemal-cord blood pairs for rubella IgG, and 
like Griffiths et al287 found that maternal serum and cord blood concentrations 
were highly correlated. They found that although preterm babies had lower cord 
blood rubella IgG GMTs than babies bom at term, these differences were not 
statistically significant. It is not clear whether there was sufficient power to detect 
a statistically significant difference however. There was, in contrast with measles 
IgG, no statistically significant difference in rubella IgG levels for babies bom to 
women who had been vaccinated and those who had not, however it is not clear 
whether the unvaccinated women had a history of rubella infection.
Doroudchi et al294 examined rubella IgG concentrations in 219 matemal-cord 
samples using an ELISA. In contrast to previous authors287;290;291;293, this group 
found lower rubella IgG levels in maternal than newborn blood, despite a higher 
birth weight than in for example Linder and colleagues’study290. Doroudchi et 
al294 found that IgG newborn antibody level did not vary by type of delivery, 
parity or birth weight, but babies bom to mothers with blood group B+ had 
significantly lower rubella IgG concentrations than babies bom to mothers with 
A+ or 0 +  blood groups. This finding could not be explained by the authors 
however, and has not been observed by other research groups. In addition, no
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multi variable, analyses were performed to assess independent effects of maternal 
characteristics on newborn antibody level.
Infections causing placental damage, such as malaria can also lead to reduced 
placental transport of IgG. Okoko et al295 demonstrated that Gambian mothers 
with placental malaria infection had significantly higher total IgG levels than their 
newborns, whereas the opposite was true for mothers who were not infected with 
malaria. Likewise, de Moraes-Pinto et al282 showed in a study of 180 Malawian 
infants that maternal malaria infection, hypergammaglobulinaemia and HIV 
infection reduced the transfer of IgG antibody to Streptococcus Pneumoniae by 
82%, 79% and 86% respectively. Parity, prematurity (ie. bom at less than 37 
weeks gestation) or previous malarial treatments were not significantly related to 
cord blood total IgG level. Transfer of measles specific IgG was not reduced by 
HIV infection, and IgG for tetanus toxoid was not affected by any of the three 
maternal conditions.
Transplacental antibody transfer is highly important since maternal IgG acts as 
passive immunisation of the newborn, providing protection from infection282. The 
transfer of antigen-specific maternal IgG across the placenta is exploited for the 
protection of newborn babies against neonatal tetanus in developing countries, by 
vaccinating the mother against tetanus toxoid during pregnancy296.
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It can be shown that maternally derived antibodies decay at a roughly exponential 
rate8. The presence of maternal antibodies can interfere with the immune response
o - i
produced by vaccination, a problem which has been observed for measles , 
therefore the length of time for which maternal antibody persists is very important 
in determining when childhood vaccinations should take place297. For example, 
maternally derived rubella antibodies persist for around three to six months, and 
are normally undetectable by nine months36:38;188. Some authors have suggested 
that in a vaccinated population without circulating virus, maternal antibody levels, 
and hence newborn antibody levels will be lower, and may not persist as long, 
leaving infants vulnerable to infection for a longer period of time297.
4.5 Defining a rubella IgG level protective against infection
One of the key aims of serosurveys is to estimate the size and characteristics of 
the population who may be susceptible to a particular infection. However, one of 
the major problems associated with these studies is that the concentration of 
antibody which is protective against infection is not clear, as immune responses to 
infection and vaccination vary between individuals. In addition, vaccine-induced 
immunity also wanes faster than immunity induced by natural infection57:58:60, and 
it is difficult to distinguish between susceptible individuals without previous virus 
contact and immunised individuals whose antibodies have waned, using 
laboratory methods.
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When the HI technique was developed, there were concerns about this assay 
reacting with lipoproteins in serum, and thus potentially leading to false positive 
results. The sensitivity of the HI assay at low antibody levels was also questioned. 
In order to avoid these problems, a titration above 1:8 was defined as a protective 
level of antibody against rubella infection185. When more specific quantitative 
assays, such as the ELISA, were developed, an HI titre of 1:8 was converted to a 
cut-off value 15 IU/ml185. O’Shea et al298 found that only one of 19 volunteers 
with rubella IgG levels of less than 15 IU/ml showed evidence of rubella infection 
when exposed to the vims.
The <15 IU/ml cut-off value was consequently adopted by the US National 
Committee for Clinical and Laboratory Standards in 1985185. However, there are 
no recent studies in which a large sample of people with a known antibody level 
has been exposed to rubella vims and studies like that of O’Shea and colleagues298 
are unlikely to be repeated due to ethical concerns655185. Asymptomatic rubella 
reinfection has been reported in subjects known to have positive rubella antibody 
titres by HI, as evidenced by the detection of IgM antibodies after exposure. 
These subjects had became rubella immune through vaccination27;185:299. Cases of 
symptomatic reinfection are very rare26.
Despite cases of asymptomatic reinfection occurring in individuals with rubella 
IgG antibody levels greater than 15 IU/ml, this cut-off value has been deemed too 
high as it generated too many false negatives in screening programmes. This was
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shown when qualitative methods, such as the ELISA became more widely used. 
For example, Steece et al300 showed that agreement between ELISA and HI 
results was poor: 4% of those who tested negative with HI tested positive on 
ELISA, and 32% of those who tested positive on HI tested negative with ELISA. 
Kleeman et al301 tested over 700 specimens with HI and ELISA; 31% of 
specimens were found to be negative with HI and positive on ELISA. In addition, 
Mortimer et al302 found that none of the 66 patients who tested negative for 
rubella IgG antibody on either ELISA, single radial haemolysis (SRH) or HI 
produced an IgM response when vaccinated with the RA27/3 rubella vaccine 
strain, thus indicating prior immunity. The authors stated that the only evidence 
for rubella immunity is IgM response to vaccination, and were concerned that 
many women who screened negative during pregnancy were immunised against 
rubella unnecessarily: although the IgG ELISA result was negative, a significant 
proportion was likely to be immune.
Orenstein et al303 demonstrated in a serosurvey of 1871 schoolchildren in 
Massachusetts that 76.4% were seropositive on HI if a cut-off level greater than 
15 IU/ml was used to indicate immunity. Using more sensitive assays including 
enzyme-immunoassays and RH, the proportion testing seropositive for rubella 
IgG with any technique increased to 93.1%. The largest increase in sensitivity was 
achieved when a cut-off level greater than or equal to 10 IU/ml was used to 
indicate immunity. The authors conclude that the majority of children who screen 
negative using the HI assay with <15 IU/ml cut-off had in fact been vaccinated,
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but their antibody levels had waned. In addition, no outbreaks of rubella were 
subsequently reported in Massachusetts, indicating that the proportion of the 
population who were immune was in fact above the threshold for herd immunity. 
The US National Committee for Clinical and Laboratory standards subsequently 
lowered the cut-off value indicating immunity, from 15 to 10 IU/ml in 1992185.
Cut-off values defined for use in screening programmes aimed at identifying 
individuals who require vaccination are likely to be set high in order to maximise 
sensitivity304. The UK Department of Health recommends using <10 IU/ml as a 
cut-off value in the antenatal screening programme for rubella antibody to 
indicate a need for post-partum vaccination153. Antibody assays such as ELISAs 
and SRH are advised for use in screening. It is also recommended that screening 
results are reported as antibody detected/not detected rather than 
immune/susceptible. However, there is no evidence that these recommendations 
are followed, and there is no available information on which cut-off values are 
currently used in the antenatal screening programme (P.Tookey and C. Peckham, 
personal communication).
As Table 4.1 demonstrates, a wide range of cut-off values has been used in rubella 
serosurveys in pregnant women, where the aim is to quantify the size of the 
susceptible population. One reason for this disparity is that assay manufacturers 
recommend different cut-off values to be used with their particular assay. In some 
studies however, there was no justification stated for why a specific cut-off value
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was used. There is also wide variation in the cut-off values used to indicate 
rubella seronegative status by the network of European seroepidemiology 
laboratories, which monitor susceptibility to vaccine preventable diseases at 
national level. Andrews and colleagues305 report a range of cut-off values used to 
indicate rubella a seronegative result between <4 IU/ml and <15 IU/ml 305.
Hence, there is no reliable evidence to indicate which level of rubella antibody is 
protective against rubella infection, particularly in a vaccinated population where 
antibody levels will wane more rapidly than in populations where the majority of 
people have had natural infection. Some individuals are likely to be immune even 
despite low antibody levels when exposed to the rubella virus66.
4.6 Latent class regression finite mixture models
There is consequently no laboratory method currently available that allows for the 
identification of individuals who would be infected or re-infected with rubella if 
exposed to the virus, which is the main parameter of interest in rubella 
serosurveys. The choice of an appropriate cut-off value to use in such surveys is 
made even more complex when alternative samples, such as oral fluid and dried 
blood spot samples are used, since the concentration of antibody is less in oral 
fluid and whole blood than in serum. The specificity of the assay is therefore 
compromised223, which makes the overestimation of the proportion of 
seronegative individuals in a population more likely if cut-off values intended for 
application to serum samples are used165.
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Because of the problems associated with setting an appropriate cut-off value for 
identifying and distinguishing between seronegative and seropositive individuals,
i.e. individuals who are likely to be susceptible and those who are likely to be 
immune, a statistical method known as latent class regression finite mixture 
models has been frequently applied in the analyses of serological surveys. These 
models represent a form of cluster analysis, and are applicable to serosurveys 
since their aim is to estimate the distribution of antibody levels in the population, 
rather than determining whether the antibody level of a specific individual is 
below or above a certain cut-off value22*306-308. Mixture models are applied to 
continuous data, thus avoiding having to introduce dichotomous classifiers by 
applying sometimes arbitrary cut-off values165. They are particularly useful for 
analysing data on antibody levels from serosurveys of childhood infections in 
vaccinated populations, which are essentially mixtures of individuals who have 
never been infected or vaccinated, those who have been vaccinated but whose 
antibody levels may have waned, and individuals who have been exposed to wild
223virus .
Mixture models are applied to identify groups, or components, within a sample 
distribution. The basic assumption of a latent class regression finite mixture model 
is that the total population is in fact a mixture of individuals belonging to a 
number of subpopulations; the number of sub-populations can either be 
determined from the data, or be known a priori. Thus, in a latent class mixture
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model, the total density function is the sum of the density functions of a number 
of components, or groups, in the population (corresponding to the number of 
subpopulations), multiplied by the weighted contribution of each component to 
the total density function (the component weight). The component weights must 
therefore add up to 1.
The total density function for a simple latent class mixture model309 is:
K
/ ( y ^ )  = where 0 < 7Ck < 1, (k = 1,2,...,J£) Equation 1
*=l
K
and = 1 Equation 2
k=1
where yj is a vector of observations, tt* is the component weight for component k, 
K  is the number of components and fifyj) is the probability density function of 
observations in component k, also known as the component density. It is also 
possible to fit mixture models with linear predictors for the component weights tt* 
and the location and scale parameters of /*310. In most applications of mixture 
models to distributions of antibody levels obtained from serosurveys, the 
distributions of /* have been assumed to be normal (see for example Gay et al223 
and Vyse et al165), however there is no biological reason why this should be the 
case. The assumption of normality for /* does not depend on an assumption of 
normality for / ( y ; ). The use of mixture models cannot be used to accurately
identify subpopulations that might be infected with rubella when exposed to the 
wild vims and only serve to detect groups with low antibody levels.
4.6.1 Approaches to mixture models in analyses of antibody levels from 
serosurveys
Mixture models have been used in two primary contexts to analyse antibody 
levels. First, they have been applied to data on antibody levels obtained from 
serosurveys. Parker et al311 applied mixture models to distributions of parvovirus 
B19 IgG and IgM antibody levels in 280 individuals. The variable modelled was 
the logarithm of the optical density (the uncalibrated result from the ELISA). 
Antibody levels are often log transformed, since the titre results given by the HI 
assay were dilutions on an exponential scale (1:2, 1:4, 1:8,1:16, etc). The GMT is 
therefore often used for analyses and comparisons of antibody levels in different 
groups180;311. Parker et al311 included up to four mixture model components, which 
were assumed to be normally distributed when models were fitted to the IgM 
levels, and up to three normally distributed components when models were fitted 
for the IgG levels. Model selection was carried out on the basis of difference in 
log-likelihood. The mixture models were used to calculate sensitivities and 
specificities of different cut-off values. Bayes’ rule was used to calculate the 
probability of a sample coming from a particular component, and hence the 
proportion of samples misclassified for a particular cut-off value.
Gay306 also applied mixture models to the results of a serosurvey of parvovirus 
B19 IgG in 3236 left-over diagnostic serum samples. Two components in the 
mixture model were assumed; a component for seronegative individuals which
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was normally distributed, and a component for seropositive individuals which was 
normally distributed with a skew parameter to take account of waning antibody 
levels in adults. The natural logarithm of the optical density was grouped into 22 
categories. Model selection was carried out by calculating model deviance (a 
function of log-likelihood). The only explanatory variable included was age, and 
modelling was carried out for the ages of 0, 10, 20 and 45 years, with results for 
the intermediate ages obtained by linear interpolation. Since this method allows 
the estimation of the proportion of the population seropositive at each age using 
the component weights, the use of cut-off values is not required.
A similar methodology was used by Gay et al223 using data from a serosurvey of 
rubella IgG antibody in 837 oral fluid samples collected in Ethiopia. The natural 
logarithm of the optical density ratios was modelled, having been discretised into 
20 categories, and age was categorised into six groups. A model with three 
components, seronegative, weak seropositive and strong seropositive, was 
hypothesised. Mixture models were stratified for each of the six age groups, so 
that the proportion seronegative in each age group could be estimated using the 
component weights. Again, model fit was assessed using deviance. Similar 
mixture model techniques have also been applied to serosurveys of measles, 
mumps and rubella in England, using left-over serum samples sent for 
confirmatory testing165.
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Baughman et al307 used mixture models for analysis of pertussis toxin IgG 
antibody levels from a large national health survey in the US. Antibody levels in 
5409 samples were analysed. The mixture model was assumed a priori to have 
four components, of which one component represented a population of individuals 
with antibody levels below the limit of detection of the assay who were assumed 
to be susceptible. The component with the highest mean antibody levels was 
assumed to represent a population of recently infected individuals. To test this 
hypothesis, up to five components were included in the mixture models and model 
selection was based on the Akaike’s Information Criterion (AIC) and the 
Bayesian Information Criterion (BIC). The models were fitted to the logarithms 
(base 10) of the antibody levels, expressed as ELISA units/ml. Left-censored 
normal distributions were assumed for the mixture model components with 
antibody levels above the assay detection limit, whereas observations below the 
assay detection limit were modelled as a point mass distribution with the 
component weight as the only parameter. The model parameters were estimated 
by maximum likelihood, with sample weights incorporated to take account of 
study design. The mixture model was also used to derive a cut-off value for the 
diagnosis of recent pertussis infection from IgG antibody levels. Sensitivity and 
specificity for different cut-off values were calculated using the two overlapping 
normally distributed components with the largest means in their optimal mixture 
model.
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A second application of mixture models to serological surveys has been the 
evaluation of antibody assays for use on oral fluid samples. Talukder et al308 and 
Sheppard et al312 applied mixture models to uncalibrated antibody levels (optical 
densities), obtained from testing oral fluid samples for varicella zoster virus 
(VZV) IgG and Epstein-Barr Virus (EBV) IgG respectively in order to define a 
cut-off value for these assays for oral fluid samples. Since the antibody capture 
ELISAs used in these studies were in-house, the cut-off value defining a 
seronegative sample could not be obtained from a manufacturer. The mixture 
models were fitted to the logarithm (base 10) of the antibody levels. Two mixture 
model components were assumed, and the distributions of the components were 
assumed to correspond to the true distributions of antibody levels in the 
seronegative and seropositive population. Normal distributions were assumed for 
the components. The sensitivity and specificity of different cut-off values could 
then be estimated using the mixture model. A similar method was also used by 
Talukder et al313 in a study of VZV IgG in pregnant women in Tower Hamlets, to 
set cut-off values to define a variable indicating seronegativity to VZV for use in 
logistic regression analyses. Mixture models were used to analyse the data on 
antibody concentrations from the serosurvey since two different assays had been 
used to test the serum samples. Similar to the method applied by Gay223, the log- 
transformed antibody levels were discretised before analysis.
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Key points
•  Serosurveys are used to determine the proportion of individuals in a 
population who lack antibodies for a particular infection. For rubella, 
serosurveys are complicated by the lack of a cut-off value determining the 
level of antibody protective against infection.
• Serosurveys are most often carried out using serum samples, however these 
are difficult and invasive to collect by venepuncture and when transported 
constitute an infection risk. Instead, dried blood spot samples are more 
acceptable to collect through finger or heelprick, and do not classify as a 
hazardous substance.
•  Dried blood spot samples are collected from a very large proportion of 
newborns in the UK and most other developed countries for the purpose of 
screening for metabolic or endocrine conditions.
•  Latent class regression finite mixture models have been used to model data 
from serosurveys for infections for which there is no clear indication of an 
antibody level protective against infection, or in which the assay sensitivity is 
low, due to the use of alternative samples such as dried blood spots.
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5. Aims and methods
5.1 Rationale for the PhD project
As outlined in chapter 2, several previous studies in the UK have highlighted the 
higher proportion of women bom abroad who are susceptible to rubella and 
consequently, the increased risk of rubella infection during pregnancy in this 
group. London has the largest migrant population of any UK region. The 
population bom in countries with no rubella vaccination programme, or with 
suboptimal uptake, tends to be concentrated in certain areas of London. In 
addition, MMR uptake in London has been below the level required to ensure 
herd immunity for rubella for many years. It is therefore of interest to quantify the 
population of pregnant women at risk of rubella infection in London, and to 
identify high-risk groups that may be targeted for interventions.
Since susceptibility to rubella is relatively rare in the UK, a large sample is 
required to examine this topic. Although there is an antenatal screening 
programme for rubella covering over 90% of pregnant women, the surveillance 
data produced through this programme are currently only available at the 
maternity unit level, and are therefore not disaggregated by maternal 
characteristics. In addition, uptake of antenatal infection screening is not 
universal, and the criteria used to define the susceptible population are not known 
and are likely to vary by maternity unit. In contrast, uptake of newborn screening 
based on dried blood spot samples is estimated to be over 99% in the UK, and the
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residual samples have been used for serosurveys of many maternal infections, 
including rubella. These specimens could potentially provide a convenient and 
cost-effective sample for obtaining unbiased estimates of the proportion of 
pregnant women seronegative to rubella. Since they are enhanced with data 
linkage, information on maternal country of birth is available. In order to use 
these samples for a rubella serosurvey, a suitable rubella IgG ELISA validated for 
use on dried blood spot samples is also required. This thesis therefore has two 
main results sections. The first is a study to validate two commercially available 
rubella IgG ELISAs for use on dried blood spot samples. These results are 
presented in chapter 6. The second is a serosurvey of rubella in pregnant women 
in North Thames, the results of which are presented in chapter 7 and 8.
5.2 Objective and aims 
Overall objective
To estimate the proportion of pregnant women seronegative to rubella in North 
Thames by maternal characteristics using dried blood spot samples from newborn 
screening.
Specific aim s
1. To validate a rubella IgG ELISA for use on dried blood spot samples.
2. To estimate the proportion of pregnant women seronegative to rubella in 
North Thames, using dried blood spot samples from newborn screening.
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To examine how this proportion varies by maternal country of birth, as well as 
maternal age and PCT of residence.
To assess the independent effect of these maternal characteristics on rubella 
IgG antibody level using latent class regression finite mixture models.
53 Methods of the rubella IgG ELISA validation study
53.1 Choice of assays to validate
The agreement in rubella IgG antibody level between serum and dried blood spot 
samples was evaluated using two widely available ELISAs (Dade Behring, 
Marburg, Germany and Diesse, Siena, Italy). The Dade Behring ELISA has 
frequently been used in rubella serosurveys (see for example Pebody et al314, 
Cutts et al37 and Fedeli et al315). The Diesse ELISA was chosen since its testing 
procedure is more easily performed by hand than for the Dade Behring ELISA, 
for which all samples are tested in tandem. Each sample therefore has its own 
control sample, which is used to adjust for inter-plate and inter-batch variation. 
This implies a probability of human error higher for the Dade Behring than the 
Diesse ELISA.
53.2 Samples
De-identified serum samples collected for routine occupational health screening 
for immunity to vaccine preventable infections, including rubella, at Great 
Ormond Street Hospital, were used for this study. The samples were collected 
between 2000 and 2005, and stored at -20°C before testing. These samples were 
chosen since their antibody levels were known from the screening result; therefore 
samples were preferentially selected so that a sizeable proportion had low 
antibody levels. Each dried blood spot-serum pair was tested with only one of the
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two assays as there was not enough material in the serum samples to test every 
pair with both assays.
533 Laboratory methods
All laboratory testing was carried out by one clinical scientist (David Williams). 
Dried blood spots were prepared by mixing serum in a 1:1 ratio with rubella IgG 
negative red cells to simulate whole blood. This mixture was spotted in 100 pi 
aliquots onto Schleicher & Schuell 903® filter paper and allowed to air dry 
overnight at room temperature. Cards were punched into 4.9 mm spots, the same 
dried blood spot punch size as used in the unlinked anonymous HIV surveillance 
programme (see section 5.4.2.2 below). The punches were placed in 96 well plates 
and eluted overnight in 100 pi PBS-Tween buffer at 4°C. Since the concentration 
of antibody in eluates from dried blood spots is considerably lower than in serum, 
the amount of dried blood spot eluate required for the two assays was evaluated in 
a small pilot study by varying the volume of eluate until the slope of antibody 
levels in serum to dried blood spots was close to 1. This is illustrated in Table 5.1.
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Dade Behring (n=15)
Eluate volume Slope Correlation coefficient (r)
25 ill 0.859 0.787
30fd 1.034 0.938
35|jI 1.319 0.897
40pl 1.227 0.914
50jil 1.942 0.910
Diesse (n=8)
Eluate volume Slope Correlation coefficient (r)
25pl 0.3875 0.8828
50fd 1.0069 0.9564
Table 5.1.Correlation of rubella IgG antibody level in serum and dried blood spot samples 
by dried blood spot eluate volume
The samples included in this pilot study were not included in the main validation 
study or in further analyses. Testing was thus performed using eluate volumes of 
30pl for the Dade Behring ELISA and 50pl for the Diesse ELISA as they yielded 
slopes closest to unity.
53.4 Measurement of rubella IgG antibody levels
The international standard for measuring rubella antibodies is international units 
per millilitre (IU/ml) 185. However, following the completion of an ELISA 
procedure, the uncalibrated results are given as optical density (OD) values, which 
are then adjusted for inter-plate variation. Test results (i.e. positive, equivocal and 
negative) can be obtained using cut-off values stated as adjusted OD values 
(known as a qualitative result). Alternatively, the optical density values can be 
calibrated into IU/ml and the results determined using cut-off values in IU/ml. It 
follows that whereas calibrated antibody levels in IU/ml are comparable and not 
assay dependent, optical density values, although adjusted for inter-plate 
variation, are not.
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In the case of the Diesse ELISA, correction for inter-plate variation is achieved by 
testing a blank sample in each plate as well as four reference samples provided by 
the manufacturer with known antibody levels (5, 10, 50 and 100 IU/ml 
respectively). Qualitative results adjusted for inter-plate variation are obtained by 
first subtracting from each optical density reading the optical density reading of 
the blank sample tested in the same plate, and secondly dividing this corrected 
value by the optical density reading of the plate control sample with a known 
antibody level of 10 IU/ml. The qualitative result is referred to as an optical 
density (OD) ratio. OD values can be calibrated into antibody levels in 
international units per millilitre (IU/ml) using a calibration curve, which is 
constructed from the four plate-specific reference samples. According to the 
manufacturer’s instructions, an antibody level of <7 IU/ml is indicative of a 
negative result (ie. possibly indicating susceptibility to rubella), antibody levels 
between 7 to 13 IU/ml are equivocal and an antibody level >13 IU/ml is positive. 
For qualitative analyses, an OD ratio of <0.7 corresponds to a negative result, OD 
ratios of between 0.7 and 1.3 indicate of an equivocal result, and an OD ratio >1.3 
implies a positive result.
For the Dade Behring ELISA, each sample is tested in with rubella antigen and 
control wells (no antigen). One reference sample per plate is also tested. The 
qualitative results are obtained by first deducting from the optical density reading 
of the tested sample the optical density reading of the corresponding control
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sample. This difference is referred to as AA. In order to obtain the qualitative 
results, the AA value for each sample is then multiplied by a correction factor, 
which is derived by dividing a batch-specific reference value by the AA for the 
reference sample. The manufacturer recommends that a sample with a corrected 
AA <0.1 is considered negative, 0.1 < corrected AA < 0.2 are equivocal and a 
corrected AA> 0.2 are positive. Antibody levels in IU/ml were obtained using the 
following formula:
IUIml =  10“*' Equation 3
where a and p  are plate-specific constants provided by the manufacturer for each 
batch of kits. If calibrated with a -  1.72 and p  = 0.46, which were the constants 
supplied by the manufacturer for the kits used in this study, the qualitative cut-off 
values stated above for a negative and positive sample are equivalent to calibrated 
values of <4 IU/ml and >7 IU/ml respectively. The equivocal range is between 4 
and 7 IU/ml.
53.5 Statistical methods
Since ELISAs can be unreliable for antibody levels above the highest control 
sample provided (>100 IU/ml for the Diesse ELISA) and low antibody levels are 
of greatest clinical significance, the analyses were limited to sample pairs with 
both serum and dried blood spot antibody levels less than 100 IU/ml. For each 
assay, the Pearson correlation coefficient (r) between antibody level in the serum
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and dried blood spot samples, as well as the proportion of serum and dried blood 
spot samples with positive, equivocal and negative results were calculated. 
Sensitivity and specificity were calculated using test result in serum as the gold 
standard. Since an equivocal result was given for both ELISAs, two estimates for 
each sensitivity and specificity were calculated, with equivocal samples classified 
as negative or positive respectively.
Correlation coefficients alone are not useful indicators of agreement. The Pearson 
correlation coefficient r can be expected to be high when the same quantity, such 
as antibody level, is measured in paired samples. However, it does not measure 
agreement, as it only indicates a linear relationship between the two variables, and 
as such could still be high despite poor numeric agreement due to 
heteroscedasticity or a change in scale o f one of the variables27*316. The relation 
between the mean and the difference in antibody level in the paired samples was 
therefore used instead to assess agreement between the two sample media, as 
suggested by Bland and Altman274. The proportion of samples with differences 
larger than two standard deviations (SDs) of the mean difference was used as an 
indicator of agreement. Statistical analyses were carried out using the R statistical 
software version 2.2.1317.
5.3.6 Sample size calculation
There was no previous information about the magnitude of the variability of the 
mean of the differences between the two measurements for the two ELISAs that
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were used in this study. However, an important aspect of the Bland-Altman 
method is the precision attained in the confidence limits for the mean of the 
differences. If s denotes the SD of the differences, and d is the mean difference,
the method establishes that the standard error of d ± 2s is approximately ^3s 2 In 
and if n equals 70, a standard error of around s/5 is obtained regardless of the 
magnitude of s. A sample size over 70 should therefore provide an adequate level 
of precision.
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5.4 Methods of the rubella serosurvey
5.4.1 Population
The serosurvey of maternally acquired rubella antibody was carried out on 
newborn dried blood spot samples received in the North Thames newborn 
screening laboratory in 2004.
5.4.1.1 Newborn screening in North Thames
All newborns in the UK are offered screening for a number of inborn conditions, 
including phenylketonuria (PKU) and congenital hypothyroidism at seven to ten 
days of age (five to eight days of age since April 2005)246. The newborn screening 
programme is regionally organised, with 17 screening laboratories across the four 
UK countries. Three newborn screening laboratories cover babies bom in London 
and the surrounding counties: North Thames (Great Ormond Street Hospital), 
South East Thames (Evelina Children’s Hospital) and South West Thames (St 
Helier Hospital). The samples used in the rubella serosurvey were from the North 
Thames Screening laboratory, which in 2004 covered five Strategic Health 
Authorities (SHAs): Bedfordshire and Hertfordshire, Essex, North Central 
London, North East London and North West London. This area corresponds to the 
previous Regional Health Authorities of North West and North East Thames. 
Figure 5.1 shows the SHAs and Primary Care Trusts (PCTs) in the North Thames 
area as of 2004.
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]  Bedfordshire and Hertfordshire SHA
|  Essex SHA | | North Central London SHA
]  North W est London SHA North East London SHA
1. Bedford
2. Bedfordshire Heartlands
3. Luton
4. North Hertfordshire & Stevenage
5. South East Hertfordshire
6. Royston, Buntingford & Bishop’s 
Stortford
7. Uttlesford
8. Witham, Braintree & Halstead
9. Colchester
10. Tendring
11. Dacorum
12. St. Albans & Harpenden
13. Welwyn Hatfield
14. Harlow
15. Epping Forest
16. Chelmsford
17. Maldon & South Chelmsford
18. Watford & Three Rivers
19. Hertsmere
20. Enfield
21. Waltham Forest
22. Redbridge
23. Havering
24. Billericay, Brentford & 
Wickford
25. Basildon
26. Castle Point & Rochford
27. Hillingdon
28. Harrow
29. Barnet
30. Haringey Teaching
3 1. Newham
32. Barking & Dagenham
33. Thurrock
34. Soutend on Sea
35. Hounslow
36. Ealing
37. Brent Teaching
38. Hammersmith & Fulham
39. Kensington & Chelsea
40. Westminster
41. Camden
42. Islington
43. City & Hackney Teaching
44. Tower Hamlets
Source: Office for National Statistics318
Figure 5.1. The Primary Care Trusts and Strategic Health Authorities in North Thames in 
2004
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The North Thames Newborn Screening Laboratory is located in the Chemical 
Pathology department at Great Ormond Street Hospital. Although the vast 
majority of newborns in the North Thames area are screened at this laboratory, 
some children, although bom and resident in PCTs in the North Thames area, 
have their samples sent to a different laboratory, usually for historic reasons. For 
example, midwives attached to the Chelsea and Westminster Hospital maternity 
unit send their samples to the South West Thames Newborn Screening 
Laboratory, despite covering births in the North Thames region. Likewise, a small 
number of samples from South East and South West Thames areas are sent to the 
North Thames Newborn Screening Laboratory.
5.4.U Characteristics of the population
The population of the North Thames area was approximately 7 750000 in the 2001 
Census319. It is a highly ethnically diverse population, with a large proportion of 
people bom outside the UK. Figure 5.2 shows the proportion of people by ethnic 
group in North Thames in 2001 and in England and Wales for comparison. Figure
5.3 shows the proportion of people bom outside the UK in the different SHAs of 
North Thames in 2001, and in England and Wales for comparison.
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■ White 
B Mixed
□ Asian
□ Black
b Chinese/other
B White 
a Mixed
□ Asian
□ Black
B Chinese/other
Note: white includes white British, white Irish and white other, Asian includes Indian, Pakistani, Bangladeshi and Asian 
other, black includes black Caribbean, black African and black other.
Adapted from Office for National Statistics320.
Figure 5.2. Percentage of the population by ethnic group A) North Thames and B) England 
and Wales, 2001 Census.
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North West London 
North Central London
North East London
Hertfordshire and 
Bedfordshire
Essex 
England & Wales
0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0%
Adapted from National Centre for Health Outcomes Development321
Figure 53 . The percentage of the population born abroad by SHA in North Thames, and 
England and Wales, 2001 Census.
The proportion of people with black or minority ethnic background and the 
proportion bom abroad also vary by Primary Care Trust within North Thames. 
For example, in Brent Teaching PCT in 2001, 70.8% of the population were from 
a non-white British ethnic group and the proportion bom outside the UK was 
53.4%. In comparison, in Maldon and South Chelmsford PCT, only 3.6% of the 
population were from a non-white British ethnic group and 96.4% of the 
population were bom in the UK 321.
There are over 100,000 births in the North Thames area each year, accounting for 
approximately one sixth of the births in England. The total period fertility rate 
(TPFR) in North Thames varies by SHA, and some of the lowest, as well as the 
highest fertility rates in the country can be found in this area. The highest TPFR in
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North Thames is in North East London SHA, with 2.07 children per woman, and 
the lowest in North Central London SHA with 1.68 children per woman. The 
TPFR in England and Wales is 1.78 children per woman322. As ethnicity is not 
recorded on the birth registration form, it is not possible to obtain ethnic group 
specific TPFR323.
5.4.13 Uptake of newborn screening
Two audits of the national screening programme, covering the periods 1984 to 
1988 and 1994 to 1998, showed that only one case of PKU was missed of a total 
of 1183 cases, indicating screening coverage of around 99.9%324:325. Several 
regional or local audits326-330 estimating the coverage of newborn screening were 
published during the 1990s. In these audits, the estimate of coverage of newborn 
screening varied from 85.1% in the Riverside Health Authority in West 
London327, to 99.9% in Bath326. These studies were based on matching babies 
screened in a particular area with maternity records or records of the number of 
registered newborns held by Child Health Records Departments (CHRD). A 
difference in screening coverage by ethnic group in West Lambeth and 
Camberwell was reported in a 1994 study328. In this study, screening coverage of 
96.3% was reported for the whole population, yet coverage for children of a white 
ethnic background was 98.5% compared to 95.6% for children of a black African 
ethnic background; these differences were not statistically significant however. 
Children without screening test results were assumed not to have been screened, 
after exclusion of children who had died or moved away. The odds ratio of not
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having a screening test result, comparing white and black African children was
3.1 (95% confidence interval 1.3 to 7.1), but this result was no longer significant 
after adjusting for mobility and district of residence. However, the authors also 
stressed that the CHRD database, which was matched against the screening 
records, was not up to date. For example, nearly a quarter of children who were 
registered as bom and resident in the district had moved away.
The most recent published study assessing coverage of newborn screening was 
published by Ades and colleagues331, who questioned the methodology of 
previous studies, claiming study areas had been small, and pointing out the 
difficulties in using screening laboratory records to measure coverage. In their 
study, Ades et al estimated screening coverage in the North East Thames area, 
using linkage between CHRD computer files and newborn screening laboratory 
electronic records. They identified 746 apparently untested infants out of 91743 
children registered in the CHRD for the North East Thames area (indicating 
99.2% coverage). A further 893 cards had been tested but had not been matched 
to a CHRD record, probably since the children had moved away. They conclude 
that apparently low screening uptake could be due to incomplete recording of 
results, rather than lacking coverage of the newborn screening programme.
The UK Newborn Screening Programme Centre, set up in 2002, carries out annual 
surveys of screening laboratories to assess coverage of newborn screening332. 
Data are requested from screening laboratories on the number of babies tested,
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and the number of babies bom and resident for whom the CHRD are responsible 
is requested from each PCT. However, in 2006 to 2007, only 101 of 152 PCTs 
(66.4%) in England returned data on the number of babies bom and resident. In 
the London SHA (which includes the former North West, North East and North 
Central London SHAs), only 8 of 31 (25.8%) PCTs returned data, making 
accurate coverage estimates difficult. In the East of England SHA, which now 
comprises the former Bedfordshire and Hertfordshire and Essex SHAs, all PCTs 
submitted data on the population of babies bom and resident, and 97.9% of babies 
bom and resident had a screening test result or parental decline of screening 
recorded.
5.4.2 Samples
5.4.2.1 Screening sample collection & tests
The newborn screening sample is a whole blood sample, collected from the heel 
of the baby as dried blood spots on a filter paper card, as depicted in Figure 5.4.
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Figure 5.4. Newborn baby having a blood spot screening sample taken.
Demographic and medical information is also recorded on the screening card. The 
screening samples are most often taken in the home by a midwife or health visitor. 
The blood spot card is air dried before it is sent by post to the screening laboratory 
in a glassine envelope. It is recommended that the samples are sent to the 
screening laboratory within 24 hours of collection246. Figure 5.5 shows a blank 
newborn screening card.
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Figure 5.5. Blank newborn screening blood spot card.
Once the card is received in the screening lab, the data collected on the screening 
card are entered into an electronic database. Specimens are punched out from the 
blood spots into discs, 4.9 mm in diameter, and tested for phenylketonuria, 
congenital hypothyroidism, and haemoglobinopathies, and from 2007 also cystic 
fibrosis. The data on the screening card are linked to the screening specimens by a 
laboratory ID number.
5.4.2.2 HIV testing and data linkage
Following completion of routine newborn screening, an extra sample is punched 
from each screening card into 96-well plates, which are anonymously tested for 
HIV as part of the newborn unlinked anonymous HIV surveillance programme, 
which is managed by the HPA, in North Thames jointly with the UCL Institute of 
Child Health (ICH). This programme was initiated at ICH in 1988266 and now
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runs in six screening laboratories in England covering nearly 400,000 newborns 
annually. As part of this programme, a robust algorithm has been set up through 
which the electronic files containing the data collected on the screening card and 
birth registration records held by the ONS are matched. The subsequent unlinking 
of identifiers ensures anonymity and confidentiality and it is not possible to relate 
an HIV test result to a mother or her baby.
Data linkage and HIV testing take place in quarterly cycles. The data linkage 
algorithm for the North Thames screening laboratory is summarised in the 
flowchart in Figure 5.6.
Newborn baby
Identifiers
irreversibly
deleted
Enhanced file
HIV antibody testing
Demographic file
Variable processing
Data linkage (using plate 
and well position)
Data linkage to  birth 
registration data
Health Protection Agency (HPA)
HPA
Institute of Child 
Health (ICH)
Office for National Statistics
Punch file
Newborn screening laboratory
Blood spot card
Figure 5.6 Data linkage algorithm used for the newborn unlinked HIV surveillance 
programme in North Thames
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Every quarter, a file from the screening laboratory, containing the information 
collected on the newborn screening card, and a punch file with numbers of the 
plates and wells containing the samples and laboratory ID numbers are sent to the 
HPA. There, the datasets are cleaned and the punch file and newborn screening 
file are linked using the laboratory ID number. This screening laboratory data file 
is then sent to ONS, where it is matched using a robust algorithm to birth 
registration records, thus providing information on maternal and paternal country 
of birth. A summary of the data linkage algorithm can be found in Appendix B. 
Linkage is normally achieved for over 95% of samples265^ 67. After data linkage 
has been completed, all identifying information, including laboratory ID number, 
names and addresses, is irreversibly deleted and other data items, such as mother’s 
and child’s date of birth, are downgraded to age in integer years and child’s year 
of birth respectively. Post codes are downgraded and mapped onto PCTs, local 
authorities and SHAs. Plate and well numbers are retained. The enhanced 
demographic data file is then returned to the HPA. It is only after identifying 
details have been removed, that testing for HIV antibody is carried out. Samples 
collected and screened in the North Thames area are tested for HIV at ICH. 
Following completion of testing, the HIV test results are matched to the enhanced 
demographic data file using plate and well numbers as unique identifiers.
The data items contained in the newborn screening laboratory dataset, the 
enhanced dataset and the proportion of linked samples with complete data in 2004 
can be found in Table 5.2.
165
Newborn screening dataset Enhanced dataset Completeness in 
enhanced dataset 
in 2004
Child’s name Child’s year of birth 99.8%
Child’s date of birth Maternal age in whole years 49.5%
Child’s address including post Mother’s country of birth 97.1%
code
Mother’s name Father’s country of birth 91.0%
Child’s NHS number PCT where resident at delivery 97.1%
Birth weight Local authority where resident at 99.8%
delivery
Sex SHA where resident at delivery 99.7%
Mother’s date of birth HIV test result/opt out/insufficient 100%
sample
Birth location (hospital) Plate 99.7%
Ethnic group Well 99.7%
Type of match 100%
Table 5.2. Data items in the screening dataset, the enhanced dataset and completeness in the
enhanced dataset in 2004.
In 2004, 316 of 106934 samples in the enhanced dataset did not have a correct 
plate and well number recorded (0.3%). In addition, maternal age was missing 
from 54002 of the samples (50.5%). Since these data were nearly complete in the 
newborn screening dataset (in which only 4.2% of entries lacked data on maternal 
date of birth), they appear to have been lost during the data linkage process. In the 
second quarter of 2004, maternal age was missing from 100% of samples, 
whereas in the other three quarters, the proportion of cases with missing maternal 
age varied between 32.3% in quarter one to 34.1% in quarter three. It was not 
possible to check the accuracy of the data linkage algorithm to investigate why 
such a large proportion of maternal ages had been removed, as the two databases 
are linked through a secure third party (ONS) and they cannot be re-matched due 
to the subsequent deletion of the identifiers.
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5.42 3  Sampling
Sampling for the rubella serosurvey was carried out from plates containing eluted 
dried blood spot samples, stored frozen at -20°C following HIV testing in 2004. 
Since these samples were already linked to birth registration data, analyses of 
rubella IgG antibody levels by maternal characteristics were possible. The 
sampling unit in this study was the 96-well plate, since it was not possible to 
select individual samples for inclusion for logistic reasons as samples were tested 
plate-wise. Since specimens are punched into plates in the order they arrived in 
the screening laboratory, and midwives often post screening cards in batches, 
samples tend to be clustered by plate according to the area of residence of the 
mother.
Samples received in the screening laboratory in the second quarter of 2004 were 
excluded from sampling due to the lack of maternal age data. In addition, around 
75% of plates from the third quarter of 2004, and all plates from the fourth quarter 
of 2004 had been discarded due to repeated problems with the freezer in which 
they were stored. This left 385 plates from quarter one and quarter three of 2004 
for sampling. Sampling from the available plates containing samples collected in 
the third quarter o f 2004 was initially carried out for a pilot study to ascertain the 
validity of the laboratory and statistical methods. The 22 plates included in the 
pilot study were randomly sampled by plate number, using random numbers 
generated by the sa m p le  function in the R statistical software, version 2.5.1317.
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The plates containing samples received in the screening laboratory in the first 
quarter of 2004 constituted the sampling frame for the main study. A random 
sample of plates was taken, using the same method as in the pilot study. The final 
sample consisted of 220 plates (including the initial pilot sample), containing 
19781 of the approximately 55,600 samples (around 36%) that were tested for 
HIV in quarters one and three of 2004. The standard errors for the proportion of 
seronegative samples were consequently adjusted for cluster sampling on plate, 
using the svy command in STATA version 9.0333.
5.4.2.4 Sample size calculation
The sample size calculation was based on two different approaches. For the 
purposes of research ethics review, it was based on a previous study by Tookey et 
al172, with the approach of estimating the proportion of Sri Lankan women 
susceptible to rubella with a specified standard error. This group had the highest 
prevalence of rubella susceptibility identified in that study, 14.9%. It was 
estimated that around 20000 newborn dried blood spot samples were required to 
achieve 95% confidence intervals for the prevalence of rubella susceptibility with 
a precision to within 2.5% of the value of the estimated prevalence among Sri 
Lankan pregnant women, taking into account the proportion of women bom in Sri 
Lanka in the antenatal population.
A second approach was based on the results of the pilot study in which the rubella 
antibody levels in 1964 specimens were analysed. Since a primary aim of this
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serosurvey was to investigate differences in rubella susceptibility between UK- 
born and migrant women, the power achieved was simulated using varying 
sample sizes in the estimation of the difference in the proportion seronegative, 
(defined as an antibody concentration of less than 5 IU/ml) between groups of 
women bom in different world regions. This definition of rubella seronegativity 
was chosen for the sample size calculation, since it yielded the lowest proportion 
of samples classified as seronegative in the pilot study. As shown in Figure 5.7, 
using a sample size between 15000 and 20000 samples would achieve over 95% 
power in detecting a difference significant at the 95% level between the 
proportions of women seronegative to rubella in different groups.
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Figure 5.7. Power achieved for different sample sizes when detecting differences in the 
proportion of rubella seronegative women by region of birth.
Available funds for this study precluded obtaining the sample sizes required to 
achieve enough power to investigate differences among non-UK bom groups in 
more detail.
5.4.3 Laboratory m ethods
Two extra samples were punched from all newborn blood spot cards sent to the 
screening laboratory between 1999 and 2006 as part of a study to determine the 
HIV-1 subtype in HIV-positive samples from the newborn unlinked anonymous 
HIV surveillance programme334. As part of the HIV testing protocol, dried blood 
spot punches are placed in 96-well plates, and eluted in 170 pi PBS-Tween 20
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solution. Following HIV tests, dried blood spot eluates were kept at -20°C for up 
to 20 months before rubella IgG antibody testing. A small number of freeze-thaw 
cycles has not been found to have a significant effect on rubella IgG antibody 
levels in serum335. A commercial ELISA (Diesse, Siena, Italy) was used to test for 
rubella IgG antibody following validation for use on dried blood spot samples, as 
described in section 5.3 and chapter 6. 50 pi of dried blood spot eluate was tested 
for rubella IgG antibody according to the manufacturer’s instructions. Testing was 
carried out in the Great Ormond Street Hospital Virology Laboratory by one 
clinical scientist (David Williams).
5.4.4 Statistical methods
Before any statistical analyses were carried out, rubella IgG test results for HIV 
positive samples were excluded, since the remaining dried blood spot eluate had 
been used for confirmatory HIV testing267. In addition, samples which had been 
marked as having insufficient blood spot material for HIV testing, and those for 
which parents had opted out of newborn screening or HIV testing were also 
excluded since in these cases a blank sample is punched into the well plates. All 
samples which did not have an entry in the enhanced dataset were also excluded 
from analyses, as they are repeat screening samples.
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5.4.4.1 Latent class regression finite mixture models
In order to avoid using pre-defined cut-off values, which may be difficult to 
interpret when alternative samples, such as dried blood spots are used, latent class 
regression finite mixture models were fitted to the natural logarithm of the optical 
density ratios (ln(OD ratio)) to analyse rubella antibody level. The calibrated 
antibody concentrations in IU/ml were not used, partly since the distribution of 
IU/ml values was left-censored at 3 IU/ml, and partly since calibrated antibody 
levels can only take integer values. The ln(OD ratio) values were not further 
categorised but kept as a continuous response variable (unlike for example the 
method employed by Gay et al223 and Vyse et al165). The natural logarithms were 
used in order to amplify the range of OD ratios between 0 and 1, which is of 
largest epidemiological and clinical significance, and to correct the right-skew of 
the distribution of OD ratios. Low OD ratios are indicative of seronegative status.
The models fitted were latent class regression finite mixture models of the form
f ( y )  = 2 X ( « i ( * i  A» ) ) f k ( y i g 2(X 2 Plk)<gl (x i A t )) Equation 4
*=1
where y is antibody level, K  is the number of components, Xj, X2 and X3 are 
design matrices for the linear predictors in the component weights (tt), the 
location and scale parameters of the fc-th component respectively. {j3lk} are the
parameters for the linear predictor in each component weight, and {fi2k} and
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{ / U  are the location and scale parameters. g i,g 2 and gs are the generalised logit, 
identity and logarithmic link functions which were used to fit the regression 
parameters for the component weights, location and scale.
The f le x m ix 336 and g a m lss .m x 337 libraries in the R statistical software 
version 2.6.0 317 was used to fit the models in this class. Both libraries use an 
expectation-maximisation (EM) algorithm that uses maximum likelihood (ML) 
methods to estimate the model parameters. The latter package was used to fit 
models with covariates for the scale parameter, since this was not allowed by the 
f l  exm ix  library. Both libraries calculate the probability of belonging to each 
component for every observation, known as posterior probabilities. The 
probability that observation j  belongs to component i is given by Bayes rule:
P rfl A . f l ]  =
Equation 5
(#1 (^1  A* )) /* ( ? ;  » (%2 &2k )»#3 (-^3 A * ))
where i = 1 ,2 ,...,# . This expression was used to assign each observation to the 
component with the maximum posterior probability.
The diagnostic tools provided by these R libraries were used to check the models’ 
goodness of fit properties. The model selection strategy was based on the 
Bayesian Information Criterion (BIC)310;338 defined as
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B1C =  p ln (n )-2 1 n  L i f t ,  J32j 3) Equation 6
where L is the value of the likelihood evaluated at the ML estimates ( $ ,  > A ) *
p  is the number of parameters in the model and n is the number of independent 
observations. The BIC is more conservative against oveiparameterisation than 
other model selection criteria, which is particularly important when fitting mixture 
models as the number of components in the optimal model may otherwise be 
overestimated. The Akaike’s Information Criterion (AIC), defined as
AIC =  2 /?-21n L (y§1,y§2> A) Equation7
is also presented for comparison.
Two approaches were taken to examine overlap of the optimal mixture model’s 
components. First the degree of overlap, defined as the probability of an 
observation lying in a region where the densities of two components coincide was 
calculated. Let fj and f 2 be two normal density functions, with means pi and P2  
and SDs 07 and 0 2  respectively, where pi > p.2 , then the point(s) of intersection of 
these two densities, c, can be found by assuming f i  = / 2, i.e.
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4 2 k <Jx
exp - ( y - M i )
2 a \
2 \
42k CF'
exp - ( y - M  2)
2 \
2<j;
Equation 8
and solving for y. It can be shown that there are two solutions if o x *  o 2 and one 
solution if o l = o 2. The total area of overlap between the two densities, a, is the 
sum of the area o f overlap under f j  and f2, denoted as aj and a2 respectively, ai 
and a2 can be calculated as follows:
2<r12
d y
2 a \  j
d y
Equation 9
Equation 10
Thus the total overlap a is equal to
a, — +  cl2 Equation 11
Second, rootograms were plotted to obtain a graphical representation of the degree 
of separation and homogeneity of the mixture model components. In a rootogram, 
which is similar to a histogram, the jc-axis represents posterior probabilities for a 
particular mixture model component, and the y-axis the square root of the counts 
of the number of samples310. Consequently the larger frequencies are weighted 
down and the lower counts are highlighted in the rootogram. A large number of 
observations with low posterior probability imply a well defined component,
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whereas a large number of observations with posterior probabilities near one 
imply components which are highly homogeneous. This graphical representation 
ignores samples with a posterior probability for any particular component smaller 
than 0.001%, thus excluding observations which have a probability close to zero 
for a particular component. Inclusion of these observations may hide the number 
of observations with higher posterior probabilities for a particular component310.
Using latent class regression finite mixture models to define a seronegative 
population
As a first approach to examining the influence of maternal characteristics on 
rubella IgG antibody levels in pregnancy, latent class regression finite mixture 
models without covariates were initially fitted to the full distribution of ln(OD 
ratio) values assuming Normal and gamma distributions for the components and 
allowing for up to five components for each model. The goodness-of-fit of these 
models was compared using BIC. In order to fit gamma-distributed components, a 
constant was added to the ln(OD ratio) values to ensure they were positive. Each 
mixture model was fitted with up to five components, and in order to avoid the 
EM algorithm converging to local, rather than global maxima, each model with 
each number of components was fitted three times.
The aim of these analyses was to define a population of samples seronegative to 
rubella. Samples assigned to the component of the optimal mixture model with the 
lowest mean, based on the posterior probabilities, were assumed to be
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seronegative. This approach was used to define a binary outcome variable for the 
logistic regression models, aimed at identifying independent predictors for 
maternal rubella seronegative status. These models are described in detail in 
section 5.4.4.2. Results of these analyses are shown in chapter 7.
Including maternal characteristics as covariates in the latent class regression 
finite mixture models
A second approach was to circumvent defining a seronegative population, and 
instead investigate the effect of maternal characteristics on the component 
weights, location and scale directly, by including in the latent class regression 
finite mixture models maternal region of birth, age and SHA of residence at 
delivery as linear predictors for these parameters. For these models, maternal 
country of birth was coded into seven world regions (Sub-Saharan Africa, North 
Africa and West and Central Asia, South Asia, South East Asia and Oceania, UK, 
other Europe, Americas) and PCTs into Strategic Health Authorities 
(Bedfordshire and Hertfordshire, Essex, North East London, North Central 
London, North West London, outside North Thames, and not known). The 
countries classified into each world region can be found in Appendix C. Maternal 
age was kept as a continuous variable, and since there was some evidence of an 
inverse u-shaped relationship between maternal age and antibody level, a 
quadratic term for maternal age was also included to investigate if this improved 
the models’ goodness-of-fit.
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The exclusion criteria for these models were as follows:
•  Samples for which the maternal region of birth was stated as not known/not 
stated were excluded, as data linkage was unsuccessful for these samples (n = 
558).
•  Samples for which the maternal PCT of residence at delivery was coded as 
unknown were excluded (n = 132), as the small number of observations in this 
group prevented the models from converging.
Normal distributions were assumed for the components of these mixture models. 
The latent class regression finite mixture models were first constructed with 
covariates for either the component weights, means or standard deviations, 
without including covariates for the other two parameters. Covariates were added 
in a systematic forward step-wise procedure, first including individual variables, 
then combinations of variables, and finally interaction terms for the different 
combinations of covariates. Each model was fitted including between two and 
five components, and each model’s parameters were estimated three times to 
avoid the EM-algorithm converging to a local maximum. Again, the optimal 
model was that which minimised BIC. The optimal models with covariates for the 
component weights, means or standard deviations were then refitted with single 
covariates for the other parameters. That is, the model with covariates for the 
component weights with the lowest BIC was refitted with single covariates for the 
location and scale, and vice versa. The results of these models are presented in 
chapter 8.
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5.4.4.2 Logistic regression models
As outlined above, the outcome variable for the logistic regression models was 
rubella seronegative status, defined as allocation to the component with the lowest 
mean of the optimal mixture model fitted to the complete distribution of samples, 
without covariates. Maternal country of birth was coded into eight categories as 
for the mixture models described in section 5.4.4.1. Maternal age was classified 
into five categories (less than 20, 20 to 24, 25 to 29, 30 to 34 and 35 and above).
The exclusion criteria for the logistic regression models were as follows:
• Samples for which maternal region of birth were coded as missing or not 
known were excluded (n = 558). Data linkage was unsuccessful for these 
samples (see section 7.1). Since the aim of these analyses was to identify 
independent risk factors for maternal rubella seronegative status in pregnancy, 
inclusion of this group was deemed to have little informative value.
• Samples for which maternal SHA of residence at delivery was coded as
missing or not known were excluded (n = 132), since the small number of
samples in this group led to collinearity in the logistic regression model.
• Samples for which maternal SHA of residence at delivery was coded as
outside North Thames (n = 340) were also excluded since this resulted in
collinearity when interaction terms were included.
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Logistic regression models were fitted to examine the independent effect of 
maternal region of birth on rubella seronegative status, with maternal age group, 
SHA of residence and interaction terms included in a forward step-wise 
procedure. The optimal logistic regression model was refitted as a mixed effects 
model, with a random effect on plate, to investigate whether fit improved. The 
significance of exposure variables and interaction terms was compared using the 
AIC. The BIC was deemed to be too conservative, since the aim of these analyses 
was to identify independent predictors of rubella seronegative status in pregnancy. 
All logistic regression and mixed effects models were fitted in STATA 9.0333.
5.4.4.3 Multiple imputation
Since maternal age was missing from a large proportion of samples following data 
linkage, this variable was imputed with multiple imputation using chained 
equations (MICE) 339, using the m ice  library in R, which allows a conditional 
distribution to be specified for the missing data, based on other non-missing data. 
The package then constructs and executes a Gibbs sampler for this conditional 
distribution. It was assumed that maternal age values were missing at random. 
Maternal age values were imputed as a linear regression function of maternal 
country of birth, area of residence, ln(OD ratio) and mixture model component 
(from the mixture model fitted to the full distribution without covariates). 
Maternal age was imputed five times, creating five different full datasets. The 
distributions of maternal ages before and after imputation, as well as the original 
distribution of maternal ages from the newborn screening dataset were compared
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using Kolmogorov-Smimov tests. The logistic regression models were carried out 
separately for each dataset, then combined using the mijoin and mim 
commands340,341 in Intercooled STATA 9.0333, which implement the method for 
combining models from multiply imputed datasets suggested by Li et al342. For 
the mixed effects model, the intraclass correlation coefficient p  was combined 
from the multiply imputed datasets using the method suggested by Rubin343 for 
scalar quantities. The notation follows that of Carlin et al341.
If Q is a scalar quantity, such as a point estimate of a regression coefficient, the
multiple imputation point estimate of Q is simply the average of Q in the multiple
imputation datasets:
  1 m ^
Q —— ]T i2 (,) Equation 12
™  i = 1
Where m is the number of imputed datasets and Q(i) is the point estimate of the 
coefficient in the ith imputed dataset.
The within-imputed dataset variance is defined as:
1 m
W — — Y l7 (,) Equation 13
m i=l
Where l / l) is the estimated variance of the coefficient in the ith imputed dataset, 
and the between imputed dataset variance is:
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B = — (^(Q m-QY  
m - 1 i=1
Equation 14
The total variance T is then given by:
T = W + ( l+ —)B 
m
Equation 15
Rubin 343 shows that:
Where:
y -  (m - l) j l+  —----- 1
{ (l + l/m )R j
Equation 16
Equation 17
and t y is the area under Student’s /-distribution on y  degrees of freedom. 
Confidence intervals can therefore be derived for Q as follows:
Q + trai2'Jr Equation 18
It was not possible to carry out multiple analyses for the latent class regression 
finite mixture models with covariates, as they are computationally expensive. 
Therefore, only one, randomly selected imputed dataset was used for these 
analyses.
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5.4.4.4 Quality control
Variation in the mean ln(OD ratio) values by plate were checked using Shewhart 
plots. ln(OD ratio) values by plate were calculated, and plotted in the order of 
date and time of testing. Control limits for the means were obtained using the 
following equation:
Where 3c is the mean ln(OD ratio) across all plates, 1, 2 ... k are the plates in the 
order of testing, o  is the SD of all observations, and n* the sample size for plate 
k. Plates with means or SDs below or above control limits were checked for 
maternal country of birth distribution.
5.4.4.5 Ecological analysis of rubella seronegative status and MMR 
uptake
Maps showing the proportion of pregnant women seronegative to rubella by PCT 
were created using the m a p to o ls  library344 in R version 2.6.0317. Boundary data 
for 2004 SHAs and PCTs was obtained from UKBORDERS179 and the Office for 
National Statistics318. Data on first dose MMR uptake in 2003/2004 and 
2004/2005 was obtained from the NHS Health and Social Care Information 
Centre134;345. The average MMR vaccine uptake for these two years was 
calculated to estimate MMR uptake in 2004. Since this year, Child Health
Equation 19
183
Records Departments in nine London PCTs have not been able to submit data on 
vaccine uptake due to ongoing problems with their computing system.
Possible spatial autocorrelation in rubella seronegative status in pregnant women
whether observations near to each other in space are correlated. It is defined as
where N is the number of spatial units with indices i and j, are a matrix of 
spatial weights, taking the value of 1 if two locations are neighbouring, and 0 if 
they are not. X is the observation of interest, and X is the mean of X. Moran’s I 
statistic varies between -1 and 1, where -1 indicates negative spatial 
autocorrelation, 1 indicates positive spatial autocorrelation, and 0 no spatial 
autocorrelation347.
In order to assess whether low levels of MMR uptake and high proportions 
seronegative women coincided at PCT level in 2004, the correlation between 
prevalence of maternal rubella seronegative status and MMR uptake in children 
by 24 months at PCT level was investigated by estimating the Pearson correlation 
coefficient r with 95% confidence intervals. A simple linear regression model was
was estimated using Moran’s I statistic, using the sp d ep  library346 in R version 
2.6.0317. Moran’s I statistic is an indicator of global spatial autocorrelation, that is
i___ j Equation 20
i  j
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also fitted to investigate the relationship between MMR uptake among children 
and the proportion of women seronegative to rubella at PCT level.
5.4.4.6 Estimation of the number of births to rubella seronegative 
women in England
The proportion of seronegative women in each region of birth and age group was 
projected to the total number of births in England by Government Office Region 
in order to estimate the number of births in England to women seronegative to 
rubella, using a method similar to that employed by Ades et al254 in a study of 
hepatitis C prevalence in pregnant women. The number of registered births in 
England 2004 by maternal region of birth and age group was obtained from the 
ONS348. For these analyses, maternal region of birth was coded into a nine 
category variable, created from the 22-category maternal region of birth variable 
into which live birth data from the ONS is coded. The categories for this variable 
were: Great Britain (i.e. England, Wales and Scotland), South Asia, West Africa, 
East Africa, rest of Africa, the Americas and the Caribbean, rest of Europe, the 
Middle East and Central Asia, and Oceania and East Asia. Maternal age group 
was coded into a three-category variable (less than 25 years, 25 to 34 years, and 
35 years and above).
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5.4.5 Research ethics approval
The study was approved by the London Multi-Centre Research Ethics Committee 
in September 2005 (study reference number 05/MRE02/18).
186
Role of the researcher
In September 2004 ,1 started my post as a research fellow and epidemiologist to 
the UK Newborn Screening Programme Centre, and subsequently started work on 
the project “Realising the research potential of the national newborn blood spot 
bank to advance science and health”. Funding for this project had been obtained 
from the Medical Research Council by Professor Carol Dezateux at the UCL 
Institute of Child Health and Dr Sandy Oliver at the Institute of Education in 
October 2004. I prepared the research ethics committee application with Carol 
Dezateux and approval was gained in May 2005.
All rubella antibody testing was carried out by David Williams. I was responsible 
for consolidating the rubella antibody data, linkage of rubella IgG results to the 
enhanced demographic dataset, and data management. I also carried out quality 
control analyses. I developed the data analysis strategy with advice from my 
supervisors, particularly Mario Cortina-Boija, and carried out all data analyses, 
also with advice from my supervisors. In the spring of 2007 I also applied for and 
received a supplementary grant from the University of London Central Research 
Fund for repair of a broken plate washer required for antibody testing.
I have prepared three papers based on the results from my PhD, two of which 
have been published (see Appendix F), as well as presented the results at three 
conferences. I have also contributed to a book chapter on rubella epidemiology.
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6. Results of rubella IgG ELISA validation
Seventy nine paired serum-dried blood spot samples were tested with the Dade 
Behring ELISA and 73 paired samples were tested with the Diesse ELISA. The 
assay validation was carried out for antibody levels measured in optical density 
(OD) ratios and IU/ml separately.
6.1 Analyses of rubella IgG antibody levels expressed as OD ratios
The correlation between rubella IgG antibody levels measured in serum and dried 
blood spot samples are shown in Figure 6.1. The correlation coefficients for the 
samples tested with the Diesse and Dade Behring ELISA were 0.96 (95% 
confidence interval (Cl) 0.94 to 0.98, p<0.001) and 0.81 (95% Cl 0.72 to 0.88, p  
<0.001) respectively.
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Figure 6.1. Serum antibody levels plotted against dried blood spot antibody levels, expressed 
as OD ratios. (Diesse n = 73, Dade Behring n = 79)
The number of samples tested with the Diesse and the Dade Behring ELISAs that 
would be considered negative, equivocal and positive can be found in Table 6.1.
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Test result in dried blood spots Test result in serum
Diesse Positive Equivocal Negative
Positive 37 4 0
Equivocal 1 8 2
Negative 0 0 21
Dade Behring Positive Equivocal Negative
Positive 70 4 0
Equivocal 1 0 1
Negative 1 2 0
Table 6.1. Number of samples by rubella IgG test result (expressed as OD ratio) in serum 
and dried blood spots. (Diesse n = 73, Dade Behring n = 79)
For the Diesse ELISA, sensitivity (using serum as the gold standard) is 97.4% if  
equivocal samples are classed as negative, and 100% if they are classed as 
positive. Specificity is 88.6% and 91.3% respectively. For the Dade Behring 
ELISA, sensitivity is 97.2% if equivocal samples are classed as negative and 
96.2% if they are classed as positive. The respective specificities are 42.9% and 
0%. The specificity equals zero since no serum or dried blood spot samples tested 
with the Dade Behring ELISA were classed as negative. For the samples tested 
with the Diesse ELISA, seven samples of 73 (9.7%) were misclassified according 
to the manufacturer’s recommended cut-off values indicating negative, positive or 
equivocal status. The only misclassification occurred where negative or positive 
samples in serum were classified as equivocal in dried blood spots and one 
equivocal sample in dried blood spots was classified as positive in serum. There 
were no positive samples being classed as negative or vice versa. For the Dade 
Behring ELISA, 9 out o f 79 (11.4%) were misclassified if antibody levels were
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measured as OD ratios. In addition, one sample was classified as being positive in 
serum, but negative in dried blood spots.
Figure 6.2 shows the means of antibody levels measured in the paired serum and 
dried blood spot samples plotted against their differences for samples tested with 
the Diesse ELISA and Figure 6.3 shows the same relationship for paired samples 
tested with the Dade Behring ELISA.
Mean of differences 
Mean ± 2*SD of differences
— r ~
2.5
~ T ~
3.00.0 0.5 1.0 1.5 2.0
Mean of serum and dried blood spot antibody concentrations (OD ratios)
~T~
3.5
Figure 6.2. Means of rubella IgG OD ratios in paired serum-dried blood spot samples 
plotted against the difference in antibody level for the Diesse ELISA (n = 73).
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Figure 63 Means of rubella IgG OD ratios in paired serum-dried blood spot samples plotted 
against the difference in antibody level for the Dade Behring ELISA (ra = 79)
For antibody levels measured as OD ratios, 68 of 73 samples (93.2%) tested with 
the Diesse ELISA were within two SDs of the mean difference. For Dade 
Behring, the corresponding proportion was 96.2 % (76 of 79). Thus, agreement is 
higher for the Dade Behring ELISA, although the difference is non-significant 
(Test for equality of proportions p  = 0.400). The number of samples larger than 
two SDs of the mean difference is not significantly different to the expected 
number for either ELISA, assuming a normal distribution of differences (Test for 
equality of proportions p  = 1.0 for both Diesse and Dade Behring respectively).
For both assays, antibody levels are higher in dried blood spot samples than in 
serum samples overall. This is unexpected as antibody level should be lower in
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the dried blood spots than in serum because antibodies in whole blood are diluted 
by red blood cells. This is particularly evident for a small number of paired 
samples with very low antibody levels tested with the Diesse ELISA. However, 
the absolute differences in antibody levels are very small. This is unlike the results 
for the Dade Behring ELISA. The samples with very low antibody levels (i.e. with 
an OD ratio of less than 0.1) have higher antibody levels if measured in serum 
than in dried blood spots. The Diesse ELISA appears to separate samples with 
lower antibody levels more distinctly than the Dade Behring ELISA; however, 
very few samples with low antibody levels were actually tested with the Dade 
Behring ELISA, since such samples were in limited supply.
6.2 Analyses of rubella IgG antibody levels in IU/ml
Figure 6.4 shows rubella antibody levels in serum plotted against that in dried 
blood spot samples. The correlation coefficient for the samples tested with the 
Diesse ELISA was 0.93 (95% Cl 0.89 to 0.95, p<0.001). For the samples tested 
with the Dade Behring ELISA, the correlation coefficient is 0.91 (95% Cl 0.87 to 
0.94, p <  0.001).
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Figure 6.4 Serum antibody levels plotted against dried blood spot antibody levels in IU/ml 
(Diesse n = 73, Dade Behring n = 79)
The number of samples tested using the Dade Behring and Diesse ELISAs that 
would be considered negative, equivocal and positive for rubella IgG antibody can 
be found in Table 6.2.
194
Test result in dried blood spots Test result in serum
Diesse Positive Equivocal Negative
Positive 38 3 0
Equivocal 1 10 2
Negative 0 0 19
Dade Behring Positive Equivocal Negative
Positive 72 2 0
Equivocal 1 0 3
Negative 0 1 0
Table 6.2. Number of samples by rubella IgG test result (In IU/ml) in serum and dried blood 
spots. (Diesse n = 73, Dade Behring n = 79)
For the Diesse ELISA, sensitivity (using serum as the gold standard) is 97.4% if  
equivocal samples are classed as negative, and 100% if they are classed as 
positive. Specificity is 91.1% and 90.5% respectively. For the Dade Behring 
ELISA, sensitivity is 98.6% if equivocal samples are classed as negative and 
98.7% if they are classed as positive. The respective specificities are 66.7% and 
0%. As above, the specificity is equal to 0 since no serum or dried blood spot 
samples were classed as negative using the Dade Behring ELISA. For the Diesse 
ELISA, six of 73 samples (8.2%) were misclassified, and misclassification was 
due to positive or negative samples in serum being misclassified as equivocal in 
dried blood spots, or equivocal samples in serum being classified as positive in 
dried blood spots. For the Dade Behring ELISA, 7 of 79 samples (8.9%) were 
misclassified. The misclassification was due to positive or negative samples in 
serum being misclassified as equivocal in dried blood spots, or equivocal samples 
in serum being classified as negative or positive in dried blood spots. No positive 
samples were classified as negative or vice versa.
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As in the previous section, the means of antibody levels measured in the paired 
serum and dried blood spot samples were plotted against their differences. These 
analyses are shown in Figure 6.5 for samples tested with the Diesse ELISA and in 
Figure 6.6 for samples tested with the Dade Behring ELISA.
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Figure 6 i. Means of rubella IgG level (in IU/ml) in the paired serum-dried blood spot 
samples plotted against the difference in antibody level for the Diesse ELISA in = 73)
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Figure 6.6. Means of rubella IgG level (in IU/ral) in the paired serum-dried blood spot 
samples plotted against the difference in antibody level for the Dade Behring ELISA (n =79).
Since variance is non-constant for the calibrated values, the assumptions for 
assessing agreement based on the proportion of paired samples with a difference 
in antibody level greater than two SDs of the mean difference are not met. In 
order to decrease this heteroscedastic effect, natural logarithms were applied to 
these results (Figure 6.7 and 6.8).
Mean of differences 
Mean ± 2*SD
T~
2.0
~r~
25
~r~
3.0
I
1.5
I
35
I
4.0
I
4.5
Mean of natural logarithm of serum and dried blood spot antibody levels in lU/ml
Figure 6.7 Means of the natural logarithm of rubella IgG level (in IU/ml) in the paired 
serum-dried blood spot samples plotted against the difference in logged antibody level for 
the Diesse ELISA (n = 73)
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Figure 6.8 Means of the natural logarithm of rubella IgG level (in IU/ml) in the paired 
serum-dried blood spot samples plotted against the difference in logged antibody level for 
the Dade Behring ELISA (n = 79)
Applying natural logarithms to the calibrated antibody levels appeared to remove 
the effect of heteroscedasticity. For the Dade Behring ELISA, one outlier was 
detected; a paired sample with a mean difference of -1.9 log IU/ml, with a mean 
antibody level of 1 log IU/ml. Agreement was satisfactory for both ELISAs, with 
differences in antibody levels in paired samples being within two SDs of the mean 
difference for 67 of 73 samples tested with the Diesse ELISA (91.8%), and for 76 
out of 79 samples tested with the Dade Behring ELISA (96.2%). The difference 
between the two assays in the proportion of samples with a difference in antibody 
levels larger than two SDs of the mean difference is therefore not statistically 
significant (Test for equality of proportions p  = 0.251). Also, the number of
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samples larger than two SDs of the mean difference is not significantly different 
to the expected number for either ELISA, assuming a normal distribution of 
differences (Test for equality of proportions p -  0.436 and p  = 0.713 for the 
Diesse and Dade Behring ELISAs respectively).
Although the agreement was satisfactory for both the Diesse and Dade Behring 
ELISAs, and there was no significant difference in agreement between these two 
assays, the ELISA manufactured by Diesse was subsequently chosen for the main 
rubella serosurvey based on newborn dried blood spots. This choice was made 
since the Diesse ELISA was much easier to perform by hand than the Dade 
Behring ELISA, thus reducing the risk of human error during the assay procedure.
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Key points
•  Two commercially available rubella IgG enzyme-linked immunosorbent 
assays (ELISAs) were validated for use on dried blood spot samples, using 
paired serum-dried blood spot samples prepared from left-over serum from 
occupational health screening at Great Ormond Street Hospital.
•  73 and 79 paired samples were tested with ELISAs manufactured by Diesse 
(Siena, Italy) and Dade Behring (Marburg, Germany) respectively.
•  Agreement in rubella IgG levels measured in serum and dried blood spot 
samples, evaluated as the proportion of samples with a difference in IgG 
levels greater than two SDs of the mean difference, was satisfactory for both 
assays.
•  The Diesse ELISA was subsequently chosen for the main rubella serosurvey 
as it was easier to perform by hand and therefore reduced the risk of human 
error in the assay procedure.
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7. Results of the rubella serosurvey
7.1 Characteristics of the serosurvey sample
For the rubella serosurvey, 220 randomly sampled 96-well plates, containing 
19781 newborn dried blood spot samples which arrived in the North Thames 
screening laboratory between January and March, and July and September 2004, 
were tested for rubella IgG antibody. Before data analysis, 796 samples were 
excluded since they were not in the enhanced data file, indicating that they were 
repeat screening samples. A further 74 samples were excluded as they were HIV 
positive and 23 samples since they had insufficient blood to punch a test specimen 
from the dried blood spots. One sample was excluded since the parents had opted 
out of newborn screening. Five further samples were excluded since the baby’s 
date of birth was recorded as a year before 2003. This left 18882 samples for 
analysis, corresponding to around 34.0% of the approximately 55600 newborn 
dried blood spot samples received in the screening laboratory and tested for HIV 
in the first and third quarter of 2004. This exclusion process is summarised in 
Figure 7.1.
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796 repeat samples
5 samples with a 
date of birth < 2003
23 samples with 
insufficient blood
74 HIV positive 
samples
220 plates tested -  19781 samples
18882 samples included 
in analyses
1 blank sample for which 
parents opted out of screening
Figure 7.1 Samples excluded before analysis
Maternal Primary Care Trust (PCT) of residence at delivery was available for 
18323 samples (97.0%), and Maternal Strategic Health Authority (SHA) of 
residence at delivery for 18750 (99.3%) of samples. For a further 57 samples, the 
maternal SHA of residence was outside the regions covered by the newborn 
screening laboratories participating in the newborn unlinked anonymous HIV 
surveillance programme. Data linkage was successful for 18410 samples (97.5%). 
After data linkage, maternal country of birth was available for 18324 samples 
(97.0% of the total number of samples). Maternal age was available for 12819 
samples, (67.9%); for a further six samples, maternal age was stated as less than 
10 years and therefore deemed to be incorrect.
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Figure 7.2 to 7.4 show the distribution of rubella IgG antibody in the 18882 
samples, expressed as OD ratios, in IU/ml and as the natural logarithms of OD 
ratios (ln(OD ratio)) respectively.
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Figure 7 2  Distribution of rubella IgG antibody levels expressed as OD ratios (n = 18882).
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Figure 7 J . Distribution of rubella IgG antibody levels expressed in IU/ml (n = 18882).
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ln(OD ratio)
Figure 7.4. Distribution of rubella IgG antibody levels expressed as the natural logarithm of 
the OD ratios (n = 18882).
The distributions of rubella antibody IgG concentrations expressed as OD ratios 
(median 1.8, interquartile range 1.1 to 2.7) and in IU/ml (median 16 IU/ml, 
interquartile range 9 to 31), are both positively skewed, particularly the latter. It 
was also found that calibration into IU/ml censors the distribution of rubella 
antibody levels at the lower end of the range: the lowest calibrated antibody level 
is 3 IU/ml, however the range of OD ratios for this antibody level is 0.02 to 0.25. 
The distribution of natural logarithms of the OD ratios is negatively skewed and 
seemingly bimodal. The median of the ln(OD ratio) distribution is 0.6 
(interquartile range 0.1 to 1.0).
206
Table 7.1 displays the distribution of maternal region of birth (coded into 20 
categories), maternal age and SHA at delivery in the serosurvey sample, as well as 
the distribution of these variables in the enhanced dataset covering all newborn 
screening samples anonymously tested for HIV in 2004. Countries classified into 
each region of can be found in Appendix C.
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Variable Number in sample (%) Total in 2004 (%) p-value*
Maternal region of birth
United Kingdom 11195(59.3%) 62614 (58.6%) 0.166
Northern Europe 340(1.8%) 1888 (1.8%) 0.969
Southern Europe 411 (2.2%) 2208 (2.1%) 0.886
Eastern Europe 305 (1.6%) 1984(1.9%) 0.718
Western Europe 284 (1.5%) 1594(1.5%) 0.987
North America 169 (0.9%) 897 (0.8%) 0.942
Central America and Caribbean 238 1.3% 1328(1.2%) 0.981
South America 129 (0.7%) 851 (0.8%) 0.892
Central Asia 199(1.1%) 1075 (1.0%) 0.951
South Asia 2117(11.2%) 11741 (11.0%) 0.761
East Asia 136 (0.7%) 853 (0.8%) 0.924
South East Asia 251 (1.3%) 1448 (1.4%) 0.974
West Asia 491 (2.6%) 2745 (2.6%) 0.968
Oceania 149 (0.8%) 839 (0.8%) 0.996
North Africa 178 (0.9%) 1079 (1.0%) 0.934
East Africa 874 (4.6%) 5289 (4.9%) 0.684
South Africa 149 (0.8%) 826 (0.8%) 0.984
Middle Africa 158 (0.8%) 950 (0.9%) 0.948
West Africa 551 (2.9%) 3589 (3.4%) 0.590
Not known 558 (3.0%) 3118(2.9%) 0.962
Total n 18882 106862
Maternal SHA at delivery
(2004 classification)
North Central London 3164(16.7%) 18387 (17.2%) 0.535
North West London 3834 (20.3%) 20663 (19.3%) 0.164
North East London 4336 (23.0%) 25929 (24.3%) 0.064
Essex 3380 (17.9%) 18771 (17.6%) 0.638
Bedfordshire and Hertfordshire 3696 (19.6%) 20833 (19.5%) 0.911
South West London 216(1.1%) 1237(1.2%) 0.986
South East London 37 (0.2%) 212 (0.2%) 0.998
Kent and Medway 9 (0.04%) 39 (0.05%) 0.989
Surrey and Sussex 14 (0.1%) 82 (0.1%) 0.997
Outside South East 7 (0.04%) 56 (0.05%) 0.986
Outside data linkage region 57 (0.3%) 473 (0.4%) 0.878
Not known 132 (0.7%) 265 (0.2%) 0.501
Total n 18882 106862
Median maternal age
(interquartile range) 30 (25 to 34) 30 (25 to 34) p  -  0.994, 
D = 0.004
Total n 12813 53899 (Kolmogomov- 
Smimov test)
♦Test for equality of proportions unless otherwise specified
Table 7.1. Distribution of maternal country of birth, SHA at delivery and median maternal 
age in the serosurvey and all samples tested for HIV in 2004
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The distribution of maternal SHA of residence at delivery, maternal region of 
birth and maternal age were all similar in the rubella serosurvey sample and for all 
samples tested for HIV and linked to birth registration data in 2004. Of the 132 
specimens in the serosurvey sample (0.7%) with an unknown maternal SHA at 
delivery, 84 (63.6%) came from just one plate. The maternal region of birth was 
also coded as not known for these 84 samples.
Among the group of women bom in East Africa, 406 (46.5%) were bom in 
Somalia. In the group of women bom in West Africa, 229 women (40.6%) were 
bom in Ghana and 241 (43.7%) in Nigeria. Nearly half of women from Western 
Asia, (237, 43.7%) were bom in Turkey. Among women bom in South Asia, the 
largest group were bom in Bangladesh (847, 40.0%), 496 (23.4%) in Pakistan, 
and 480 (22.7%) in India. A further 232 (13.3%) women in this group were bom 
in Sri Lanka.
In the rubella serosurvey sample, as well as among all specimens tested for HIV 
in 2004 and linked to birth registration data, region of birth was stated as 
unknown for around 3% of samples. Of the 558 women with missing maternal 
region of birth, 130 (23.2%) did not have a known maternal SHA of residence at 
delivery, accounting for 98.5% of the 132 women without known a maternal 
SHA. Maternal age was available for 311 of 558 the samples for which maternal 
region of birth were coded as not known. As Figure 7.5 shows, the median
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maternal age is similar for samples with a known region of birth and those without 
(Wilcoxon rank-sum test p=0.152).
Known maternal region of birth (n=12502) Maternal region of birth not known (n=311)
Note: The Ihick black lines indicate the median, the boxes the interquartile range, and the whiskers extend to the most 
extreme observation less than 1.5 times the interquartile range from the box.
Figure 7.5. Boxplot of maternal age for samples with and without known region of birth 
(total n=12813).
In addition, the median ln(OD ratio) for the samples with an unknown maternal 
region of birth (equal to 0.42) was significantly lower than in samples with a 
known maternal region of birth, for which the median was equal to 0.59 
(Wilcoxon rank sum test p  <0.001).
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Although 472 of 558 samples for which the maternal country of birth was stated 
as unknown were not successfully linked to birth registration data (84.6%), it is 
likely that data linkage was also unsuccessful for the other 86 samples in this 
category. Although it is possible that some women in this group had reasons not 
to state their country of birth on their baby’s birth registration form, this is likely 
to only be a very small group if at all existent. In all of England and Wales, only 
14 women did not state a country of birth in 2004349.
The proportion of samples with a maternal region of birth outside the UK varied 
by SHA of residence in the serosurvey sample, as demonstrated in Figure 7.6.
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Figure 7.6. Proportion of samples in the serosurvey by maternal place of birth (n = 18882)
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In Essex and Bedfordshire and Hertfordshire SHAs, 339 of 3380 (10.0%) and 
712 of 3696 (19.3%) women were bom outside the UK respectively. This was 
lower than for example North West London SHA, where 2057 of 3834 (53.7%) 
women were bom outside the UK. In North East and North Central London 
SHAs, 2312 of 4336 (53.3%) and 1593 of 3164 (50.3%) women were bom 
outside the UK.
Likewise, the age distribution of women bom abroad varied according to maternal 
region of birth (Figure 7.7).
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Figure 7.7 Number of samples by maternal age group and region of birth (n = 18882).
Among women bom in the UK, 6.5% were under the age of 20 years, compared to 
3.3% of women bom outside the UK. A higher proportion of UK-bom women 
were over the age of 35 than among women bom outside the UK; 22.8% and
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19.4% respectively. Of women aged less than 20 years, 74.2% were born in the 
UK, compared to only 54.9% of women aged 25 to 29 years.
7.2 Multiple imputation of maternal age values
Since maternal age was missing for over 30 % of linked samples these values 
were obtained through multiple imputation, as described in section 5.4.4.3. Figure 
7.8 below shows a box plot of rubella antibody level (expressed as ln(OD ratio)), 
in samples with maternal age available and those without.
Maternal a g e  available (n=12 8 1 3 ) Maternal a g e  m issin g  (n = 6069)
Note: The thick black lines indicate the median, the boxes the interquartile range, and the whiskers extend to the most 
extreme observation less than 1.5 times the interquartile range from the box.
Figure 7.8. Box plot of rubella antibody level in samples with and without data on maternal 
age (/t=18882).
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The medians of the ln(OD ratio) distributions in samples with maternal age 
available and those without maternal age were similar (Wilcoxon rank sum test 
p=0.580). Figure 7.9A shows the distribution of maternal country of birth and 
Figure 7.9B shows the distribution of maternal SHA of residence at delivery, in 
samples with and without maternal age.
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Figure 7.9. Distribution of maternal country of birth (A) and maternal SHA (B) in samples 
with and without data on maternal age (n = 18882).
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The difference in the distribution of samples by maternal region of birth 
comparing those with and without maternal age data available was statistically 
significant (%2= 112.3 on 7 degrees of freedom (d.f.), p  < 0.001). Similarly, the 
distribution of maternal SHA of residence at delivery was significantly different 
among samples with and without maternal age data {%2= 124.8 on 11 d.f., p < 
0.001). This difference could be accounted for by the high proportion of samples 
with missing data for maternal age and SHA of residence at delivery.
Through multiple imputation of maternal age values, five full datasets were 
created. Figure 7.10 shows the density of the maternal age variable in these five 
imputed datasets, as well as the maternal age distribution in the enhanced dataset 
before imputation (n = 18882 and n = 12813 respectively). Figure 7.11 shows the 
density of maternal age in the dataset created in the newborn screening laboratory 
for quarter one and quarter three o f 2004 (n = 53819), and the distribution of 
maternal ages in the enhanced dataset before imputation.
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Figure 7.10. The distribution of maternal age before multiple imputation (n=12813) and 
the five different imputed datasets (/i=18882 respectively).
Densities of maternal age distributions
Pre-imputation age 
Screening lab data Q1+Q3
COo
o
•^ro
o
<NOd
o
d
oo
d
10 20 30 40 50
Maternal age
Figure 7.11. Maternal age distribution in the newborn screening dataset (n=53819) and the 
enhanced dataset before multiple imputation (n=12813).
Graphically, the maternal age distribution in the enhanced dataset before multiple 
imputation and the multiply imputed maternal age distributions appear very 
similar (Figure 7.10). The median maternal ages in the imputed datasets were all 
equal to 30 years, and the interquartile ranges were between 25 and 34 years. 
There were no significant differences between the maternal age distributions in 
any of the imputed datasets and the maternal age distribution before imputation; 
the Kolmogorov-Smimov statistics varied between 0.003 to 0.005, with p  = 1.0 
for four of the imputed maternal age distribution, and p  = 0.998 for the fifth. As
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demonstrated in Figure 7.11, the maternal age distribution from the newborn 
screening laboratory dataset (which is sent to the HPA and subsequently to the 
ONS for record linkage) for quarter one and three of 2004 differed significantly 
from the maternal age distribution in the enhanced dataset before imputation, 
(Kolmogorov-Smimov statistic = 0.04, p  < 0.001). This implies that the maternal 
age distribution before and after data linkage differ. The distribution of maternal 
age after data linkage is slightly shifted to the left (by approximately six months), 
and less smooth than the maternal age distribution in the dataset from the newborn 
screening laboratory, particularly in the range between 28 and 30 years. This shift 
most likely reflects a difference in the method used to calculate maternal age from 
maternal date of birth in the newborn screening laboratory dataset.
7.3 Laboratory quality control
The possible effects of laboratory conditions and assay manufacturing batches on 
rubella IgG levels was carried out by creating Shewhart plots of the means of 
ln(OD ratio) by 96-well plate. The 220 plates were ranked in order of testing. The 
Shewhart plot for the mean of ln(OD ratio) by plate can be found in Figure 7.12.
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Figure 7.12. Mean ln(OD ratio) by plate in order of testing (n = 18882 in 220 plates)
There is no significant trend in mean ln(OD ratio) by plate ranked in order of 
testing. This was confirmed by linear regression: when ln(OD ratio) was modelled 
as a function of plate rank number, this resulted in a regression coefficient of 
3.5X104 (95% Cl 7.5xl0'6 to 7.0X10-4, p=0.055).
Overall, the means of 32 plates (14.5%) were outside the control limits; 15 below 
and 17 above. These outlying means can be explained by variations in maternal 
age, country of birth and SHA at delivery within each plate. For example, in the 
plate with the lowest mean antibody level, 62 of 85 samples (72.9%) were
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collected in North West London SHA. This was a significantly higher proportion 
than among samples in other plates (test for equality of proportions p  <0.001), 
among which 20.1% were collected in North West London SHA. This plate also 
had a higher proportion of samples for which the maternal region of birth was 
Sub-Saharan Africa (14 of 85 samples, 16.5%) than among other samples (1718 
of 18797 samples, 9.1%). This difference was also statistically significant (test for 
equality of proportions p  =0.020). In order to control for any independent effects 
of plate clustering on the odds of rubella seronegative status, plate identity was 
included as a random effect in the logistic regression models (described in section 
7.6) and its effect on improving the models’ goodness-of-fit was examined using 
AIC.
7.4 Results of latent class regression finite mixture models 
(without covariates)
Latent class regression finite mixture models without covariates were fitted to the 
full distribution of rubella IgG antibody levels (n = 18882), expressed as natural 
logarithms of the OD ratios. Gamma or normal distributions were assumed for up 
to five components. To fit gamma-distributed components, a constant was added 
to the ln(OD ratio) values to ensure they were positive. Among the models with 
gamma distributed components, the lowest BIC corresponded to the model with 
five components. A model with six components was also fitted to investigate if  
this decreased the BIC further. The results of these latent class mixture models 
can be found in Table 7.2. The AIC is included for comparison.
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Number of 
components
Degrees of freedom (cLf.) Log-likelihood AIC BIC
Normal components
1 2 -20983.4 41970.8 41986.5
2 5 -19165.2 38340.5 38379.7
3 8 -18669.7 37355.5 37418.2
4 11 -18539.7 371013 37187.6*
5 14 -18525.3 37078.6 37188.4
Gamma components
1 2 -22960.3 45924.6 45940.3
2 5 -19615.4 39240.9 39280.1
3 8 -18765.9 37547.7 37610.5
4 11 -18575.2 37172.4 37258.7
5 14 -18549.4 37126.9 37236.7
6 17 -18549.4 37132.8 37266.1
*Model with lowest BIC
Table 7.2. Results of latent dass regression finite mixture models assuming gamma and 
normal distributions for the components (n=18882).
The optimal mixture model, using BIC as a selection criterion, had four normally 
distributed components. Overall, the models for which normal distributions were 
assumed had lower BICs than models with gamma-distributed components. All 
further models were therefore fitted assuming that the components were normally 
distributed. If AICs are considered, the model with the lowest AIC was a model 
with five normally distributed components. This illustrates that the BIC is more 
conservative against overfitting than the AIC, as it penalises the maximised 
likelihood value for sample size338; this is a desirable property of a model 
selection strategy that involves comparing many models with potentially large 
numbers of parameters.
Figure 7.13 shows the densities of the components of the optimal mixture model 
for the rubella antibody levels expressed as ln(OD ratio) from Table 7.2, as well
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as the component weights and the density function of the ln(OD ratio) values for 
the 18882 samples.
Low
Medium
High
Highest
Total density function
ln(OD ratio)
Note: 7c shows the component weights
Figure 7.13 Density functions of the components of the best-fit mixture model (n = 18882).
Table 7.3 shows the characteristics of the components in this model.
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Component Component 
weight (7T)
% of samples in component 
(95% Cl)
Mean OD 
ratio*
SD 95% Cl for mean*
1 (Low) 2.8% 2.7% (2.5%, 2.9%) 0.14 0.45 0.12,0.18
2 (Medium) 37.8% 31.3% (30.6%, 31.9%) 0.99 0.56 0.97,1.01
3 (High) 38.0% 41.6% (40.9%, 42.3%) 1.95 0.33 1.93,1.97
4 (Highest) 21.4% 24.5% (23.9%, 25.1%) 3.19 0.21 3.15, 3.23
♦Note that means and confidence intervals have been exponentiated.
Table 7.3. Components of the optimal mixture model based on BIC (n = 18882).
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The terms “low”, “medium”, “high” and “highest” components refer to the relative 
sizes of the component means, which were significantly different (Table 7.3). These 
terms will be used throughout this chapter to refer to these components from the 
optimal mixture model. Note that the component weights are not equal to the 
proportion of samples in each component: the former are weights of the 
components’ respective contribution to the total density function, whereas the latter 
are derived from the posterior probabilities for each observation. Each individual 
observation was assigned to the component for which the posterior probability was 
maximised.
The component with the lowest mean antibody level is well separated from the 
other three components, with little overlap (Figure 7.13). Misclassification error in 
the allocation of samples to components based on this mixture model was therefore 
likely to be small for the component with the lowest mean antibody level. However, 
the components of the optimal mixture model with the medium, high and the 
highest mean antibody levels were less well defined with considerable overlap 
among them. Table 7.4 shows, for each set of mixture model components, the 
degree of overlap (a) between two components expressed as the probability of an 
observation lying in a region where the densities of two components overlap.
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Mixture model 
component Low Medium
Mixture model component
High Highest
Low
Medium
High
Highest
Table 7.4. Overlap between the components of the optimal mixture model (described in Table
From Table 7.4, it is clear that there is very minimal overlap between the low 
mixture model component and the others: only 6% of the component density for the 
component overlaps with the medium component density, and there is no overlap 
between the low and the high and highest components. However, there is 
considerable overlap between the other three components. For example, 43% of the 
high component density overlaps with the medium component.
A graphical method of examining the degree of separation and homogeneity of the 
mixture model components is shown in Figure 7.14, displaying rootograms of the 
posterior probabilities for each of the components of the optimal model.
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Figure 7.14. Rootograms for the components the optimal mixture model from Table 7.3 (n 
18882).
The low component is well separated as it has a large number of observations with 
probability nearing zero, and few observations with posterior probabilities greater 
than zero. The medium, high and highest components are less well defined, as they 
have a substantial number of samples with posterior probabilities between 0 and 1.
7.5 Estimates of rubella seroprevalence in North Thames
Using the definition of assignment to the component of the optimal latent class 
regression finite mixture model (described in Table 7.3 and Figure 7.13) with the 
lowest mean based on posterior probabilities, 509 of 18882 samples were found to
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be seronegative for rubella IgG antibody. This corresponds to 2.7% of pregnant 
women in North Thames being seronegative to rubella, with a 95% Cl (adjusted for 
sampling strategy) of 2.4% to 3.0%. The classification of samples assigned to the 
low component as seronegative is justified by the degree of separation between this 
component and the others (see Figures 7.13 and 7.14, and Table 7.4 above), as the 
misclassification error is likely to be small.
The maximum value of the OD ratio for samples assigned to the low component is 
0.246, whereas the minimum OD ratio for samples assigned to the medium 
component is 0.247. The definition of rubella seronegative status derived from the 
latent class mixture model is therefore similar to using a cut-off value of an OD 
ratio of less than 0.247 to define the seronegative population. The proportion of 
samples classified as seronegative to rubella IgG in the serosurvey using five 
alternative definitions is shown in Figure 7.15.
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Figure 7.15. Proportion of samples classified as seronegative by definition of rubella 
seronegative status
The proportion of samples classified as seronegative varies greatly by the definition 
used. The lowest proportion of samples classified as seronegative, 1.5% (95% Cl 
1.2% to 1.7%) was achieved using a cut-off value of <5 IU/ml. If a cut-off value of 
<5 IU/ml is used instead, over three times as many samples would be classified as 
seronegative. This demonstrates that, since there is no evidence regarding which 
antibody level is protective against rubella infection or re-infection, the choice of a 
cut-off value to define the seronegative population is arbitrary and has a large 
impact on the estimated proportion of samples considered seronegative. The 
manufacturer of the Diesse ELISA which was used to test for rubella IgG in this 
study recommends using a cut-off value of <7 IU/ml to define the seronegative 
population. This cut-off value, as well as that recommended for use in antenatal 
screening in the UK (<10 IU/ml)153 would vastly overestimate the proportion of
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rubella seronegative samples. These two cut-off values are therefore not suitable 
for use in a rubella serosurvey based on newborn blood spot samples. They were 
designed for use in screening programmes to identify individuals requiring booster 
immunisation, and are therefore not specific enough to be used in serosurveys, 
where the aim is to estimate the size of the seronegative population304.
Rubella seronegative status will be defined as assignment, based on the maximum 
posterior probability, to the component with the lowest mean of the optimal mixture 
model (defined in Table 7.3 and Figure 7.13) throughout the rest of this chapter. 
Table 7.5 shows the number and percentage of samples classified as seronegative by 
maternal region of birth.
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Variable Number Total number of samples (95% Cl for %
seronegative (%)____________________________ seronegative)
Maternal region of birth
United Kingdom 128(1.1) 11195 (0.9,1.4)
Northern Europe 7(2.1) 340 (1.0,4.2)
Southern Europe 11 (2.7) 411 (1.5,4.7)
Eastern Europe 12 (3.9) 305 (2.3,6.7)
Western Europe 4(1.4) 284 (0.5, 3.7)
North America 3 (1.8) 169 (0.6,5.3)
Central America and 13 (5.5) 238 (3.2,9.3)
Caribbean
South America 6(4.7) 129 (2.1,9.8)
Central Asia 11 (5.5) 199 (3.1,9.6)
South Asia 131 (6.2) 2117 (5.2,7.4)
East Asia 10 (7.4) 136 (3.8,13.9)
South East Asia 10 (4.0) 251 (2.2,7.1)
West Asia 16 (3.3) 491 (2.0,5.2)
Oceania 1 (0.7) 149 (0.0,4.2)
North Africa 4(2.3) 178 (0.9,5.8)
East Africa 46 (5.3) 874 (4.0,7.0)
South Africa 8(5.4) 149 (2.5,11.0)
Middle Africa 12 (7.6) 158 (4.3,13.2)
West Africa 22 (4.0) 551 (2.6, 6.1)
Not known 54 (9.7) 558 (7.1,13.1)
Total n = 18882_________________________________________________________
Note: All confidence intervals have been adjusted far sampling strategy
Table 7.5. Number and percentage of seronegative samples by maternal region of birth
Only 1.1% and 0.7% (95% CIs 0.9% to 1.4% and 0% to 4.2% respectively) of 
newborn samples for which the mother was bom in the UK and in Oceania 
respectively were found to be seronegative, compared to over 6% of mothers bom 
in East Asia, Middle Africa or South Asia. The highest proportion of seronegative 
samples was found among those without a known maternal region of birth, for 
which 9.7% were considered seronegative (95% Cl 7.1% to 13.1%). As outlined in 
section 7.1, record matching was unsuccessful for these samples. Since the data 
linkage algorithm is partly based on postcode of residence, it is likely that for 
samples not successfully linked to birth registration data, mothers are more likely to 
be homeless or highly mobile. This may explain the higher proportion of samples in
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this group seronegative to rubella. Table 7.6 shows the number and percentage of 
seronegative samples by maternal age group
Variable Number seronegative
(%)
Total number of 
samples
(95% Cl for % 
seronegative)
Maternal age group
<20 years 36 (5.2) 689 (3.8,7.1)
20-24 years 74 (3.5) 2124 (2.7,4.5)
25-29 years 82 (2.5) 3038 (1.9,3.2)
30-34 years 81 (2.1) 3937 (1.6,2.6)
35-39 years 45 (2.0) 2255 (1.5,2.6)
>40 years 16 (3.2) 500 (1.8,5.6)
Total n = 12813
Note: All confidence intervals have been adjusted for sampling strategy
Table 7.6 Number and percentage of seronegative samples by maternal age group
The largest proportion of seronegative samples was found in the less than 20 year 
age group, of which 5.2% of samples were seronegative (95% Cl 3.8% to 7.1%). 
There were much smaller differences in the proportion of seronegative samples for 
maternal ages over 25 years, yet 3.2% of samples for which the maternal age was 
over 40 years were seronegative (95% Cl 1.8% to 5.6%), suggesting a t/-shaped 
relationship between maternal rubella seronegative status and age. This issue is 
further explored below. Table 7.7 shows the number and percentage of seronegative 
samples by maternal SHA of residence.
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Variable Number 
seronegative (%)
Total number of 
samples
(95% Cl for % 
seronegative)
Maternal SHA at delivery
(2004 classification)
North Central London 81 (2.6) 3164 (2.0,3.2)
North West London 172 (4.5) 3834 (3.7,5.5)
North East London 137 (3.2) 4336 (2.7,3.7)
Essex 41 (1.2) 3380 (0.9,1.7)
Bedfordshire and 65 (1.8) 3696 (1.4,2.3)
Hertfordshire
Outside North Thames 5(1.5) 340 (0.6,3.5)
Not known 8 (6.1) 132 (2.4,12.4)
Total n = 18882
Table 7.7 Number and percentage of seronegative samples by maternal SHA of residence.
Among samples for which the maternal SHA of residence was coded as Essex and 
Bedfordshire and Hertfordshire SHAs, less than 2% were seronegative. The 
proportion of seronegative samples from Essex SHA was found to be significantly 
lower than in any of the three urban SHAs in North London. The proportion of 
seronegative samples from North East and Central London SHA was around 3%, 
whereas 4.5% of samples from North West London SHA were seronegative (95% 
Cl 3.7% to 5.5%). This proportion was significantly higher than in all other SHAs 
in North Thames apart from North East London.
Table 7.8 shows the proportion of seronegative samples by maternal age group, 
maternal region of birth and maternal SHA at delivery (using the same grouping as 
in the logistic regression analyses) as well as unadjusted odds ratios for maternal 
rubella seronegative status in each group.
233
Exposure variable 
Maternal region of birth
Total number of Number
______ samples seronegative (%)
(95% Cl for % Unadjusted odds ratio
seronegative) (95% Cl)
UK 11195 128(1.1) (0.9,1.4) 1
Sub-Saharan Africa 1732 88 (5.1) (4.1,6.3) 4.63 (3.51,6.1 l)a
North Africa, West & Central Asia 868 31 (3.6) (2.5, 5.2) 3.20(2.15,4.77)a
South Asia 2117 131 (6.2) (5.2,7.4) 5.70(4.44,7.33)a
East, South East Asia & Oceania 536 21 (3.9) (2.3,6.5) 3.53(2.20,5.64)a
Rest of Europe 1340 34 (2.5) (1.9, 3.4) 2.25(1.54,3.30)“
Americas 536 22(4.1) (2.6,6.5) 3.70 (233,5.87)“
n =18324
Maternal age group
<20 years 689 36 (5.2) (3.8,7.1) 2.62(1.75,3.92)“
20-24 years 2124 74 (3.5) (2.7,4.5) 1.72 (1.25,237)b
25-29 years 3308 82 (2.5) (1.9, 3.2) 1.21 (0.89,1.65)
30-34 years 3937 81 (2.1) (1.6,2.6) 1
35+ years 2755 61 (2.2) (1.7,2.9) 1.08 (0.77,1.51)
n = 12813
Maternal SHA at delivery
North East London 4336 137 (3.2) (2.7, 3.8) 1
North Central London 3164 81 (2.6) (2.0,3.2) 0.80(0.61,1.06)
North West London 3834 172 (4.5) (3.7,5.5) 1.44 (1.14,1.81)c
Bedfordshire & Hertfordshire 3696 65 (1.8) (1.4, 2.3) 0.55 (0.41,0.74)d
Essex 3380 41 (1.2) (0.9,1.7) 0.38 (0.26,0.54)“
n =  18410 ____kv-----» -- A /lv ~Note: Odds ratios in bold indicate p <0.05.a) p <0.001b) p = 0.001c) p = 0.002d) p = 0.0001
Table 7.8. Unadjusted odds ratios for rubella seronegative status by maternal characteristics.
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Tests for interactions between the different maternal exposure categories using the 
X 1 test for heterogeneity o f odds ratios yielded no significant results; however some 
comparisons resulted in empty groups. The unadjusted odds ratios in Table 7.8 
demonstrate that women bom outside the UK are significantly more likely to be 
seronegative to rubella than women bom in the UK. The odds were highest for 
women bom in South Asia, for whom the odds of being rubella seronegative were 
nearly six times higher than women bom in the UK. The lowest odds ratio was 
found for women bom in other parts o f Europe, however the odds of rubella 
seronegative status was still significantly increased in this group compared to 
women bom in the UK. Women resident in Bedfordshire and Hertfordshire, and 
Essex SHAs were significantly less likely than women resident in North East 
London SHA (baseline) to be seronegative, whereas women resident in North West 
London SHA were significantly more likely to be seronegative than women resident 
in North East London SHA.
Young mothers, under the age of 25 years, but in particular under the age of 20 
years, were significantly more likely to be rubella seronegative than women having 
children in their early thirties. Figure 7.16 shows the odds of rubella seronegative 
status by maternal age group.
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Figure 7.16. The odds of rubella seronegative status by maternal age group (n=12813).
It is clear from Figure 7.16 that the point estimate of the odds of rubella 
seronegative status is higher in the group of women aged over 40 than in women in 
their thirties, implying a 17-shaped relationship between the odds of rubella 
seronegative status and maternal age group. Yet due to the relatively small number 
of women in this group, the confidence intervals are very wide and do not differ 
significantly from the odds of rubella seronegative status among women in their 
thirties, who have the lowest odds. In order to avoid empty groups in the logistic 
regression models, the two oldest maternal age groups from Table 7.6 were 
combined. Through combining the two oldest age groups the 17-shaped effect of 
maternal age group on rubella seronegative status will be diluted, as demonstrated 
in Table 7.8.
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7.6 Results of logistic regression models
As outlined in section 5.4.4.2, women without a known region of birth (n = 558) 
were excluded from the logistic regression analyses, as it was not possible to 
characterise this group accurately due to the lack of successful data linkage. Their 
inclusion would have limited informative value since the aim of these analyses was 
to indentify independent risk factors for maternal rubella seronegative status in 
pregnancy. After exclusion of the samples without a known country of birth, only 
two samples remained for which the maternal SHA of residence was unknown. 
These samples were excluded since their inclusion resulted in collinearity when the 
logistic regression models were fitted. In order to include interaction terms, and to 
be able to compare regression models, samples for which maternal SHA of 
residence was coded as outside the five North Thames SHAs were also excluded (n 
= 337). Their inclusion resulted in collinearity when interaction terms were 
included. This exclusion process is summarised in the flow chart in Figure 7.17.
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18882 eligible samples
17985 samples included in 
logistic regression models
2 remaining samples 
without a known SHA of 
residence
337 remaining samples with an 
SHA of residence outside North 
Thames
558 samples without successful 
data linkage (unknown region of 
birth)__________
Figure 7.17 Exclusion process for logistic regression analyses
Logistic regression models were fitted to identify maternal characteristics which 
were independent risk factors for the odds of rubella seronegative status, defined as 
allocation to the component with the lowest mean of the optimal mixture model 
(described in section 7.4), based on posterior probabilities. The logistic regression 
models were fitted separately for each multiply imputed dataset. Six models were 
fitted for each dataset, with covariates and interaction terms added in a forward 
step-wise procedure. The best-fit model based on BIC was refitted as a mixed 
effects model, with plate as a random effect. Table 7.9 shows the AICs obtained for 
each logistic regression model in each dataset.
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AIC by multiply imputed dataset number
Model Covariates for maternal rubella seronegative status__________________1_______ 2_______ 3_________ 4_______ 5
1 Region of birth 3990.0 3990.0 3990.0 3990.0 3990.0
2 Region of birth + age group 3968.6 3973.7 3970.4 3960.1 3964.9
3 Region of birth + age group + SHA 3954.5 3959.3 3956.0 3945.1 3951.2
4 Region of birth*age group + SHA 3979.7 3982.8 3968.4 3963.2 3975.6
5 Region of birth + age group*SHA 3970.6 3977.5 3966.2 3959.9 3964.8
6 Region of birth + age group + SHA + random effect (plate) 3942.7 3947.4 3943.7 3932.5 3938.3
Note that AICs are only comparable within each dataset.
Table 7.9. AICs obtained in each multiply imputed dataset for the logistic regression models.
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Inclusion of more covariates lowered the AIC in all the multiply imputed datasets, 
but the inclusion of interaction terms did not improve model fit. The inclusion of an 
interaction term for maternal SHA of residence and maternal region of birth resulted 
in empty groups since no women classified as seronegative and bom in North 
Africa, West and Central Asia, and South East Asia and Oceania were resident in 
Essex or Bedfordshire and Hertfordshire SHAs. It was therefore not possible to 
consider interaction terms between SHA and maternal region of birth in this study. 
A basic ^ 2 test for heterogeneity of odds ratios did not show any significant 
interaction between maternal region of birth and SHA of residence for women bom 
in other regions, although this analysis does not take account of the effect of 
maternal age.
The optimal logistic regression model based on AIC (model 3), containing the three 
covariates was therefore refitted as a mixed effects model including a random effect 
on plate identity, which improved the goodness of fit. Table 7.10 shows the odds 
ratios and associated confidence intervals for logistic regression models number 1 to 
3 and the mixed effects model (numbered model 6 in Table 7.9). The odds ratios 
and standard errors were combined from the five multiply imputed datasets, as 
outlined in section 5.4.4.3.
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Predictors Model 1 Model 2 Model 3 Mixed effects model
Adjusted odds ratios* (95% Cl) Adjusted odds ratios* 
(95% Cl)
Maternal region of birth
UK
Sub-Saharan Africa
North Africa, West & Central Asia
South Asia
East, South East Asia & Oceania
Rest of Europe
Americas
1
4.56 (3.45,6.03)a 
3.19(2.14,4.76)“ 
5.59 (4.35,7.18)“ 
3.63 (2.27,5.81)“ 
2.26 (1.54,332)“ 
3.73 (2.35,5.93)“
1
4.73 (3.57,6.26)“ 
3.22 (2.15,4.81)“ 
5.60(4.34,7.22)“ 
3.93 (2.45,6.31)“ 
2.33(1.59,3.43)“ 
3.85 (2.42,6.11)“
1
4.15 (3.09,538)“ 
2.64 (1.74,4.01)“ 
4.86 (3.70,638)“ 
3.50(2.17,5.65)“ 
2.07 (1.40,3.07)* 
3.39(2.11,5.44)“
1
4.19(3.11,5.64)“ 
2.70(1.77,4.11)“ 
4.96(3.76,632)* 
338 (2.21,5.80)“ 
2.11 (1.42,3.13)“ 
3.42 (2.13,532)“
Maternal age group
<20 years 
20-24 years 
25-29 years 
30-34 years 
35+ years
2.45 (1.68,338)“
1.42(0.99, 2.02) 
1.00(0.74,1.36) 
1
0.97 (0.62,1.52)
2.51 (1.72,3.66)* 
1.44(1.00,2.06)b
1.00(0.74,1.36) 
1
0.97 (0.62,1.52)
233 (1.72,3.72)“ 
1.44 (1.01,2.06)d
1.00(0.74,1.36)
1
0.96(0.61,1.51)
Maternal SHA at delivery
North East London 
North Central London 
North West London 
Bedfordshire & Hertfordshire 
Essex
1
0.92(0.68,1.24) 
1.47 (1.15,1.88)c
0.80 (0.57,1.12) 
0.77 (0.52,1.13)
1
0.94 (0.69,1.27) 
1.41 (1.09,1.83)e
0.79(0.56,1.11) 
0.76(0.51,1.13)
Random effect on plate cru = 0.19 (0.09,0.36) 
p  = 0.05 (0.02,0.09)
Note: Odds ratios in bold indicate j x 0.05. *) p<0.001b) p=0.048c) p=0.020 d) p=0.044e) p=  0.009
Table 7.10. Combined results of multivariable logistic regression models (n = 17985).
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Compared to model 1 for which only maternal region of birth was included, 
inclusion of maternal age group in model 2 did not sizeably alter the odds ratios for 
maternal region of birth. However, when maternal SHA of residence at delivery was 
included in model 3, the point estimates of the adjusted odds ratios for maternal 
country of birth were slightly reduced (although the reduction was not statistically 
significant), implying that some of the increased odds in rubella seronegative status 
observed among women bom abroad was due to their area of residence within 
North Thames. In the mixed effects model which had the lowest AIC in Table 7.9,
the combined estimate of the random intercept Gu was 0.19 (95% Cl 0.09 to 0.36), 
and the intraclass correlation coefficient p  was 0.05, indicating that around 95% of 
the variation in maternal seronegative status was due to variation in maternal 
characteristics, and 5% due to variation between plates. Adjusting for random 
variation by plate therefore did not alter the odds ratios substantially.
The optimal model described in Table 7.10 shows that women bom abroad were 
more likely than women bom in the UK to be seronegative to rubella. Women bom 
in South Asia were at highest risk, with an odds ratio of 4.96 (95% Cl 3.76 to 6.52), 
implying they are nearly five times more likely than UK-bom women to be 
seronegative. Women bom in Sub-Saharan Africa were over four times as likely as 
UK-bom women to be seronegative, with an odds ratio of 4.19 (95% Cl 3.11 to 
5.64). Women bom in the Americas, and East and South East Asia and Oceania, 
were over three times more likely than UK bom women to be seronegative. In the 
former group, the increased odds of rubella seronegative status compared to the
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UK-bom group could mainly be accounted for by the high proportion of 
seronegative women bom in the Central America and the Caribbean and in South 
America (see Table 7.5). Among women bom in East and South East Asia and 
Oceania, the increased odds compared to UK bom women were due to the higher 
proportion of seronegative women bom outside Oceania. Likewise, the significantly 
increased odds ratio for women bom in European countries outside the UK (odds 
ratio 2.11, 95% Cl 1.42 to 3.13) was accounted for by the high proportions of 
seronegative women bom in Eastern and Southern Europe. The difference in the 
proportion of seronegative women bom in Western or Northern Europe and in the 
UK was not statistically significant.
Women under the age of 25 years, but particularly women under the age of 20 years 
were at significantly higher odds of being seronegative to rubella than women who 
give birth in their thirties. The women aged under 20 years were around two and a 
half times as likely to be seronegative than women aged 30 to 34 years. In addition, 
women resident in North West London SHA were significantly more likely to be 
seronegative to rubella than women resident in other SHAs in North Thames. As 
demonstrated in section 7.8 below, Brent Teaching PCT had the highest proportion 
of seronegative samples of all PCTs in North Thames. The significantly increased 
odds ratio in the group of samples for which the maternal SHA of residence was 
North West London could therefore be accounted for by the high proportion of 
seronegative samples from Brent Teaching PCT. When these samples were 
excluded, the odds ratio for North West London SHA in the mixed effects model
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decreased to 1.20, and was no longer significantly higher than the baseline (95% Cl 
0.90 to 1.59, p = 0.211).
Table A1 in Appendix D shows a version of Table 7.10, but with only complete 
cases (i.e. excluding missing cases for maternal age). Compared to the analyses of 
the complete case data, when analyses were carried out on the multiply imputed 
datasets the point estimate of the odds ratio for maternal age group was slightly 
reduced among women in the < 20 year age group and the 20 to 24 year age group. 
However, this difference in odds ratios before and after imputation was not 
statistically significant. For women bom in South Asia, the point estimate of the 
odds ratio was also lower when the analyses were carried out on the multiply 
imputed datasets, whereas for women bom in Sub-Saharan Africa or Europe, the 
odds ratio for rubella seronegative status compared to UK-bom women was higher 
in the analyses based on the multiply imputed datasets. In addition, the odds for 
rubella seronegative status for women resident in North West London SHA was not 
significantly higher than for women resident in North East London SHA (baseline) 
when the analyses was carried on the complete case dataset, but it was significant in 
the analyses carried out on the multiply imputed data, since the confidence intervals 
were smaller and the point estimate had increased.
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7.7 Characteristics of the mixture model components with larger 
means
The primary aim of fitting latent class regression finite mixture models without 
covariates was to define a seronegative population to be used as an outcome 
variable for the logistic regression models, which in turn were constructed to 
identify maternal characteristics which were independent risk factors for rubella 
seronegative status. The component of the optimal mixture model (described in 
Figure 7.13 and Table 7.3) with the lowest mean was thus used to define the 
seronegative population and the three components of the model with larger means 
(labelled “medium”, “high” and “highest” in Table 7.3) were grouped, with samples 
in these components assumed to be seropositive for rubella antibody. In order to 
examine the maternal characteristics of samples in the three components of the 
optimal mixture model with higher means, maternal variables were tabulated 
against allocation to the components of the optimal mixture model, based on 
maximised posterior probability. Figure 7.18 shows the proportion of samples 
allocated to each mixture model component by maternal age group.
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Figure 7.18. The distribution of samples by mixture model component and maternal age group.
As discussed in sections 7.5 and 7.6, a significantly higher proportion of samples 
with maternal ages less than 20 years were assigned to the low component, than 
samples with a maternal age over 25 years. Also, the proportion of samples assigned 
to the medium mixture model component (47.9%) was significantly higher for 
samples with a maternal age less than 20 years than for samples with a maternal age 
between 30 and 34 years. In the latter group, only 29.2% of samples were allocated 
to the medium component (test for equality of proportions p  < 0.001). Similarly, the 
proportion of samples in the highest mixture model component was lower if the 
maternal age was less than 20 years. 12.5% of samples with this maternal age group 
were assigned to the highest component, whereas 26.2% of samples for which the 
maternal age was between 30 and 34 years were allocated to the highest component 
(test for equality of proportions p  < 0.001). This indicates that overall, women under 
the age of 20 years appear to have lower antibody levels than older women. For
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samples with maternal ages over 20 years, there was little difference in the 
proportion assigned to the four mixture model components, with around 30% of 
samples assigned to the medium component, 40% of samples assigned to the high 
component and around 25% assigned to the highest component. However, for 
samples with maternal ages between 20 and 24 years, a significantly lower 
proportion was assigned to the highest mixture model component than for samples 
with a maternal age between 30 to 34 years (test for equality of proportions p < 
0.001), although the absolute difference in percentages only amounts to only 5.4%.
Figure 7.19 shows the proportion of samples allocated to each mixture model 
component by maternal SHA of residence.
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Figure 7.19. The distribution of samples by mixture model component and maternal SHA of 
residence.
Apart from the higher proportion of samples from North East, North West and 
North Central London SHA allocated to the low component of the mixture model 
compared to samples from Essex and Bedfordshire and Hertfordshire SHA, the 
proportion of samples from North East London SHA allocated to the highest 
component is significantly lower than samples from for example Bedfordshire and 
Hertfordshire SHA (test for equality of proportions p<0.001). The absolute 
difference in proportions is small however, 4.6%.
Figure 7.20 shows the distribution of samples allocated to each mixture model 
component by maternal region of birth.
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Figure 7.20. The distribution of samples by mixture model component and maternal region of 
birth.
Figure 7.20 shows that for samples with a maternal region of birth coded as the UK 
or the rest of Europe, a lower proportion were assigned to the low and medium 
component and a higher proportion to the high and highest components, than 
samples with a maternal region of birth outside Europe. For example, the proportion 
of samples for which the maternal region of birth was Europe and allocated to the 
high mixture model component was 42.5% compared to only 35.6% of samples for 
which the mother was bom in East and South East Asia and Oceania. This 
difference was statistically significant (test for equality of proportions p  <0.001). 
However, the proportion of samples assigned to the low component was 
significantly higher if the maternal region of birth was in Europe than in the UK, as 
described in section 7.6. The difference in the distribution of samples assigned to 
the four components of the optimal mixture model by maternal age group was
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further explored by stratifying the samples by whether the maternal region of birth 
was in or outside the UK. These distributions are shown in Figure 7.21 A and 7.21B 
below.
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Figure 7.21. The distribution of samples by mixture model component by maternal age group 
for women born in the UK (A) and outside the UK (B).
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The distribution of samples allocated to the four mixture model components by 
maternal age group differs depending on whether the mother was bom in or outside 
the UK, as shown in Figure 7.21. Apart from the higher proportion of samples with 
a maternal region of birth outside the UK allocated to the low component, 54.2% of 
samples for which the mother was UK-born and aged less than 20 years were 
allocated to the medium component of the mixture model, whereas for samples with 
a maternal region of birth outside the UK and the same maternal age group, only 
28.8% were allocated to the medium component. Conversely, 36.7% of samples 
with a maternal age over 40 years in the non-UK bom group were allocated to the 
medium component, compared to only 26.4% of samples with the same maternal 
age group and for which the mother was bom in the UK. Both these differences 
were statistically significant (test for equality of proportions p  < 0.001 and p -  
0.016 respectively). A higher proportion of samples for which the mother was non- 
UK bom and under the age of 20 was allocated to the high or highest component 
(60.9%) than if the mother was UK-born and of the same age. Only 42.3% of 
samples where the mother was UK-bom and aged less than 20 years were in the two 
highest components (test for equality of proportions p  < 0.001).
These analyses should be interpreted with some caution. Whereas the component 
with the lowest mean appears well defined and separated from the other four in the 
optimal mixture model (see Figure 7.13 on page 223), the three components with 
larger means are not well separated. There is therefore significant scope for 
misclassification of samples between the three components with higher means.
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Results of comprehensive analyses of the influence of maternal characteristics on 
the component weights are presented in the next chapter.
7.8 Ecological analysis of rubella seronegative status and MMR 
uptake by PCT
The estimate of the proportion of pregnant women seronegative to rubella by PCT 
was used to assess the relationship between MMR uptake among children and 
prevalence of maternal rubella seronegative status at PCT level to identify PCTs 
with high proportions of seronegative women and low MMR uptake among 
children. Table 7.11 shows the prevalence of maternal rubella seronegativity and the 
proportion of children who have received their first dose MMR vaccine by their 
second birthday by PCT in North Thames in 2004, using data from the rubella 
serosurvey and the NHS Health and Social Care Information Centre134;345 
respectively. In Table 7.11, PCTs are grouped by SHA. Figure 7.22 shows a map of 
the point estimates of the proportion of women in the serosurvey estimated to be 
seronegative to rubella by PCT in North Thames in 2004.
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Number PCT Number of samples in % of seonegative women (95% Cl) % MMR uptake*
on maps serosurvey
Bedfordshire and Hertfordshire SHA
1 Bedford 316 2.5% (0.9,7.2) 85%
2 Bedfordshire Heartlands 521 1.3% (0.7, 2.7) 80%
3 Luton 575 1.6% (0.9, 2.8) 73%
4 North Hertfordshire & Stevenage 382 2.6% (1.3, 5.2) 82%
5 South East Hertfordshire 375 0.3% (0,1.9) 79%
6 Royston, Buntingford & Bishop's 
Stortford
149 0.7% (0.1,4.6) 78%
11 Dacorum 290 1.0% (0.3, 3.2) 78%
12 St. Albans & Harpenden 262 0.8% (0.2, 2.9) 81%
13 Welwyn Hatfield 170 0.6% (0.1,4.0) 80%
18 Watford & Three Rivers 374 2.9% (1.5, 5.6) 82%
19 Hertsmere 191 0% (0,1.9) 78%
Essex SHA
7 Uttlesford (124) 124 0.8% (0.1, 5.5) 76%
8 Witham, Braintree & Halstead (311) 311 1.0% (0.2,4.1) 79%
9 Colchester (328) 328 1.5% (0.7, 3.6) 78%
10 Tendring (179) 179 3.9% (1.2,12.1) 78%
14 Harlow (205) 205 2.0% (0.7, 5.0) 85%
15 Epping Forest (266) 266 1.5% (0.5,4.8) 76%
16 Chelmsford (265) 265 0.8% (0.2, 2.9) 81%
17 Maldon & South Chelmsford (106) 106 0% (0, 3.4) 79%
24 Billericay, Brentwood & Wickford (241) 241 0.8% (0.2, 3.3) 71%
25 Basildon (282) 282 0.7% (0.2, 2.7) 80%
26 Castle Point and Rochford (289) 289 1.7% (0.8, 3.9) 77%
33 Thurrock (416) 416 1.0% (0.4, 2.4) 79%
34 Southend on Sea (343) 343 0% (0,1.1) 74%
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Number PCT Number of samples in % of women seronegative to rubella % MMR uptake*
on maps serosurvey (95% ci)
North West London SHA
27 Hillingdon (642) 642 2.5% (1.7, 3.6) 73%
28 Harrow (584) 584 4.1% (2.3,7.4) 79%
35 Hounslow (470) 470 3.2% (1.6,6.2) 78%
36 Ealing (728) 728 3.9% (2.8, 5.3) 80%
37 Brent Teaching (776) 776 6.7% (5.1,8.7) 76%
38 Hammersmith & Fulham (19) 19 0% (0,17.6) 64%
39 Kensington & Chelsea (132) 132 2.3% (1.1,6.7) 50%
40 Westminster (326) 326 4.0% (2.2,7.0) 68%
North Central London SHA
20 Enfield (628) 628 3.7% (2.5, 5.3) 73%
29 Barnet (714) 714 2.0% (1.1, 3.4) 73%
30 Haringey Teaching (679) 679 1.9% (1.1, 3.3) 73%
41 Camden (547) 547 2.6% (1.6,4.0) 64%
42 Islington (500) 500 2.0% (1.1, 3.7) 68%
North East London SHA
21 Waltham Forest (725) 725 4.0% (2.8, 5.6) 86%
22 Redbridge (512) 512 1.4% (0.7,2.8) 82%
23 Havering (444) 444 1.1% (0.5, 2.6) 74%
31 Newham (829) 829 4.2% (3.3, 5.4) 77%
32 Barking and Dagenham (386) 386 4.2% (2.4, 7.2) 77%
43 City & Hackney Teaching (680) 680 2.2% (1.4,3.5) 72%
44 Tower Hamlets (703) 703 3.7% (2.5,5.5) 67%
*MMR uptake adapted from Table 8 in NHS Health and Social Care Information Centre
Table 7.11. The percentage of seronegative women and first dose MMR uptake among two-year old children by PCT in 2004
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□  Denominator <100 samples 
Q 0-1.49%
■ 1.50-3.49%
■ 3.50-5.00%
■ >5.00%
Figure 7.22. The proportion of rubella seronegative samples by maternal PCT of residence, 
2004.
Brent Teaching PCT had the highest proportion of seronegative pregnant women in 
this serosurvey, with 6.7% of women found to be seronegative (95% CI 5.1% to 
8.7%). In both Barking and Dagenham and Newham PCTs, 4.2% of women were 
seronegative (95% CIs 2.4% to 7.2% and 3.3% to 5.4% respectively). Overall, the 
PCTs with the highest prevalence of maternal rubella seronegativity in North 
Thames were concentrated in North West and North East London, with the 
exception of Tendring PCT in north eastern Essex, where 3.9% of women were 
found to be seronegative (95% CI 1.2% to 12.1%).
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In this serosurvey, the lowest prevalence of maternal rubella seronegativity was 
found in Southend on Sea, Hertsmere, and Maldon and South Chelmsford PCTs. No 
samples from these PCTs were found to be seronegative (95% CIs 0 to 1.1%, 0 to 
1.9% and 0 to 3.4% respectively). Although no women resident in Hammersmith 
and Fulham PCT were found to be seronegative, this estimate was based on only 19 
samples (see Table 7.11), since most of the newborn screening samples collected in 
this PCT are sent to a neonatal screening laboratory outside North Thames. All 
other estimates of the prevalence of maternal rubella seronegativity by PCT were 
based on at least 100 samples. Hammersmith and Fulham PCT was therefore 
excluded from further analyses in this section.
Moran’s I statistic for the prevalence of rubella seronegativity in pregnant women 
by PCT was 0.35, (p < 0.001), indicating significant positive spatial autocorrelation. 
That is, for each PCT, neighbouring PCTs have similar a prevalence of rubella 
seronegativity. This pattern can also be observed in the map in Figure 7.22; overall, 
the PCTs with the highest proportions of seronegative women were located in 
central London.
Figure 7.23 shows a map of the proportion of children who have received their first- 
dose MMR vaccine by their second birthday by PCT in 2004, created using the data 
in Table 7.11.
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■ <65%
■ 65-74%
■ 75-84%
□ over 85%
Adapted from NHS Health and Social Care Information Centre134;345.
Figure 7.23. First dose MMR uptake among two-year old children by PCT in North Thames in 
2004.
In 2004, only 12 of 44 PCTs in North Thames (27.3%) had achieved a first dose 
MMR uptake in 2-year old children of 80% or over. This is the level of uptake 
required in the long term to ensure herd immunity to, and eventually eradicate 
rubella81:82. PCTs in North Central London and North West London SHAs had the 
lowest MMR uptake in North Thames.
Figure 7.24 shows the uptake of first dose MMR vaccine in children by their second 
birthday by PCT in 2004 plotted against the point estimates of the percentage of 
seronegative women obtained from the serosurvey, together with the fitted 
regression line and its prediction confidence intervals.
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Figure 7.24. First dose MMR uptake in children by the second birthday (in %) plotted against 
the percentage of women who are seronegative (n=43).
The Pearson correlation coefficient between first dose MMR uptake in two-year old 
children and the prevalence of rubella seronegativity in pregnant women at PCT 
level was equal to -0.1, with a 95% CI of -0.4 to 0.2. The slope of the regression 
line shown in Figure 7.24 equalled -0.02 with a 95% CI of -0.10 to 0.05, p  = 0.528), 
implying no significant inverse relationship between MMR uptake among children 
and the proportion of seronegative women at PCT level. Two outliers in Figure 7.24 
were identified: Brent Teaching PCT, where 6.7% of women were estimated to be
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seronegative, and Kensington and Chelsea PCT, where only 50% of two-year old 
children had received their first dose MMR vaccine. Both of these are marked in 
Figure 7.24. When these PCTs were excluded from the linear regression model, the 
regression coefficient was slightly reduced to -0.03 (95% CI -0.13 to 0.06).
The results of this cross-sectional ecological regression analysis imply that overall, 
PCTs with relatively low MMR uptake such as Kensington and Chelsea PCT, do 
not also have high proportions of women who are seronegative to rubella. However, 
in the three PCTs with the highest proportions of women seronegative, Brent 
Teaching, Barking and Dagenham and Newham, the uptake of MMR among 
children was still below the level required to ensure herd immunity among children 
in 2004 (76%, 77% and 77% respectively).
7.9 Estimated number of births to seronegative women in England
Using the estimated proportion of seronegative samples by maternal age group and 
region of birth, the estimated number of births to women seronegative to rubella in 
England, by Government Office Region in 2004 was obtained. This projection was 
based on the complete case dataset, without imputed values for maternal age. These 
results are shown in Table 7.12. The uncertainty ranges were obtained from the 95% 
CIs around the estimated proportion of women seronegative to rubella by age group 
and region of birth from the serosurvey, adjusted for sampling strategy.
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Government % seronegative Number of Estimated number Uncertainty
Office Region pregnant women births in of births to range
(uncertainty range) 2004* seronegative women
London 2.8% (1.5% -5.5%) 113474 3154 1690 to 5865
South East 1.6% (0.9% -2.8%) 93580 1544 816 to 2590
South West 1.4% (0.8% - 2.3%) 52270 754 400 to 1222
East 1.7% (0.9% - 2.7%) 64229 1061 576 to 1765
West Midlands 2.0% (1.2%-3.1%) 65890 1294 767 to 2037
East Midlands 1.6% (0.9% - 2.6%) 48228 773 435 to 1242
Yorkshire and
Humber 1.8% (1.1%-2.8%) 60182 1073 639 to 1669
North West 1.7% (1.0%-2.7%) 81145 1391 810 to 2188
North East 1.5% (0.9% - 2.3%) 27184 418 242 to 649
England 1 3 %  (l.l-3.2%) 606812 11462 6374 to 19227
*Note: excludes births for which a Government Office Region was not stated and births where maternal country of birth was coded 
as “Rest of World”.
Table 7.12. Projected number of births to rubella seronegative women by Government Office 
Region in England 2004.
Around 11500 births were to seronegative women in England in 2004. However, 
the uncertainty range around this estimate is wide, from around 6000 to nearly 
20000 births, reflecting the wide confidence intervals around the proportion of 
women seronegative to rubella in some age- and region of birth categories. The 
estimated numbers of births to seronegative women varies greatly by Government 
Office Region, due to differences both in the population bom abroad as well as birth 
rates. London had the highest proportion of births to rubella seronegative women, 
whereas the South West had the lowest.
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Key points
• A latent class regression finite mixture model was fitted to the full distribution 
of the natural logarithms of maternally-derived rubella IgG levels from 18882 
newborn dried blood spot samples collected in the North Thames area in 2004. 
The samples allocated to the component with the lowest mean of the optimal 
mixture model, based on posterior probabilities, were assumed to be 
seronegative.
• Based on this definition, 509 of 18882 samples were seronegative, implying that 
2.7% of pregnant women in North Thames were seronegative to rubella (95% 
CI 2.4% to 3.0%) in 2004.
• Women bom outside the UK were more likely to be seronegative to rubella than 
women bom in the UK. Also, women under the age of 20 years were more 
likely to be seronegative than women having children in their thirties.
•  6.7% of samples from Brent Teaching PCT were seronegative; this was the 
highest proportion for any PCT in North Thames. Overall, the PCTs with the 
highest proportions of seronegative women did not also have the lowest 
proportions of MMR uptake among children.
• Using the estimated proportion of rubella seronegative samples by maternal age 
and region of birth from the serosurvey, it was estimated that around 11500 
births in England and Wales in 2004 were to women seronegative to rubella 
(uncertainty range 6374 to 19227).
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8. Results of latent class regression finite mixture models 
with covariates
8.1 Models with covariates for one parameter in, ji or &) only
Latent class regression finite mixture models with covariates, as described by 
equation 4 on page 172 were fitted to the natural logarithms of the OD ratios of 
rubella IgG antibody levels (ln(OD ratio)). Normal distributions were assumed for 
the components since this led to a better fit for the mixture models without 
covariates (see section 7.4). Maternal age was kept as a continuous variable, and 
since there was some evidence of a quadratic relationship between maternal rubella 
IgG antibody level and age (see for example Figure 7.16 in chapter 7), a quadratic 
term for age was also included to investigate if this improved the models’ goodness- 
of-fit. As described in section 5.4.4.1, samples for which the maternal region of 
birth was coded as not known or not stated were excluded (n = 558). A further two 
samples for which maternal SHA of residence was coded as missing or not known 
were also excluded, since their inclusion kept the models from converging. This left 
18322 samples for analyses. This exclusion process is described in the flowchart in 
Figure 8.1.
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18882 eligible samples
18322 samples included in latent class 
regression finite mixture models
2 remaining samples 
without a known SHA of 
residence
558 samples without successful 
data linkage (unknown region of 
birth)
Figure 8.1 Exclusion process for latent class regression finite mixture models
Initially, three sets of models were fitted with covariates for the component weights 
(a),  means ( / / )  and SDs ( o ) separately, without including covariates for the other 
two parameters. For each set of models, covariates and interaction terms were 
included in a forward stepwise procedure. Table 8.1 shows the covariates included 
in the linear predictors for each model set.
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Model
number
Covariates included
1 None
2 Age
3 Age + age2
4 Region of birth
5 SHA
6 Age + region of birth
7 Age + SHA
8 SHA + region of birth
9 Age + region of birth + SHA
10 Age + Age2 + region of birth
11 Age + Age2 + SHA
12 Age + Age2 + region of birth + SHA
13 Age * region of birth
14 Age * SHA
15 SHA * region of birth
16 Age * region of birth + SHA
17 Age * SHA + region of birth
18 Age + region of birth * SHA
19 Age * region of birth * SHA
20 (Age + age2) * region of birth
21 (Age + age2) * SHA
22 (Age + age2) * SHA + region of birth
23 (Age + age2) * region of birth + SHA
24 Age + age2 + SHA * region of birth
25 (Age + age2) * SHA * region of birth
Table 8.1. Covariates and interaction terms included in the latent dass regression finite 
mixture models.
The components of the mixture models were assumed to be normally distributed, 
since the assumption of gamma distribution components lead to a worse fit for the 
mixture models fitted without covariates on the basis of BIC as described in section 
7.4 in the previous chapter. Each of the models described in Table 8.1 were fitted 
assuming between two to five components. Thus, for each of the three parameters, 
100 models were fitted, and in total for this first stage of the model selection 
strategy, 300 models were fitted. The results of these models, stratified by the 
parameter for which covariates were included in the linear predictor can be found in
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Table A.2A to A.2C of Appendix E. The models have been ordered by BIC, in 
ascending order.
Overall, in the best-fit model based on minimisation of BIC, maternal age (with a 
quadratic term) and maternal region of birth were included as covariates in the 
linear predictor of the component weight (tt). This model had four components. The 
BIC attained for this model was 35227.3. Similarly, of the models with covariates 
for the mean ( / / )  only, the model with the lowest BIC also had four components 
and maternal region of birth and maternal age with a quadratic term as covariates. 
This model had a BIC of 35343.8, but as shown in Table A2.A in Appendix E, the 
BIC was lower than this for six models with covariates for the component weights. 
Of the models with covariates for the component SDs only, the lowest BIC was 
attained when five components were assumed and maternal region of birth, age as a 
quadratic term and an interaction term were included as covariates. The BIC 
attained for this model was 35682.7.
The BICs obtained for these models varied according to the mixture model 
parameter for which covariates were included, as demonstrated in the boxplot in 
Figure 8.2 below.
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Figure 8.2. BICs obtained by parameter for which covariates were included (n=300).
The lowest values of BIC were obtained when covariates were fitted to the 
component weights {n). However some of the highest BIC values also resulted from 
these models. Fitting covariates to the component means (ju) also resulted in some 
very large values for BIC. For these two sets of models, the models with the highest 
values of BIC were those including all three maternal variables (age, region of birth 
and SHA) as predictors and an interaction term (models 19 and 25 in Table 8.1). 
The median BICs for models with covariates for the component weight, mean and 
SD were 35782.6, 35781.4 and 35808.0 respectively.
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The BIC obtained from these models also varied by the number of components 
included in the models, as demonstrated in Figure 8.3.
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Note: The thick black lines indicate the median, the boxes the interquartile range, and the whiskers extend to the most extreme 
observation less than 1.5 times the interquartile range from the box.
Figure 8.3. BIC obtained by the number of components included in the mixture model
(n=300).
Overall, the lowest values of BIC were attained for models with four or five
components, for which the median BICs were 35688.3 and 35687.6 respectively.
Models with only two components had the highest values of BIC overall. The
median BIC attained for these models was 36784.9. The lowest BIC was attained
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with a four-component model when the mixture models were fitted without 
covariates. As the number of components increases, the number of outliers with 
extreme values, both high and low, of BIC also increased. The outliers with high 
BIC values were attained for the models with an interaction between all three 
maternal variables (model number 19 and 25 in Table 8.1).
The use of AIC instead of BIC would have favoured models with five, rather than 
four components. Of the 25 groups of covariates described in Table 8.1 and fitted as 
linear predictors for the component weight, mean and SD, for 20 of the total 75 
model groups (26.7%) the lowest BIC was attained when fitted with five 
components. However, if AIC had been used as a model selection criterion, models 
with five components would be optimal for 59 of 75 model groups (78.7%). If AIC 
had been used as a model selection criterion, the optimal model would have been a 
model with five components, and including maternal age as a quadratic term, region 
of birth and SHA as covariates for the component weights. An AIC of 34831.4 was 
attained for this model.
8.2 Refitting of models including covariates for other parameters
The three models with the lowest values of BIC with in Tables A.2A to A.2C in 
Appendix E were refitted with single covariates for the other two parameters, to 
investigate whether model fit improved. This resulted in 72 new models, 24 for each 
of the three optimal models with covariates for one parameter only. Tables 8.2, 8.3
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and 8.4 show the results of refitting the optimal model with covariates for the 
component weights, means and SDs respectively.
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Optimal model Number of 
components
AIC BIC
it -  age + age51 + region of birth 4 34953.7 35227.3
Parameters also included in refitted model Number of 
components
AIC BIC
H -  age 4 34949.7 35254.5
// -  age + age2 4 34947.1 35283.2
// -  region of birth 4 34968.8 35430.0
//-SH A 4 34917.4 35347.3
<7- age 4 34972.0 35276.8
a  -  age + age2 4 35201.0 35537.1
<r~ region of birth 4 34989.5 35450.6
a  -SHA 4 34984.7 35414.5
// -  age, a  -  age 4 34942.1 35278.2
/ /  -  age, a  -  age + age2 4 34949.6 35254.2
// -  age, <7 -  region of birth 4 34951.9 35256.7
// -  age, <7 -  SHA 4 35197.4 35658.6
// -  age + age2, a  -  age 4 34952.4 35288.5
// -  age + age2, <7 -  age + age2 4 34982.7 35318.8
fx -  age + age2, a  -  region of birth 4 34953.3 35289.4
ix -  age + age2, a  -  SHA 4 34952.7 35288.8
fx -  region of birth, -  age 4 34994.9 35456.1
fx -  region of birth, a  -  age + age2 4 34991.8 35453.0
// -  region of birth, a  -  region of birth 4 34983.0 35444.1
ix -  region of birth, a  -  SHA 4 34985.8 35446.9
fx -  SHA, <7 -  age 4 34924.6 35354.5
fx -  SHA, <7 -  age + age2 4 34923.6 35353.5
H -  SHA, a  -  region of birth 4 35069.3 35499.1
//-SH A , <7-SHA 4 34924.6 35354.4
Table 8.2. Results of refitting the optimal model with covariates for the component weights (n 
= 18322).
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Optimal model Number of components AIC BIC
H ~ age + age2 + region of birth 4 35007.7 35343.7
Parameters also included in refitted 
model
Number of components AIC BIC
it ~ age 4 35046.9 35383.0
it ~ age + age2 4 35007.8 35390.8
7t ~ region of birth 4 35024.5 35501.3
tt-SHA 4 35104.8 35558.1
age 4 35017.0 35353.1
a  ~ age + age2 4 34956.7 35261.6
o  ~ region of birth 4 35000.5 35297.5
<r~ SHA 4 34951.9 35256.7
7t ~ age, a  ~ age 4 34901.3 35268.6
it ~ age, a  ~ age + age2 4 34992.0 35335.9
it ~ age, a  ~ region of birth 4 35026.3 35385.8
7t ~ age, a  ~ SHA 4 35010.8 35370.3
it ~ age + age2, a  ~ age 4 35118.5 35532.7
7t ~ age + age2, a  ~ age + age2 4 35009.6 35392.6
it ~ age + age2, a  ~ region of birth 4 35087.2 35470.2
it ~ age + age2, a  ~ SHA 4 35044.0 35426.9
7t ~ region of birth, a  ~ age 4 35032.6 35540.6
it ~ region of birth, a  ~ age + age2 4 34979.9 35456.6
it ~ region of birth, a  ~ region of birth 4 34999.9 35476.6
it ~ region of birth, a  ~ SHA 4 35001.8 35478.6
^ ~ SHA, a  ~ age 4 35477.9 35915.6
it ~ SHA, <j ~ age + age2 4 34961.1 35414.5
^ ~ SHA, a  ~ region of birth 4 35046.0 35499.3
it ~ SHA, a  ~ SHA 4 35271.6 35724.9
Table 8.3. Results when refitting optimal model with covariates for the component means (it = 
18322).
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Optimal model Number of components AIC BIC
a  -(Age + agez) * region of birth 5 35573.2 35682.7
Parameters also included in refitted model Number of components AIC BIC
J t~  age 5 35480.4 35621.1
Jt -  age + age2 5 35435.1 35607.1
Jt ~ region of birth 5 35085.2 35382.2
?r-SHA 5 35439.2 35704.9
//-age 5 35498.8 35647.3
// -  age + age2 5 35468.1 35655.7
fx -  region of birth 5 35164.9 35508.8
//-SH A 5 35582.1 35886.9
j t  -  age, // -  age 5 35458.0 35637.7
i t  -  age, // -  age + age2 5 35428.7 35647.5
i t  -  age, // -  region of birth 5 35053.1 35428.3
7t -  age, // -  SHA 5 35433.2 35769.3
Jt -  age + age2, //-a g e 5 35455.7 35666.7
i t  -  age + age2, // -  age + age2 5 35452.6 35702.7
i t  -  age + age2, // -  region of birth 5 35017.6 35424.0
7t -  age + age2, // -  SHA 5 35121.2 35480.8
i t  -  region of birth, // -  age 5 35015.4 35351.5
i t  -  region of birth, fx -  age + age2 5 34957.2 35332.4
Jt -  region of birth, [x -  region of birth 5 35143.6 35675.1
Jt -  region of birth, fx -  SHA 5 35060.5 35552.9
j t  -  SHA, [x -  age 5 35359.2 35664.1
Jt -  SHA, fx -  age + age2 5 35324.4 35668.3
j t  -  SHA, fx -  region of birth 5 35120.6 35620.8
Jt -  SHA, fx -  SHA 5 35470.9 35900.7
Table 8.4. Results when refitting optimal model with covariates for the component SDs (n = 
18322).
Including single covariates for the means and SDs in the optimal model with 
covariates for the component weights did not improve model fit based on BIC. 
However, including further covariates led to a reduction in the BIC for the models 
with covariates for the component means and SDs respectively. For example, as 
shown in Table 8.3, including maternal SHA of residence at delivery as a covariate 
for the component weight would decrease the BIC of the original model from 
35343.7 to 35256.7. Likewise, as demonstrated in Table 8.4, including maternal 
region of birth as a covariate for the component weight and maternal age with a 
quadratic term for the component mean would reduce the BIC of the model with
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covariates for the component SDs from 35682.7 to 35332.4. However, the lowest 
BIC overall was achieved when maternal age as a quadratic term and maternal 
region of birth were included as covariates for the component weights. As the fit of 
this model was not improved by inclusion of covariates for the component means 
and SDs, this implies that the majority of the total variation in rubella IgG antibody 
level can be explained by variation in maternal characteristics in the component 
weights. That is, the variation in rubella antibody level by maternal region of birth 
for example, is mostly explained by the component weights varying between 
women bom in different world regions, rather than the mean or SD for a given 
component varying according to the women’s region of birth age. SHA was not 
included as a covariate in the final model. This is most likely a result of using BIC 
as a model selection criterion, as it is highly conservative against overfitting. 
However, the use of BIC was justified in these models in order to control against 
overfitting the number of components of the mixture model, as well as the number 
of covariates.
8.3 Characteristics of the optimal model
The best-fit model based on BIC takes the following form:
/,<?;) = i> .(& o  +A>AM; + ^ MAj + ... + 0 l>R o B ? % (y / ,/ik<rk)
k=1
Equation 21
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where yj is an observation of ln(OD ratio), k is the number of components, MA is 
maternal age, RoB is region of birth, and RoB\m) is an indicator function taking the
value 1 if RoB = m and 0 otherwise. This model had 35 parameters. Figure 8.4 
shows the densities of the components of the optimal model with covariates, the 
component weights, and the density function of the 18322 ln(OD ratio) values. 
Table 8.5 shows the proportion of samples allocated to each component, together 
with means and confidence intervals.
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Figure 8.4. Density functions of the components of the optimal mixture model, component 
weights and the total density function (n = 18322).
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Component Number of samples 
allocated to 
component
% of samples in 
component (95% Cl)
Mean optical
density
ratio*
95% Cl for 
mean*
Low 460 2.5% (2.3%, 2.7%) 0.15 0.12,0.19
Medium 5380 29.4% (28.7%, 30.0%) 0.97 0.95,0.99
High 7680 41.9% (41.2%, 42.6%) 1.90 1.87,1.92
Highest 4802 26.2% (25.6%, 26.9%) 3.15 3.11,3.19
Table 8.5. The number of samples allocated to each component based on posterior 
probabilities, and component means with confidence intervals (n = 18322).
The terms “low”, “medium”, “high” and “highest” components refer to the relative 
sizes of the component means. These terms will be used throughout this chapter to 
refer to these components of the optimal mixture model. The component densities in 
this model are similar to those shown in the mixture model without covariates in 
Figure 7.13 in chapter 7. Figure 8.5 shows the rootogram of the posterior 
probabilities in this model, and Table 8.6 shows the overlap between the 
components, expressed as the probability of an observation lying in a region of 
overlap between the densities of two components.
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Figure 8.5. Rootogram of the components of the optimal m ixture model presented in Figure 8.4 
and Table 8.5 (n = 18322).
M ixture model M ixture model component
component Low M edium  High Highest
Low 0.06 0.001 0
Medium n  0.43 0.11
High
Highest . . .  . . . .
Table 8.6. Overlap between the m ixture model components.
The degree of separation of the posterior probabilities for the optimal model with 
covariates appears very similar to those for the mixture model without covariates 
shown in Figure 7.14 and Table 7.4 in chapter 7. The component with the lowest 
mean was well defined but the three components with higher means were not, as
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evidenced by the high proportion of samples with posterior probabilities greater 
than zero, and the large overlap between the high and medium, and high and highest 
component. In contrast, the probability of an observation lying in a region of 
overlapping densities of the low and the medium component was only 6%.
The linear predictors for the component weights, means and standard deviations of 
the optimal model are shown in Table 8.7.
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Component 7t a
Low (baseline) Intercept 0 -1.90 0.46
Age 0
Age2 0
Region of birth
UK 0
Americas 0
Rest of Europe 0
N Africa, W & C Asia 0
South Asia 0
E & SE Asia, Oceania 0
Sub-Saharan Africa 0
Medium Intercept 1.47 -0.03 0.55
Age 0.12
Age2 -0.002
Region of birth
UK 1 (baseline)
Americas -1.27
Rest of Europe -1.08
N Africa, W & C Asia -1.16
South Asia -1.52
E & SE Asia, Oceania -1.08
Sub-Saharan Africa -1.54
High Intercept -1.74 0.64 0.34
Age 0.36
Age2 -0.006
Region of birth
UK 1 (baseline)
Americas -1.89
Rest of Europe -1.04
N Africa, W & C Asia -1.49
South Asia -2.23
E & SE Asia, Oceania -1.98
Sub-Saharan Africa -2.02
Highest Intercept -3.32 1.15 0.22
Age 0.41
Age2 -0.006
Region of birth
UK 1 (baseline)
Americas -2.07
Rest of Europe -0.84
N Africa, W & C Asia -1.69
South Asia -2.46
E & SE Asia, Oceania -2.11
Sub-Saharan Africa -1.99
Table 8.7. The linear predictors for the component weights (n), means (p) and SDs (a) in  = 
18322).
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The variation in component weights by maternal age is shown for women bom in 
the seven different world regions in Figure 8.6. These graphs were obtained by 
applying the linear predictors in Table 8.7.
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Figure 8.6. Predicted component weights (n) by maternal age and region of birth, from the optimal mixture model (n = 18322).
2 8 1
There is a <7-shaped relationship between the component weights for the low and 
medium component and maternal age, whereas the high and the highest component 
have an inverse {/-shape relationship with maternal age. This indicates that rubella 
IgG antibody levels were lower in the youngest and the oldest women, which was 
also observed in section 7.6 in the previous chapter, when antibody levels were 
dichotomised according to the components of the optimal mixture model.
The component weights also vary by maternal region of birth. This is also 
illustrated in Table 8.8, showing the component weights for each component for a 
woman of median age (30 years) by maternal region of birth. These component 
weights were obtained by applying the linear predictors presented in Table 8.7 
above.
Mixture model component
Region of birth Low Medium High Highest
UK 0.1% 28.3% 43.9% 27.0%
Americas 4.4% 42.1% 35.4% 18.1%
Rest of Europe 2.2% 25.5% 41.3% 31.0%
West & Central Asia, North 3.4% 35.9% 40.5% 20.2%
Africa
South Asia 5.9% 43.9% 33.7% 16.4%
East & South East Asia, 4.2% 48.6% 30.7% 16.5%
Oceania
Sub-Saharan Africa 5.1% 36.9% 35.5% 22.5%
Table 8.8. Component weights for women of median age (30 years) by region of birth
For the component with the lowest mean, women aged 30 years and bom in the UK 
had the smallest component weight (0.1%), whereas women of the same age bom in 
South Asia, Sub-Saharan Africa, and the Americas had the largest weights for this
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component, 5.9%, 5.1% and 4.4% respectively. This is also illustrated in Figure 8.6 
above.
Overall, the component weights for the medium component were higher at every 
age for women bom abroad than for women bom in the UK. On the other hand, the 
component weights for the components with the two largest means are greater at 
every age for UK-bom women. For example, the component weight for the high 
component is equal to 43.9% for UK-bom women aged 30 years, whereas it is 
33.7% and 30.7% for 30-year old women bom in south Asia, and south east Asia 
and Oceania respectively. The difference in the component weights for the high 
component is less pronounced between UK-bom women and women bom in the 
rest of Europe.
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Key points
• Latent class regression finite mixture models were fitted to the distribution of 
rubella IgG levels. Maternal age, region of birth and SHA of residence were 
included as linear predictors for the component weights, means and SDs.
•  The optimal model (based on the lowest BIC value obtained) included maternal 
age and maternal region of birth as linear predictors for the component weight. 
This model had four components.
•  A 17-shaped relationship was found between maternal age and the component 
weights for the components with the two smallest means. For the components 
with the two largest means, an inverse (/-shaped relationship was identified.
•  The greatest component weights for the component with the lowest mean for a 
woman of median age (30 years) was found among women bom in South Asia 
and Sub-Saharan Africa.
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9. Discussion
9.1 Introduction
Maternal rubella infection during the first trimester in pregnancy can result in severe 
and multiple birth defects in the fetus. Congenital rubella infection is a significant 
cause of childhood disability worldwide28, but in the UK cases of rubella and 
congenital rubella are now rare as a result of a successful vaccination programme, 
first introduced in 1970 and initially targeted at schoolgirls. Since 1988, 
immunisation has been offered to all pre-school children as part of MMR vaccine, 
however uptake has declined since the late 1990s following widespread media 
reporting of an alleged link to autism and bowel disease133. Although uptake has 
increased since 2003, it has not yet reached the level required to ensure herd 
immunity81182. MMR uptake is particularly low in London, where it has been below 
the level required to maintain herd immunity for many years. Several studies18;169'172 
in the UK have highlighted a higher prevalence of rubella susceptibility among 
women bom outside the UK. In London, which has inadequate MMR uptake among 
children, and an increasing migrant population bom in countries without rubella 
vaccination programmes, the risk of rubella outbreaks is of concern, as it may 
spread to pregnant women.
In this thesis, the results of a large serosurvey of rubella IgG antibody in pregnant 
women in the highly ethnically diverse North Thames area of England are 
presented. Since dried blood spot samples from newborn screening rather than
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serum samples were used to estimate maternally acquired antibody, this required 
som e important methodological adjustments. First, appropriate ELISAs were 
validated for use on dried blood spot samples. Second, due to the low sensitivity of 
the assay when used on samples alternative to serum such as dried blood spots, 
latent class regression finite mixture models were used to analyse rubella IgG 
antibody levels. Two approaches to these models were employed: first, defining a 
seronegative population from the mixture model and investigating the effect of 
maternal characteristics on the odds of seronegative status using logistic regression 
and second, including maternal characteristics as covariates for the parameters of 
the mixture model. The results provide a prevalence estimate of the proportion of 
pregnant women seronegative to rubella in North Thames, as well as estimates of 
the influence of maternal characteristics on rubella IgG antibody level.
9.2 Rubella IgG ELISA validation on dried blood spot samples
The aim of the first part of this thesis was to validate a rubella IgG ELISA for use 
on dried blood spot samples, since commercially available ELISAs are optimised 
for use on serum. Three previous studies comparing rubella IgG concentrations in 
serum and dried blood spots have been carried out by Helfand and colleagues2711272 
and Vejtorp and Leerhoy273. In these studies, agreement between rubella IgG 
antibody in serum and dried blood spot samples was assessed only using the 
Pearson correlation coefficient, which was shown to be high: 0.94 in Helfand et al’s 
tw o studies (in which rubella IgG levels were expressed as OD values) and 0.98 in
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Vejtorp and Leerhoy’s study (in which rubella IgG levels were expressed as E- 
values, which are similar to OD ratios).
A high correlation between rubella IgG antibody levels in serum and dried blood 
spots was also found in this study. If antibody levels were expressed in IU/ml, the 
correlation coefficient was 0.93 (95% Cl 0.89 to 0.95) for the Diesse ELISA and 
0.91 (95% Cl 0.87 to 0.94) for the Dade Behring ELISA. When rubella antibody 
levels were expressed as OD ratios, the equivalent values were 0.96 (95% Cl 0.94 to 
0.98) and 0.81 (95% Cl 0.72 to 0.88) respectively. The estimate of the Pearson 
correlation coefficient for rubella IgG measured in serum and dried blood spot 
samples reported here is slightly lower than that presented by Helfand et al271 using 
the same Dade Behring ELISA, however it is not clear if Helfand and colleagues 
multiplied the OD values by a correction factor before analysis. Also, Helfand et al 
did not report confidence intervals for their estimate.
A high correlation coefficient should be expected when the same quantity is 
measured in two different media. In addition, since it is possible to attain high 
correlation in the absence of good agreement, or without taking heteroscedasticity 
into account, assessment of agreement based on correlation coefficients alone has 
been questioned by Bland and Altman274 who instead suggest a method for 
assessing agreement in which the mean antibody level in paired measurements are 
plotted against their differences. These methods were employed in the present 
study.
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Agreement between rubella IgG levels in serum and dried blood spot samples was 
assessed as the proportion of samples with a difference in antibody level greater 
than two SDs of the mean difference. For uncalibrated antibody levels (OD ratios), 
this proportion was not found to be significantly different for either ELISA to the 
proportion expected assuming a normal distribution of the differences. Variance 
was found to be non-constant for calibrated antibody levels expressed as IU/ml, 
tested with either the Diesse or the Dade Behring ELISA. For the Dade Behring 
ELISA, calibration seemed to introduce heteroscedasticity, whereas for the Diesse 
ELISA, calibration reduced the clustering of samples with low antibody levels that 
was observed when antibody levels were expressed as OD ratios. Applying natural 
logarithms to the antibody levels removed heteroscedasticity. The number of paired 
samples with differences in antibody level between serum and dried blood spots 
greater than two SDs of the mean difference was then not significantly different to 
that expected assuming a normal distribution of differences.
Based purely on the results of this validation study, agreement was satisfactory for 
both the Dade Behring and Diesse ELISAs, and either could have been chosen to be 
used for the main rubella serosurvey based on left-over newborn blood spot 
samples. Subsequently, the Diesse ELISA was chosen for the main serosurvey 
mainly because it avoids the logistical problems associated with carrying out the 
Dade Behring ELISA by hand. The Dade Behring ELISA was primarily designed to 
be used with an automated procedure. In addition, the calibration procedure for the
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Diesse ELISA was more straightforward than that for Dade Behring (as described in 
section 5.3.4). For example, the a  - and p  - values were provided by Dade Behring 
without information on how they were derived.
One limitation of this validation study was the necessity to produce dried blood spot 
samples from stored serum rather than using fresh whole blood. Using stored semm 
enabled a sizeable proportion of samples known to have low antibody levels to be 
selected, which would not have been possible had they been obtained from a 
random sample of the population, due to the small proportion of the UK population 
susceptible to rubella. Although the dried blood spots employed here contain only 
serum and red blood cells, this technique has been satisfactorily employed 
previously for preparing dried blood spot samples when only serum samples were 
available in order to achieve representative haematocrits 240;241.
It would have been ideal to carry out a validation study using serum samples from 
mothers paired with their newborn’s dried blood spot samples, using maternal sera 
as the gold standard. This would give a better assessment of how well newborn 
blood spot antibody level reflects maternal antibody level. However, there was no 
access to stored paired maternal - newborn serum or whole blood samples. It would 
therefore have been necessary to collect these, which was impossible operating 
under time and financial constraints. Since the validation study showed that 
agreement between serum and dried blood spot antibody levels was satisfactory for 
the Diesse ELISA, it is less likely that any problems of validity arising in the main
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serosurvey would be due to issues with the ELISA not being sensitive enough to be 
used on dried blood spot samples. Instead, issues such as decreased antibody levels 
in premature infants could act to overestimate the proportion of seronegative 
samples (see below). In addition, the quality of real newborn screening samples is 
likely to be worse than the dried blood spot samples created from serum samples in 
this validation study. Any potential problems with assay sensitivity were however 
addressed by the use of latent class mixture models to analyse antibody levels.
93  Seroprevalence of rubella in pregnant women in North Thames
In this large serosurvey of maternally derived rubella IgG antibody, it was estimated 
that 2.7% (95% Cl 2.4% to 3.0%) of pregnant women in North Thames were 
seronegative to rubella, assuming samples assigned to the component with the 
lowest mean of the optimal mixture model were seronegative. By projecting the 
proportion of women seronegative to rubella by age group and region of birth in the 
serosurvey to all of England and Wales, it was estimated that approximately 11500 
births were to women seronegative to rubella (uncertainty range 6374 to 19227) in 
England and Wales in 2004.
Comparisons with other studies are complicated by the use of different measures to 
define rubella seronegative status. The estimate presented here is lower than that 
obtained by Giraudon et al156, who report that around 4% of women tested negative 
to rubella antibody through the antenatal screening programme in London in 2004. 
The report by Giraudon and colleagues covered only maternity units in inner and
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outer London, whereas the North Thames area also includes suburban and rural 
areas outside greater London. This could partly explain our lower prevalence 
estimate. Giraudon et al also did not state what cut-off value was used to define the 
screen negative population, although it is likely that <10 IU/ml was used153. Since 
this study was based on data from an antenatal screening programme, it can be 
assumed that cut-off values were set high to minimise false negative results.
Nardone et al350 reported that 6.2% of women aged 15 to 39 years in England and 
Wales between 1996 and 2004 were seronegative to rubella, in a study using left­
over diagnostic samples. This estimate is over twice as high as that reported in this 
study. As the authors used a cut-off value of <10 IU/ml, it is likely that they 
overestimated the proportion of seronegative samples.
WHO recommends that overall susceptibility in women of childbearing age should 
be kept at less than 5% at a national level in order to eliminate congenital rubella 
and maintain the birth prevalence of congenital rubella to less than 1/100 000 
births101. In the UK, the number of births affected by congenital rubella has been 
below this since 1996 (NCRSP unpublished data). This study has shown that this 
target has been met among pregnant women in the North Thames region overall 
using a definition of the seronegative population derived from a mixture model.
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Maternal region of birth
This results presented in this thesis confirm that women bom abroad remain at 
increased risk of rubella infection during pregnancy compared to UK bom women. 
Whereas only 1.1% of women bom in the UK were seronegative (95% Cl 0.9% to 
1.4%) 6.2% of women bom in South Asia, 5.1% of women bom in Sub-Saharan 
Africa and 4.1% of women bom in the Americas or the Caribbean (95% CIs 5.2% 
to 7.4%, 4.1% to 6.3% and 2.6% to 6.5% respectively) were found to be 
seronegative. After adjustment for maternal age and SHA of residence at delivery, 
women bom outside the UK were between twice and five times more likely to be 
seronegative to rubella as UK-bom women, depending on their region of birth.
The findings presented here are similar to those reported by Tookey et al172, who 
found that in 1996 to 1999, women from a non-British ethnic background were 
significantly more likely to screen negative for rubella antibody in pregnancy than 
British women. For example, 5.0% of women from an Asian (i.e. Indian, Pakistani, 
Bangladeshi or Sri Lankan) ethnic group and 6.2% of women from a black African 
ethnic group screened negative to rubella. Although confidence intervals were not 
reported by Tookey et al, and a variable combining both ethnic group and country 
of birth was used, our estimates for comparable groups of women are similar.
The increased odds of being seronegative to rubella among women bom abroad can 
be explained by the absence of rubella vaccination programmes in their country of 
origin. The majority of countries in Sub-Saharan Africa and South Asia have not
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implemented either selective or universal rubella immunisation programmes, and 
MMR vaccination has only recently been included in the national schedules in 
countries in Central and South America and South East and East Asia. In some 
countries of Eastern and Southern Europe, although rubella vaccination has been in 
place, uptake has been suboptimal93:95:351.
Published data indicate that in many countries in South Asia28;201;213;215'217 and Latin 
America and the Caribbean194*196 and South East Asia28;218:219, the force of infection 
and consequently rubella seroprevalence among women of childbearing age is 
similar to or lower than that observed in the UK prior to introduction of rubella 
vaccination. In Sub-Saharan African countries, there is greater variation in rubella 
seroprevalence among women of reproductive age187;188;191;192, but even in settings 
were the force of infection is high, the proportion of seronegative women of 
childbearing age is comparatively greater than among vaccinated cohorts of UK- 
bom women.
In this study, country of birth was used as an indicator of maternal migrant status. 
One disadvantage of this approach is that the date of entry to the UK is not known. 
Some women who are bom abroad may have been resident in the UK from an early 
age, thus benefiting from the UK vaccination programme. It was therefore not 
possible to estimate the odds of rubella seronegative status separately for newly 
arrived migrants and those who have been resident in the UK for many years. It is 
likely that the odds of rubella seronegative status are higher in the former group,
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particularly among those pregnant for the first time in the UK who will not have 
benefited from antenatal screening and post-partum vaccination.
Maternal age
The results presented in chapter 7 represent the most up-to-date estimates of the 
proportion of pregnant women seronegative to rubella by age in any region in 
England. This study has demonstrated that pregnant women aged less than 25 years, 
and particularly those under the age of 20 years are significantly more likely to be 
seronegative to rubella than pregnant women in their early thirties. Women aged 
less than 20 years were at over twice the odds of being seronegative compared to 
women aged 30 to 34 years. This pattern was not reported by Tookey et al172, who 
found that similar proportions of pregnant women under the age of 20 and women 
in their early thirties screened negative to rubella. For some women of a non-British 
background, a U-shaped relationship between the proportion susceptible to rubella 
and maternal age was identified by Tookey and colleagues172, which was similar to 
the pattern identified in this study (see for example chapter 8). Vyse et al165 showed 
in a study of left-over diagnostic samples collected in England and Wales in 2000, 
that while around 5% of samples from women aged between 15 and 19 years were 
classified seronegative, this was the case for less than 1% of women aged between 
25 and 44 years.
The age-specific pattern of maternal rubella seronegative status demonstrated in this 
study is partly a reflection of the antenatal screening programme. Women in their
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thirties are more likely to have experienced previous pregnancies and if they 
received antenatal care for a previous pregnancy in the UK, should have been 
offered post-partum vaccination if they screened negative for rubella antibody. 
Lower prevalence of rubella susceptibility in multiparous women have been 
reported in several studies109’116’172. Data on parity were not available in this study; 
although birth order is recorded on the birth registration form, it is only for married 
women and not available as a public record. Parity is not recorded on the newborn 
blood spot card. The effect of parity on rubella seronegative status could therefore 
not be assessed in this study although it is a known risk factor.
Women who have children at a young age in the UK are more likely to have grown 
up under adverse socio-economic circumstances than women having children in 
their twenties and thirties (see for example Botting et al352). Although there are no 
studies on the uptake of schoolgirl vaccine by social class, children living in more 
deprived areas and from poor socio-economic backgrounds are less likely to receive 
childhood vaccines than children in more affluent areas and families1375140. Women 
becoming mothers at a young age could also be less likely to have received a 
schoolgirl vaccine. Since there was no indicator of socio-economic circumstances in 
this study, either at an individual or area level, this issue could not be further 
explored.
It has been suggested that rubella antibody levels in children who receive MMR 
vaccine early in life may wane to low levels by the time they reach reproductive age
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in populations without circulating virus60. It was not possible to fully evaluate this 
aspect in the present study, in which only 404 women would have qualified for 
MMR vaccine (as they were bom in or after 1986), and the vast majority of these 
women would also have been offered MR vaccine in the catch-up campaign in 
1994. In the absence of data on vaccination history it is difficult to evaluate the 
possible impact of waning immunity on antibody levels. Likewise, it was not 
possible to examine why a higher proportion of women giving birth over the age of 
40 years were seronegative than women in their thirties, although these differences 
were not significantly different. A similar pattern was identified by Vyse165 but is 
unanticipated since women giving birth in their forties are likely to be multiparous, 
and should therefore have received post-partum vaccination if found to be 
susceptible in previous pregnancies. In 2004, women aged 40 years and over would 
have been bom in 1964 or earlier, and those bom before 1960 in the UK are 
unlikely to have received schoolgirl vaccine. One possible reason for the higher 
proportion of seronegative women in this group could therefore be waning antibody 
levels in the absence of contact with circulating vims. However, a larger study with 
access to vaccination records is required to comprehensively examine the possibility 
of waning immunity in different cohorts of women.
Maternal area of residence
This serosurvey provided an opportunity to examine differences in the proportion of 
women seronegative to rubella by SHA and PCT of residence within North Thames. 
Although confidence intervals were wide for some PCTs, the proportion of women
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seronegative to rubella was generally higher in PCTs in inner and outer North 
London than in Bedfordshire, Hertfordshire and Essex. Significant spatial 
autocorrelation in the point estimates indicated spatial clustering of the prevalence 
of maternal rubella seronegativity.
A very basic estimate of the correlation between the proportion of women 
seronegative to rubella and the uptake of first dose MMR vaccine among children in 
2004 showed no significant inverse relationship, although the PCTs with the highest 
proportions of seronegative women had not attained an MMR uptake among 
children sufficient to ensure herd immunity in the long term. As the results 
presented in section 7.8 are from a cross-sectional analysis for 2004, a more 
thorough study needs to be carried out in order to estimate the risk of a rubella 
outbreak among children in London and the potential for spread to pregnant women. 
This would require estimating the effective reproduction number for rubella353, 
which requires a different class of data, including rubella seroprevalence by age in 
children in London (since London has lower MMR uptake than the rest of England). 
Assumptions need to be made about contact patterns, which is an unobserved 
quantity. However, Farrington et al353:354 have suggests methods for testing 
assumptions about contact matrices using age seroprofiles from another infection 
with a similar contact route.
The odds of rubella seronegative status was only significantly increased among 
women resident in North West London SHA compared to women resident in North
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East London SHA, after adjustment for maternal age group and country of birth. 
The higher odds ratio could mainly be attributed to women resident in Brent 
Teaching PCT, and when samples from babies whose mothers were resident in this 
PCT were excluded, the odds ratio for North West London SHA was no longer 
significantly different to the baseline. The adjusted odds ratios of maternal rubella 
seronegative status did not differ significantly between the other SHAs in North 
Thames, indicating that the observed spatial pattern in rubella seronegative status 
could mainly be accounted for by demographic characteristics of the childbearing 
population.
The high proportion of seronegative samples from Brent PCT could be explained by 
poor sample quality. Newborn screening samples are collected and sent in by 
midwives or health visitors attached to a maternity unit in a particular area. Taking 
the newborn screening sample can be difficult as it may cause considerable pain and 
distress for the baby 355"357, and sample quality has been found to be positively 
related to the experience of the midwife358. Therefore, if a midwife or a number of 
midwives in a particular PCT are less experienced at taking samples, sample quality 
would be poorer, and antibody levels in these samples would be lower. Thus, the 
proportion of seronegative samples from this PCT would be overestimated. As the 
degree to which the punched out blood spot is soaked through with blood is difficult 
to quantify and therefore not possible to take into account in these analyses.
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9.4 Strength and weaknesses of using newborn dried blood spot 
samples for serosurveys of rubella in pregnant women
Strengths of using newborn dried blood spot samples
Dried blood spot samples from newborn screening have not previously been used in 
the UK to estimate seroprevalence of rubella in pregnant women. Using these 
samples had major benefits. Due to the high coverage of screening, newborn 
bloodspot specimens represent a large and unbiased sampling frame. This was of 
great importance for a rubella serosurvey in a UK setting, since rubella 
susceptibility is rare in the antenatal population and consequently a large sample 
was required to achieve sufficient power to investigate differences in the proportion 
of rubella seronegative women bom in different world regions. As these specimens 
were collected for the purpose of screening, no additional blood sampling was 
required, and invasive methods such as venepuncture could be avoided. It would 
have been highly challenging to achieve such a large, unbiased sample by collecting 
blood specimens from pregnant women specifically for this study.
Another major advantage of the use of left-over newborn screening samples from 
the North Thames area was the availability of record linkage to birth registration 
data through the unlinked anonymous HIV surveillance programme. Using record 
linkage, it was possible to obtain information on maternal country of birth, which 
has been shown to be a significant predictor of rubella susceptibility in pregnant 
women169'172. The data linkage algorithm is robust and carried out through a trusted 
third party (ONS), ensuring complete confidentiality and anonymity, and that no
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HIV or rubella antibody test result can ever be linked back to a particular mother or 
baby. It is unlikely that it would have been possible to carry out a study of similar 
size with minimal bias and relevant demographic information in the absence of data 
linkage between the newborn screening laboratory and birth registration datasets.
Issues with the current implementation of data linkage between screening and 
birth registration datasets
However, there were some issues with the enhanced dataset used in this study, the 
most apparent of which was that maternal age was missing from nearly a third of 
the samples linked to birth registration data. Since maternal age was missing from 
less than 5% of the entries in the newborn screening dataset, it seems that a large 
section of the maternal age values was removed during the record matching process. 
As the data are anonymised and unlinked, it was not possible to explore at which 
stage of data linkage these values had disappeared and for what reason. To 
overcome the large proportion of missing maternal age values, multiple imputation, 
and subsequent adjustment of the logistic regression analyses was successfully used 
as demonstrated in chapter 7. However, this was not possible for the latent class 
regression finite mixture models, where carrying out separate models for each 
imputed dataset was not feasible due to the computational cost. The large proportion 
of missing maternal age values also led to large standard errors for the estimate of 
the proportion of seronegative samples by maternal age group, and the estimated 
number of births to seronegative women in England in 2004. A continuous and
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more stringent control of data quality before and after record linkage may prevent 
this loss of data in the future.
With the current data linkage algorithm, which is based on a deterministic 
algorithm, data linkage was achieved for 18410 samples (97.5%), and a further 86 
samples also lacked information on maternal country of birth. Data linkage was 
therefore unsuccessful for only a small proportion of specimens; however the record 
matching algorithm could still be improved. Probabilistic record matching 
algorithms (see for example Herman et al359 and Howe360) are now often used in 
epidemiological studies to allow matching of records when there is no unique 
identifier. In probabilistic record matching, probability weights are applied to each 
potential pair of matches in two datasets. These weights are proportional to the 
likelihood of a correct and incorrect match for two pairs of observations. Based on 
the combined weights, pairs of observations in two datasets can be classified as 
correct matches, possible matches or not matched. Using a probabilistic record 
linkage algorithm would allow inclusion of further samples in the analyses for 
which a match to a birth registration record may not be exact but the probability of a 
match is high.
Lower newborn IgG levels due to prematurity
The use of residual dried blood spot samples from newborn screening to estimate 
maternal rubella IgG levels required newborn antibody level to be used as a proxy 
for the maternal level. Several studies have reported high agreement between
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rubella IgG antibody levels in maternal and newborn blood287;291‘293, but IgG titres 
in premature newborns have been found to be lower. This is because placental 
transfer of IgG, which begins at around 13 to 15 weeks of gestation, is particularly 
efficient in the last trimester of pregnancy2781289. As outlined in chapter 4, evidence 
is inconclusive regarding the influence of prematurity on newborn rubella IgG 
levels, although two studies290:291 have indicated lower rubella IgG titres in 
premature newborns. If some of the babies with low antibody level in the rubella 
serosurvey were premature babies, this may have led to an overestimate of the 
seronegative population. Data on gestational age or birth weight were not available 
in this study. Although both are recorded on the newborn screening card, they are 
not retained after data linkage due to an increased risk of individual disclosure, and 
it was therefore not possible to adjust antibody levels for gestational age or birth 
weight, or exclude extremely premature babies.
A difference in rubella IgG antibody levels between cord and maternal blood 
appears significant only in babies bom at less than 30 weeks290. Gestational age is 
not recorded on the birth registration form in England and Wales, however in a 
study using NHS Number for Babies (NN4B) data linked to birth and death 
registration records361 it was found that 5363 of the 640599 live births (0.8%) in 
England and Wales in 2005 with a known gestational age occurred before 30 weeks 
gestation, however 1034 of these babies (19.2%) died in the early neonatal period 
and are therefore unlikely to have had a newborn screening sample taken. This left 
0.7% of the total number of babies in England and Wales bom before 30 weeks and
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alive for long enough to have had a screening sample taken. Applying this 
proportion to the present study, a maximum of 132 (0.7% of the total sample size) 
of the 509 samples that were classified as seronegative could have been 
misclassified due to premature birth, lowering the point estimate of the proportion 
of seronegative pregnant women from 2.7% to 2.0%. It is therefore unlikely that the 
misclassification of samples as seronegative due to prematurity would lead to a 
great overestimate, particularly since our estimate of the proportion of seronegative 
pregnant women is comparable to or lower than that obtained in similar 
studies'5* 17*350.
Gestational age at birth has also been found to vary by maternal ethnic group, with 
Asian, black Caribbean and black African women at significantly higher risk than 
white mothers of delivering prematurely3621363. In addition, women aged less than 20 
years have also been found to be more likely to deliver prematurely than women 
aged between 20 and 24 years (see for example Fraser et al364). Low levels of 
maternally transferred antibody due to premature delivery could potentially 
introduce differential misclassification bias in defining women as seronegative, thus 
inflating the odds of rubella seronegative status for women bom outside the UK and 
in younger women. It is however difficult to establish the degree to which our 
estimated odds ratio could be biased, not least since it is difficult to assess from the 
literature the possible impact of prematurity on antibody transfer from mother to 
fetus. Inclusion of an indicator of premature birth in the linked dataset would have 
been helpful in assessing this issue.
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In summary, it is likely that the proportion of pregnant women found to be 
seronegative in this study is a slight overestimate due to the (likely non-differential) 
effect of poor quality of some samples, and the influence of prematurity on antibody 
levels in newborns, which may also have marginally inflated the odds ratios 
comparing young women with women in their thirties, and women bom in and 
outside the UK. Although it is difficult to quantify the degree of overestimation, it is 
likely to be minor as the overall prevalence estimate is lower than the proportion of 
women who screened negative for rubella antibody in London in the same year. In 
addition, prevalence estimates by country of birth are not significantly different 
from those presented by Tookey et al172. Availability of data on parity and 
gestational age at delivery would be useful in order to control for the possible 
influence of prematurity on antibody levels. In addition, the influence of sample 
quality could be assessed by testing the eluted dried blood spot samples for total 
IgG levels.
9.5 Use of latent class regression finite mixture models
This thesis presents two applications of latent class regression finite mixture models 
to data on antibody levels from a rubella serosurvey. In chapter 7, a mixture model 
was used to define a population of seronegative women, using the definition of 
allocation to the component of the optimal mixture model with the lowest mean. 
This allocation was in turn based on the posterior probabilities estimated for each 
sample. Similar to the approach taken by Baughman et al307, BIC was used to select
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the optimal model and avoid overfitting the number of components. The mixture 
modelling framework presented here is different to that presented by for example 
Gay306, Gay et al223 and Vyse et al109, who estimate age-specific seroprevalence via 
stratified mixture models for each age group, use discretised values of optical 
density, and consider component weights for the mixture model component with the 
lowest mean only as an indicator of the proportion seronegative in each age group. 
The method presented in chapter 7 has the advantage that the maternal 
characteristics for the samples allocated to the component with the lowest mean 
could be determined without multiple stratified models, thus allowing independent 
maternal risk factors for rubella seronegative status to be determined through 
logistic regression models. This was of particular importance in our study since not 
only maternal age group but also country of birth had been identified as an 
important risk factor for maternal rubella susceptibility during pregnancy. The risk 
of misclassification according to posterior probabilities could be assessed 
graphically using rootograms and quantified using estimates of the pairwise overlap 
between component densities.
The work presented in chapter 8 represents a novel application of latent class 
regression finite mixture models to the results of a serosurvey, in which covariates 
were included for the component means, weights and SDs. Using a model selection 
strategy based on BIC, the best-fit model included maternal region of birth and age 
as a quadratic term as covariates for the component weight. The fit was not 
improved when further covariates were included for the component means and SDs;
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thus the main variation in rubella antibody level could be explained by the 
component weights varying by maternal characteristics. This also appears more 
intuitive than for example the mean of a particular component differing by maternal 
country of birth, as within each component, the antibody levels in the samples 
would be expected to be similar.
The approach taken in chapter 8 is useful as it is possible to investigate the effect of 
covariates on rubella antibody levels directly through the effect on the parameters of 
a mixture model, thus avoiding dichotomising the outcome variable as in chapter 7. 
However, this method also has some disadvantages. First, the results presented in 
chapter 7, where a seronegative population was defined using a mixture model, is 
easier to interpret as it allows the identification of independent risk factors using 
logistic regression models. The results presented in chapter 8 clearly show the U- 
shaped relationship between maternal age and rubella IgG antibody level, as well as 
higher component weights at all ages for the low and medium component for 
women bom outside the UK, thus indicating lower antibody levels in non-UK bom 
women. However, component weights are less easy to interpret than odds ratios, 
and do not directly translate into an estimate of the proportion of seronegative 
samples in a particular group. It is also not possible, using either of the R libraries 
used in this study, to obtain standard errors for the component weights or the linear 
predictors for the component weights, whereas binomial confidence intervals can be 
calculated for the proportion of observations allocated to a particular component on 
the basis of the posterior probabilities. McLachlan and Peel309 suggest bootstrap
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methods to obtain confidence intervals for mixture model parameters; however 
these methods are difficult to apply in practice due to the problems with label- 
switching in current implementations of mixture models in for example R. That is, it 
is currently not possible to impose an order on the component means (i.e. jui < pi2  
<•.. < fik), and consequently, bootstrapping to obtain confidence intervals for the 
coefficients of the component weights is complex due to changing baselines for 
each fitted model.
However, the main drawback of fitting the latent class regression finite mixture 
models with covariates was their large computational cost for large datasets, as ML 
estimates are obtained using an EM algorithm. Models with all three maternal 
characteristics included as covariates and those with interaction terms or covariates 
for more than one parameter (such as models with covariates for both the 
component weight and mean) took up to several days to run; for example, a model 
with all three covariates and an interaction term (219 parameters in total) took 55 
hours to converge on a PC with a 2.6 GHz processor. The long running time made it 
unfeasible to fit models with all possible combinations of covariates, and parallel 
computing facilities to speed up the model fitting were not available. Therefore, 
rather than searching for an optimal model using a brute-force approach, an ad-hoc 
model selection strategy had to be used. The model selection strategy employed and 
presented in chapter 8 allowed comparing the models’ goodness-of-fit when the 
same combination of covariates were fitted to each of the mixture model parameters 
separately, thus indicating which parameter most of the variation in antibody levels
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were explained by. When the optimal model (which included maternal age and 
region of birth as covariates in the linear predictor for the component weight) was 
refitted with covariates for the component mean and SDs, model fit did not 
improve. This provides some support that fitting all possible combinations of 
models may not have yielded a different result.
9.6 Further work
This study demonstrates that newborn dried blood spot samples can be used to 
estimate rubella seroprevalence in pregnant women by age. By using a dataset 
linked to birth registration records, estimates of the proportion of seronegative 
women by maternal country of birth can be obtained. In order to further enhance the 
possibilities of carrying out maternal serosurveys for vaccine-preventable diseases 
including rubella using these samples, the record linkage process could be improved 
by employing probabilistic record linkage methods to include samples with 
probable matches to a birth registration record. In addition, a regular quality control 
programme of the record linkage process should be introduced to prevent further 
losses of data. In order to investigate the possible misclassification errors introduced 
by prematurity, further linkage to the NN4B dataset could be implemented, thus 
providing information on gestational age. Linkage to NN4B data would also 
provide information on parity. These improvements would allow the residual 
newborn blood spots to be used for regular serosurveys of rubella, and other vaccine 
preventable diseases, in pregnant women in areas of the UK where record linkage 
between the newborn screening samples and birth registration data is in place.
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Using data on childhood vaccination and vaccine efficacy to estimate rubella 
seroprevalence among childen in London, effective reproduction numbers could be 
estimated to quantify the risk of an outbreak, although heterogeneities in contact 
patterns could be difficult to assess without using more extensive seroprevalence 
data from other infections with similar infection routes.
Latent class regression finite mixture models with covariates have been shown to be 
a useful tool when analysing antibody levels for which more than one predictor has 
been identified. Further development of the current implementation of mixture 
models, for example in R, would include bootstrap methods to obtain standard 
errors for the component weights and the parameters for the component weights, 
means and SDs.
9.7 Implications of findings for rubella control in London
This work has confirmed that the proportion of women seronegative to rubella in 
pregnancy is low in the North Thames area. It has also highlighted the continued 
increased risk of rubella infection during pregnancy for women bom abroad, with 
women bom in South Asia and Sub-Saharan Africa most likely to be seronegative 
during pregnancy. In addition, women who are young mothers also appear to be at 
increased risk of being seronegative compared to women having children in their 
thirties.
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Confirmed cases of rubella and congenital rubella are currently rare in the UK159;16°. 
However, even in settings where a disease is successfully controlled through 
immunisation, outbreaks can still be expected, due to importation of infection365. In 
addition, an estimated 15.7% of children aged up to 14 years in England and Wales 
were seronegative in 2000350, although this proportion is likely to be higher in 
London where MMR uptake is lowest, increasing the risk of outbreaks among 
children. Strategies for preventing a possible rubella outbreak spreading to 
susceptible pregnant women should therefore be explored.
The most urgent of these would be promoting an increase in the uptake of MMR 
vaccine among children in London, which would immediately decrease the risk of 
outbreaks, thus indirectly protecting pregnant women. A London-wide MMR catch­
up campaign was carried out in the winter of 2005, however data on uptake during 
this campaign have not been published, possibly due to problems with computer
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systems . Increasing MMR uptake as well as improving computer systems to 
accurately measure the proportion of children who have received their MMR 
vaccine should therefore be a priority.
The antenatal screening programme for rubella antibody was implemented to 
identify susceptible women and offer post-partum vaccination to protect against 
rubella infection during any future pregnancies. Currently, data on post-partum 
vaccination uptake are not routinely available. A system for routinely measuring 
uptake of post-partum vaccination following a negative screening test result for
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rubella antibody is therefore required to examine the effectiveness of the antenatal 
screening programme.
Primiparous women, or those who have had no previous pregnancies in the UK, will 
not benefit from the antenatal screening programme. In order to protect women bom 
abroad, the importance of ensuring migrants and migrant families are offered 
vaccination, including MMR, needs to be strongly advocated among health care 
professionals. For example, the HPA recommends the promotion of an extended 
new patient check when new migrants register with a GP practice, which would 
include supplementary immunisation for those whose vaccinations are not 
complete366. Health professionals would need to ensure that any women offered 
vaccination were not pregnant. Offering vaccines to newly arrived migrants in a 
primary care setting would be a first step, however it has been suggested that some 
migrant groups and particularly recent migrants are less likely to be registered with 
a GP than UK or Irish bom people367. Although data on use of primary health 
services by migrants are scarce, the first contact with health services appears to be 
through an Accident and Emergency department367 for a substantial number of 
migrants. Offering supplementary vaccination in these settings will present a greater 
challenge.
9.8 Conclusions
This thesis has demonstrated the value of newborn dried blood spot samples to 
estimate rubella seroprevalence among pregnant women in a setting of low MMR
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uptake. It has also highlighted the continuing increased risk to women bom abroad 
of rubella infection during pregnancy, should virus begin to circulate in the 
population. These findings can be used to inform vaccination policy.
This work has also demonstrated the usefulness of latent class regression finite 
mixture models to analyse data on antibody concentrations obtained from a 
serosurvey, thus avoiding the use of possibly non-specific cut-off values. First, 
these models were used to define a variable indicating seronegative status to be used 
in a logistic regression model, and second to directly examine the effect of maternal 
characteristics on rubella IgG antibody levels by including linear predictors for the 
weights, means and SDs of the components in the mixture model.
Lastly, this thesis has shown that the use of newborn dried blood spot samples for 
serosurveys of rubella in pregnant women could be enhanced through extended data 
linkage, so that the effect of parity and gestational age on maternally transferred 
antibody levels in newborns could be examined. This would allow further 
serosurveys in pregnant women to be carried out using these samples, not only for 
rubella but also other vaccine preventable diseases.
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Appendix A. Current rubella vaccination schedule and 
year of introduction of rubella vaccination by country
Country Vaccine currently 
used
Year of introduction 
of rubella vacdne
Schedule
Africa
Mauritius MMR 1996 12 months, 5 years
Seychelles MMR 1980 15 months, 6 years
Americas
Antigua and 
Barbuda
MMR 1998 12 months, 5 years
Argentina MMR 1997 12 months, 6 years
Bahamas MMR 1991 12 months, 4 to 5 years
Barbados MMR 1982 12 months, 3 to 5 years
Belize MMR 1996 12 months, 2 years
Bolivia MMR 2000 12 to 23 months
Brazil MMR 2000 12 months, 4 to 6 years
Canada MMR 1983 12-18 months, 4 to 6 years
Chile MMR 1992 12 months, 6 years
Colombia MMR 1995 12 months, 5 years
Costa Rica MMR 1992 15 months, 7 years
Cuba MMR 1986 12 months, 6 years
Dominica MMR 1989 12 months, 18 months
Dominican
Republic
MMR 2004 12 months
Ecuador MMR 1999 12 to 23 months
El Salvador MMR 1997 12 months, 4 years
Grenada MMR 1993 12 months, 18 months
Guatemala MMR 2001 12 months
Guyana MMR 1995 12 months, 3 years
Honduras MMR 1997 12 months
Jamaica MMR 1993 12 to 23 months, 4 to 6 
years
Mexico MMR 1998 12 months, 6 years
Nicaragua MMR 1998 12 months
Panama MMR 1992 12 months, 4 to 5 years
Paraguay MMR 2000 12 months
Peru MMR 2003 12 months
St Kitts and Nevis MMR 1987 12 months, 2 years
St Lucia MMR 1986 12 months, 5 years
St Vincent and the 
Grenadines
MMR 1991 12 months, 24 months
Suriname MMR 1993 12 months, 5 years
Trinidad and 
Tobago
MMR 1984 12 months, 4 to 5 years
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USA MMR 1969 12-15 months, 4 to 6 years
Uruguay MMR 1982 12 months, 5 years
Venezuela MMR 1998 12 months
Eastern Mediterranean
Bahrain MMR 1974 12 months, 5 years, 12 years
Egypt MMR 1999 18 months
Iran MMR 2004 12 months, 4 to 6 years
Iraq MMR Before 1995 15 months
Jordan MMR 2000 18 months
Kuwait MMR, rubella 1975 12 months 3.5 years, also 
rubella vaccine for girls 
aged 12 years
Lebanon MMR 1995 18 months, 4 to 5 years
Libyan Arab 
Jamahiriya
MMR Before 1995 12 months, 18 months
Morocco MMR 2003 6 years
Oman MMR 1994 12 to 18 months
Qatar MMR 1992 12 months, 4 to 6 years
Saudi Arabia MMR 1991 12 months, 4 to 6 years
Syrian Arab 
Republic
MMR 1999 15 months
Tunisia Rubella 2004 12 years (girls only)
United Arab 
Emirates
MMR, rubella 1985 15 months 6 years, also 
rubella vaccine for girls 
aged 12 years
Europe
Albania MMR 2001 12 months, 5 years
Andorra MMR 1988 15 months, 5 years
Armenia MMR 2002 12 months, 6 years
Austria MMR 1973 12 to 24 months, second 
dose at any age
Azerbaijan MMR 2003 12 months, 6 years
Belarus MMR 1996 12 months, 6 years
Belgium MMR 1985 12 months, 10 to 13 years
Bosnia and 
Herzegovina
MMR 1976 12 months, 6 years
Bulgaria MMR 1993 13 months, 12 years
Croatia MMR 1975 12 months, 6 years
Cyprus MMR 1974 12 to 15 months, 4 to 6 
years
Czech Republic MMR 1983 15 months, 21 months
Denmark MMR 1987 15 months, 12 years
Estonia MMR 1992 12 months, 13 years
Finland MMR 1975 14 to 18 months, 6 years
France MMR 1970 9 to 12 months, 13 to 23 
months
Georgia MMR 2004 12 months, 5 years
Germany MMR 1991 11 to 14 months, 15 to 23 
months
Greece MMR 1975 15 months, 4 to 6 years
Hungary MMR 1989 15 months, 11 years
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Iceland MMR 1979 18 months, 12 years
Ireland MMR 1971 12 to 15 months, 4 to 5 
years
Israel MMR 19S8 12 months, 6 years
Italy MMR 1972 12 to 15 months, 4 to 5 
years
Kazakhstan MMR, rubella 2004 12 months, rubella vaccine 
for girls aged 15 years
Kyrgyzstan MMR, MR 2001 12 months (MMR), 6 years 
(MR)
Latvia MMR 1993 15 months, 7 years
Lithuania MMR 1992 15 months, 6 to 12 years
Luxembourg MMR prior to 1995 18 to 18 months, 5 to 6 
years
Malta MMR 1985 15 months, 7 to 8 years
Monaco MMR 1970 12 months, 3 to 6 years
Montenegro MMR 1994 12 months, 6 years
Netherlands MMR 1974 14 months, 9 years
Norway MMR 1978 15 months, 12 years
Poland MMR 1988 13 to 14 months, 10 years
Portugal MMR 1984 15 months, 5 to 6 years
Republic of 
Moldova
MMR 2002 12 months, 6 to 7 years
Romania MMR 2002 12 to 15 months, 7 years
Russian Federation MMR, rubella 
depending on 
region
2000 12 months, 6 years
San Marino MMR 1995 15 to 16 months, 5 to 6 
years
Serbia MMR 1994 12 months, 7 years
Slovakia MMR 1985 14 months, 10 years
Slovenia MMR 1972 12 months, 6 years
Spain MMRV 1978 12 to 15 months, 3 to 6 
years
Sweden MMR 1982 12 to 15 months, 6 to 8 
years
Switzerland MMR 1973 12 months, 15 to 24 months
FYR of Macedonia MMR 1982 13 months, 7 years
Turkey MMR 2006 12 months, 6 years
Turkmenistan MMR 2007 12 to 15 months, 6 years
Ukraine MMR 2001 12 months, 6 years
United Kingdom MMR 1970 13 months, 3 to 5 years
Uzbekistan MMR 2006 12 months, 6 years
South East Asia
Bhutan MR 2006 9 months, 24 months
Sri Lanka MR 1996 3 years, rubella vaccine for 
girls aged 8 years
Thailand MMR 1993 First year of school
Western Pacific
Australia MMR 1971 12 months, 4 years
Brunei Darussalam MMR 1984 12 months, 10 to 12 years
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Cook Islands MR 2006 12 months
Fiji MR Before 1995 12 months, 4 to 6 years
Japan Rubella 1977 12 months to 8 years
Kiribati MR 2004 12 months
Malaysia MMR 1998 12 months, 7 years
Marshall Islands MMR 1998 12 months, 13 months
Federated States of 
Micronesia
MMR 1982 12 months, 13 months
Nauru MR 2006 12 months
New Zealand MMR 1979 15 months, 4 years
Niue MMR 1975 12 months, 4 years
Palau MMR Before 1995 12 to 15 months
Republic of Korea MMR 1982 12 to 15 months, 4 to 6 
years
Samoa MR 2004 12 months, 13 months
Singapore MMR 1990 12 to 24 months, 11 to 12 
years
Tonga MR 2002 12 months, 18 months
Tuvalu MR 2005 12 months, 18 months
" I. M*. i an 1 aj 1 "" w r
Source: World Health Organisation , Panagiotopoulos et al , Makhseed et al
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Appendix B: Summary of data linkage algorithm
The data linkage algorithm was developed by Jane Walker (Institute of Child 
Health) in collaboration with Beverly Botting (Office for National Statistics). The 
following matching algorithm was summarised by collaborators at the Office for 
National Statistics in 2002.
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Matching algorithm
June 7th 2002
1. The regional records are m atched against data held on an interm ediate file w hich holds
selected data from O N S Births records. The interm ediate file has sufficient fields for the 
m atching to  take place and fo r the results to  be passed to ICH. No attempt is m ade to 
match any input records show n as being repeat records.
2. The interm ediate file is m aintained by reloading the ONS Births records each quarter.
3. The m atching algorithm  is sum m arised -
3.1 DOB N IISN O  SEX
3.2 N IISN O  SF.X FULL 1ST PO STCO D L
3.3 DOB 10 CH A R A D D RESS 8 CH A R  SURNAM E
3.4 DOB 6 CH A R A D D R ESS 6 CH A R SURNAM E
3.5 DOB 4 CHAR A D D R ESS 4 CH A R SURNAM E
3.6 DOB FU LL I ST PO STC O D E 8 C H A R  SURNAM E
3.7 DOB 10 CH AR A D D RESS (includes health area and strategic health area check)
3.8 DOB 4 Cl IAR SU R N A M E (includes health area and strategic health area check)
3.9 DOB FULL 1ST PO STCO D E
3.10 D O B + 1 FULL 1 ST PO STC O D E
3 .1 1 D O B -1 FULL 1 ST PO STCO D E
The address used for m atching is form atted on both the regional input data and the Births 
interm ediate data to replace punctuation with spaces and to remove com m on phrases such as 
“ Room ”, "F lat” from the beginning o f  the address. The first 10 characters o f  the result is held on 
the tw o files.
In the follow ing descriptions, if  only one m atching Birth record is found using the criteria stated, 
then this m atch is accepted as a valid match. W here tw o or more matching Birth records are 
found, we check w hether the records found are all from a m ultiple birth and, if  so, we accept one 
o f  them as the m atching record. See the A ppendix for details o f  the checks made to determ ine a 
m ultiple birth.
3.1 This check looks for a match on the Births interm ediate tile by nhs number, sex and date o f 
birth W here no match can be m ade on the exact dale o f  birth, a date one day either side is 
attempted. No m atch is m ade i f  the births record selected for m atching has already been matched 
to a previous regional record.
3.2 This check looks for a match on the Births interm ediate file by nhs number, sex 3nd full first 
postcode. N o m atch is m ade if  the births record selected for m atching has already been matched 
to a previous regional record.
3.3 This check takes the unm atched record and looks for a match on the Births intermediate by 
full date o f  birth and the first 10 characters o f  the formatted address and up to the first 8
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characters o f  the first surname held on the regional record. The surname held on the input 
regional record is used to match either to the child 's surname or to the m other's surname on 
Births. A significant number o f  Births hold a different child’s surname to that held on input, but 
many match by m other's surname. If there is no match using the first surname from the input 
record, an attempt is made to match on the second surname from the input, if present. No match 
is made if the Births record selected to match has already been matched to a previous regional 
record.
3.4 l his check takes the unmatched record and looks for a match on the Births intermediate b> 
full date o f  birth and the first 6 characters o f the formatted address and up to the first 6 characters 
o f  the first surname held on the input regional record. The surname held on input »s used to 
match either to the ch ild 's  surname or to the m other's surname on Births. If there is no match 
using the first surname from the input record, an attempt is made to match by the second 
surname from the input record, if  present. No match is made if the Births record selected to 
match has already been matched to a previous regional record.
3.5 This check takes the unmatched record and looks for a match on the Births intermediate by 
full date o f  birth and the first 4 characters o f the formatted address and up to the first 4 characters 
o f  the first surname held on the input regional record. 14te surname held on input is used to 
match either to the ch ild 's  surname or to the m other's surname on Births, i f  there is no match 
using the first surname from the input record, an attempt is made to match by the second 
surname from the input record, if present. No match is made if the Births record selected to 
match has already been matched to a previous regional record.
3.6 I his check takes the unmatched record and looks for a match on the Births intermediate by 
full date o f  birth and the full first postcode and up to the first 8 characters o f the first surname 
held on the input regional record. The surname held on input is used to match either to the 
child 's surname or to the m other’s surname on Births. If there is no match using the first surname 
from the input record, an attempt is made to match is made by the second surname from the input 
record, if present. No match is made if  the Births record selected to match has already been 
matched to a prev ious regional record.
3.7 This check takes the unmatched record and looks for a match on the Births intermediate by 
full date o f  birth and the first 10 characters o f  the formatted address held on the input record. If a 
potential match is found, the Strategic Health Authority code for mother's usual residence 
(HRORM ) code on the births record is compared to the supplier code on the input record using a 
look-up table. If the codes are inconsistent, the match is rejected. No match is made if  the Births 
record selected to match has already been matched to a prev ious regional record.
3.8 This check takes the unmatched record and looks for a match on the Births intermediate by 
full date o f  birth and the first 4 characters o f  the first surname held on the input record. The 
surname is matched to cither the child’s surname or the m other's surname on Births.
If there is no match using the first surname from the input record, an attempt to match is made by 
the second surname from the input record, if present. If a potential match is found, the HRORM 
code on the births record is compared to the supplier code on the input record using a look-up
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table. If the codes are inconsistent, the match is rejected. No match is made if  the Births record 
selected to  match has alreadv been matched to a previous regional record.
3.9 This check takes the unmatched records and looks for a match on the births intermediate by 
full date o f  birth together with the full first postcode as held on the input record. No match is 
made if  the Births record selected to match has already been matched to a previous regional 
record.
3.10 This check takes the unmatched record and looks for a match on the Births intermediate b> 
using a date one day on from the date o f birth together with the full first postcode as held on the 
input record. No match is made if  the Births record selected to match has already been matched 
to a previous regional record.
3 .11 This check lakes the unmatched record and looks for a match on the Births intermediate by 
using a date one day before the date o f birth together w ith the full first postcode as held on the 
input record. No match is made if  the Births record selected to match has already been matched 
to a previous regional record.
Und o f Algorithm 
Appendix
During the matching algorithm, if  a regional input record is matched to two or more Births 
records, a check is made to see whether the number o f  live births found in Births w ith the current 
criteria is the same as the number o f births found on the input w ith the current criteria. If so, we 
accept a match with the first Birth record in the multiples that we haven't already matched to.
Appendix C. M aternal region of birth: 20 category classification
Maternal region of birth- 
20 categories
Country name Number of 
samples
%
UK England and Wales 10956 58.0%
Northern Ireland 69 0.4%
Scotland 170 0.9%
Northern Europe Channel Islands 0 0.0%
Ireland 192 1.0%
Isle of Man 0 0.0%
Denmark 18 0.1%
Faeroe Islands 0 0.0%
Estonia 0 0.0%
Finland 0 0.0%
Iceland 0 0.0%
Norway 0 0.0%
Sweden 35 0.2%
Latvia 0 0.0%
Lithuania 48 0.3%
Southern Europe Albania 22 0.1%
Andorra 0 0.0%
Bosnia & Herzegovina 0 0.0%
Croatia 0 0.0%
Gibraltar 0 0.0%
Greece 0 0.0%
Italy 68 0.4%
Macedonia 0 0.0%
Malta 0 0.0%
Montenegro 0 0.0%
Portugal 81 0.4%
Portugal 0 0.0%
San Marino 0 0.0%
Serbia 126 0.7%
Slovenia 0 0.0%
Spain 49 0.3%
Yugoslavia 17 0.1%
Eastern Europe Belarus 0.0%
Bulgaria 36 0.2%
Russia 0 0.0%
Czech Republic 21 0.1%
Hungary 2 0.0%
Moldova 0 0.0%
Poland 127 0.7%
Romania 36 0.2%
Russia 31 0.2%
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Slovakia 15 0.1%
Armenia 0 0.0%
Ukraine 22 0.1%
Czechoslovakia 0.0%
Russian independent states 0.0%
Western Europe Austria 0 0.0%
Belgium 14 0.1%
France 107 0.6%
Germany 120 0.6%
Liechtenstein 0 0.0%
Luxembourg 0 0.0%
Monaco 0 0.0%
Netherlands 17 0.1%
Switzerland 14 0.1%
North America Bermuda 0 0.0%
Canada 39 0.2%
Greenland 0 0.0%
USA 127 0.7%
Central America and 
Caribbean
Belize 0 0.0%
Costa Rica 0 0.0%
El Salvador 0 0.0%
Guatemala 0 0.0%
Honduras 0 0.0%
Mexico 0 0.0%
Nicaragua 0 0.0%
Panama 0 0.0%
Anguilla 0 0.0%
Antigua & Barbuda 0 0.0%
The Bahamas 0 0.0%
Barbados 0 0.0%
British Virgin Islands 0 0.0%
Cayman Islands 0 0.0%
Cuba 0 0.0%
Dominica 0 0.0%
Dominican Republic 0 0.0%
Guadeloupe 0 0.0%
Martinique 0 0.0%
Grenada 0 0.0%
Haiti 0 0.0%
Jamaica 159 0.8%
Montserrat 0 0.0%
Netherland Antilles 0 0.0%
Puerto Rico 0 0.0%
St Kitts & Nevis 0 0.0%
St Lucia 0 0.0%
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Grenadines 0 0.0%
Trinidad & Tobago 29 0.2%
Turks & Caicos 0 0.0%
US Virgin Islands 0 0.0%
Guadeloupe 0 0.0%
South America Argentina 0 0.0%
Bolivia 0 0.0%
Brazil 32 0.2%
Chile 0 0.0%
Colombia 34 0.2%
Ecuador 19 0.1%
Falkland Islands 0 0.0%
French Guiana 0 0.0%
Guyana 0 0.0%
Paraguay 0 0.0%
Peru 0 0.0%
Surinam 0 0.0%
Uruguay 0 0.0%
Venezuela 2 0.0%
Central Asia Afghanistan 146 0.8%
Iran 43 0.2%
Kazakhstan 0 0.0%
Kyrgyzstan 0 0.0%
Tajikistan 0 0.0%
Turkmenistan 0 0.0%
Uzbekistan 0 0.0%
South Asia Bangladesh 847 4.5%
Bhutan 0 0.0%
British Indian Ocean Territory 0 0.0%
India 480 2.5%
Maldives 0 0.0%
Nepal 0 0.0%
Pakistan 496 2.6%
Sri Lanka 282 1.5%
0.0%
East Asia China 42 0.2%
Hong Kong 27 0.1%
Solomon Islands 0 0.0%
Japan 54 0.3%
North Korea 0 0.0%
South Korea 0 0.0%
Mongolia 0 0.0%
Macao 0 0.0%
Taiwan 0 0.0%
Guam 0 0.0%
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South East Asia Brunei 0.0%
Burma 0 0.0%
Cambodia 0 0.0%
Indonesia 0 0.0%
Laos 0 0.0%
Malaysia 46 0.2%
Philippines 114 0.6%
Singapore 15 0.1%
Thailand 30 0.2%
Vietnam 32 0.2%
Western Asia Azerbaijan 0 0.0%
Bahrain 0 0.0%
Cyprus 27 0.1%
Georgia 0 0.0%
Iraq 74 0.4%
Israel 36 0.2%
Jordan 0 0.0%
Kuwait 24 0.1%
Lebanon 45 0.2%
Oman 0 0.0%
Palestine 0 0.0%
Qatar 0 0.0%
Saudi Arabia 0 0.0%
Syria 14 0.1%
United Arab Emirates 0 0.0%
Yemen 0 0.0%
Turkey 237 1.3%
Oceania British Antarctic Territory 0 0.0%
French Antarctica 0 0.0%
Norwegian Antarctic Territory 0 0.0%
Australia 97 0.5%
New Zealand 46 0.2%
Fiji 0 0.0%
New Caledonia 0 0.0%
Papua New Guinea 0 0.0%
Solomon Islands 0 0.0%
Vanuatu 0 0.0%
Caroline Islands 0 0.0%
Marshall Islands 0 0.0%
Micronesia 0 0.0%
Nauru 0 0.0%
East Samoa 0 0.0%
Northern Mariana Islands 0 0.0%
Howland Island 0 0.0%
Wake Island 0 0.0%
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Cook Islands 0 0.0%
French Polynesia 0 0.0%
Wallis and Futuna Islands 0 0.0%
Niue 0 0.0%
Pitcairn Islands 0 0.0%
Samoa 0 0.0%
Tokelau Islands 0 0.0%
Tonga 0 0.0%
Tuvalu 0 0.0%
American East Samoa 0 0.0%
Johnston Island 0 0.0%
Kingman Reef 0 0.0%
Palmyra Islands 0 0.0%
Kiribati 0 0.0%
Curacao 0 0.0%
North Africa Algeria 55 0.3%
Egypt 19 0.1%
St Pierre et Miquelon 0 0.0%
Libya 0 0.0%
Morocco 60 0.3%
Sudan 26 0.1%
Tunisia 0 0.0%
0.0%
East Africa Burundi 10 0.1%
Comoros 0 0.0%
Djibouti 0 0.0%
Ethiopia 23 0.1%
Kenya 120 0.6%
Madagascar 0 0.0%
Malawi 1 0.0%
Mauritius 42 0.2%
Mozambique 0 0.0%
Reunion Island 0 0.0%
Rwanda 0 0.0%
Seychelles 0 0.0%
Somalia 406 2.2%
Tanzania 27 0.1%
Uganda 62 0.3%
Zambia 20 0.1%
Zimbabwe 110 0.6%
Eritrea 17 0.1%
South Africa Botswana 0 0.0%
Lesotho 0 0.0%
Namibia 0 0.0%
South Africa 146 0.8%
Swaziland 0 0.0%
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0.0%
Middle Africa Angola 35 0.2%
Cameroon 0 0.0%
Central African Republic 0 0.0%
Chad 0 0.0%
Congo 38 0.2%
Equatorial Guinea 0 0.0%
Gabon 0 0.0%
Sao Tome & Principe 0 0.0%
Democratic Republic of Congo 76 0.4%
Burundi 0 0.0%
Western Africa Benin 0 0.0%
Burkina Faso 0 0.0%
Cape Verde 0 0.0%
The Gambia 13 0.1%
Ghana 229 1.2%
Guinea 0 0.0%
Guinea-Bissau 0 0.0%
Cote d'Ivoire 15 0.1%
Liberia 0 0.0%
Mali 0 0.0%
Mauritania 0 0.0%
Niger 0 0.0%
Nigeria 241 1.3%
St Helena & Dependencies 0 0.0%
Senegal 0 0.0%
Sierra Leone 30 0.2%
Togo 0 0.0%
Not known Not known 574 3.0%
Sample size too low to be kept separate* 379 2.0%
*If there are less than 10 samples in a country of birth category, they are coded as “sample size too 
low” to maintain confidentiality.
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Appendix D. Logistic regression models using only complete case data
Predictors Model 1 Model 2 Model 3 Mixed effects model
Adi listed odds ratios* (95% Cl) Adjusted odds ratios* (95% Cl)
Maternal region of birth
UK 1 1 1 1
SubSaharan Africa 3.73(2.60,536)“ 3.95 (2.75,5.67)“ 3.54 (2.42,5.18)“ 3.62(2.46,532)“
North Africa, West & Central Asia 3.22 (1.95,533)“ 3.40(2.05,5.63)“ 2.93 (1.73,4.95)“ 3.10 (1.82,5.28)“
South Asia 5.85(435,7.87)® 6.26(4.62,8.48)“ 5.48 (3.95,7.61)“ 5.65 (4.05,7.88)“
East, South East Asia & Oceania 3.41 (1.92,6.05)“ 3.90(2.19,6.94)“ 3.59(2.00,6.44)® 3.72(2.06,6.73)*
Rest of Europe 2.23 (1.41,3.51)b 2.40 (1.52,3.80)® 2.18 (136,3.48)b 2.22(138,336)b
Americas 3.66(2.13,630)* 3.79(2.20,6.53)“ 3.46(1.99,6.04)“ 3.48 (1.98,6.11)“
Maternal age group
<20 years 3.44(2.25,5.26)® 3.56(234,5.48)“ 3.68(238,5.67)“
20-24 years 1.49 (1.05,2.10)c 130 (1.06,2.13)d 132 (1.07,2.16)e
25-29 years 1.03 (0.74,1.44) 1.02 (0.73,1.42) 1.03 (0.74,1.43)
30-34 years 1 1 1
35+ years 1.17 (0.82,1.67) 1.18(0.83,1.68) 1.17(0.82,1.68)
Maternal SHA at delivery
North East London 
North Central London 
North West London 
Bedfordshire & Hertfordshire 
Essex
1
0.75 (0.51,1.09) 
1.42 (1.06,1.91)e
0.75 (0.49,1.12) 
0.81 (0.52,1.27)
1
0.77 (0.52,1.13) 
1.33 (0.96,1.82) 
0.73(0.47,1.11) 
0.80 (0.50,1.28)
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Random effects on plate a u =0.56 (0.41,0.77) 
p  =0.09(0.05,0.15)
AIC 2687.5 2663.0 2653.3 2638.2
Note: *)p < 0.001, b)p  = 0.001,c) p  = 0.024, *)p = 0.021 c) p  = 0.019
Table A.l Results of logistic regression models using only complete case data (n = 12273)
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Appendix £ . Results of latent class regression finite mixture models
Table AJLA. Results of latent class mixture models with covariates for the component weights 
(*)
Note: Models are ordered by BIC.
Model
number
Covariates Number of 
components
AIC BIC
10 Age -t- Age2 -I- region of birth 4 34953.69 35227.25
10 Age + Age2 + region of birth 5 34920.17 35279.7
12 Age + Age2 + region of birth + SHA 4 34895.9 35286.69
4 Region of birth 4 35101.88 35328.54
9 Age + region of birth + SHA 4 34964.36 35331.71
9 Age + region of birth + SHA 5 34852.26 35336.84
12 Age + Age2 + region of birth + SHA 5 34831.38 35347.23
4 Region of birth 5 35074.77 35371.77
8 SHA + region or birth 4 35036.42 35380.32
10 Age + Age2 + region of birth 3 35204.57 35392.15
13 Age * region of birth 4 35010.38 35401.17
12 Age + Age2 + region of birth + SHA 3 35150.87 35416.61
13 Age * region of birth 5 34931.18 35447.02
17 Region of birth + age * SHA 4 34964.43 35449.01
16 SHA + age * region of birth 4 34954.14 35462.17
9 Age + region of birth + SHA 3 35219.24 35469.35
8 SHA + region or birth 5 35021.04 35474.36
4 Region of birth 3 35342.4 35498.72
20 (Age + age2) * region of birth 4 34950.34 35505.26
17 Region of birth + age * SHA 5 34864.6 35505.5
8 SHA + region or birth 3 35279.31 35513.78
22 Region of birth + (Age + age2) * SHA 4 34897.24 35522.51
13 Age * region of birth 3 35268.23 35533.97
16 SHA + age * region of birth 5 34869.62 35541.78
17 Region of birth + age * SHA 3 35218.35 35546.62
16 SHA + age * region of birth 3 35216.07 35559.97
23 SHA + (Age + age2) * region of birth 4 34892.57 35564.73
11 Age + Age2 + SHA 4 35321.41 35571.52
22 Region of birth + (Age + age2) * SHA 3 35151.72 35573.77
20 (Age + age2) * region of birth 3 35201.82 35576.98
7 Age + SHA 5 35292.82 35589.82
3 Age + age2 4 35458.57 35591.44
6 Age + region of birth 4 35458.57 35591.44
3 Age + age2 5 35427.29 35599.23
6 Age + region of birth 5 35427.29 35599.23
7 Age + SHA 4 35374.86 35601.52
23 SHA + (Age + age2) * region of birth 3 35149.72 35603.04
2 Age 5 35469.86 35610.55
2 Age 4 35510 35619.43
11 Age + Age2 + SHA 5 35300.25 35628.52
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5 SHA 4 35449.68 35652.89
20 (Age + age2) * region of birth 5 34934.59 35669.28
1 None 5 35572.14 35681.56
1 None 4 35597.7 35683.67
5 SHA 5 35431.16 35696.9
14 Age * SHA 4 35373.2 35717.1
22 Region of birth + (Age + age2) * SHA 5 34897.32 35725.8
11 Age + Age2 + SHA 3 35585.62 35757.57
14 Age * SHA 5 35310.85 35764.16
23 SHA + (Age + age2) * region of birth 5 34879.35 35770.36
7 Age + SHA 3 35638.47 35794.79
3 Age + age2 3 35710.76 35804.55
6 Age + region of birth 3 35710.76 35804.55
21 (Age + age2) * SHA 4 35321.62 35806.2
5 SHA 3 35701.31 35842
2 Age 3 35764.73 35842.89
14 Age * SHA 3 35635.77 35870.24
1 None 3 35842.4 35904.93
21 (Age + age2) * SHA 3 35587.02 35915.29
24 Age + age2+ region of birth * SHA 3 35183.69 35918.38
21 (Age + age2) * SHA 5 35312.86 35953.76
18 Age + region of birth * SHA 3 35254.55 35973.61
15 SHA * region of birth 3 35313.07 36016.5
24 Age + age2+ region of birth * SHA 4 34952.12 36046.34
18 Age + region of birth * SHA 4 35019.84 36090.61
15 SHA * region of birth 4 35092.42 36139.74
10 Age + Age2 + region of birth 2 36301.1 36402.71
12 Age + Age2 + region of birth + SHA 2 36277.21 36417.9
24 Age + age2+ region of birth * SHA 5 34967.31 36421.06
18 Age + region of birth * SHA 5 35034.7 36457.19
9 Age + region of birth + SHA 2 36341.25 36474.12
20 (Age + age2) * region of birth 2 36289.33 36484.72
22 Region of birth + (Age + age2) * SHA 2 36268.66 36487.5
13 Age * region of birth 2 36349.78 36490.46
15 SHA * region of birth 5 35105.3 36496.52
23 SHA + (Age + age2) * region of birth 2 36266.55 36501.02
4 Region of birth 2 36415.1 36501.07
17 Region of birth + age * SHA 2 36336.12 36508.07
16 SHA + age * region of birth 2 36328.65 36508.41
8 SHA + region or birth 2 36387.34 36512.4
24 Age + age2+ region of birth * SHA 2 36282.98 36658.15
18 Age + region of birth * SHA 2 36346.24 36713.59
11 Age + Age2 + SHA 2 36621.55 36715.34
3 Age + age2 2 36685.21 36739.92
6 Age + region of birth 2 36685.21 36739.92
19 Age * region of birth * SHA 3 35385.28 36745.24
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15 SHA * region of birth 2 36393.46 36752.99
7 Age + SHA 2 36672.24 36758.21
2 Age 2 36734.42 36781.32
21 (Age + age2) * SHA 2 36612.97 36784.92
14 Age * SHA 2 36668.49 36793.54
5 SHA 2 36721.18 36799.34
1 None 2 36793.34 36832.42
19 Age * region of birth * SHA 2 36351.57 37039.37
25 (Age + age2) * SHA * region of birth 2 36334.29 37350.35
19 Age * region of birth * SHA 4 35513.49 37545.61
25 (Age + age2) * SHA * region of birth 3 36148.71 38165.2
19 Age * region of birth * SHA 5 35824 38528.29
25 (Age + age2) * SHA * region of birth 4 36178.8 39195.72
25 (Age + age2) * SHA * region of birth 5 36347.5 40364.85
Table AJ2B. Results of latent class mixture models with covariates for the component means(/i)
Note: Models are ordered by BIC.
Model
number
Covariates Number of 
components
AIC BIC
10 Age + Age2 + region of birth 4 35007.68 35343.77
6 Age + region of birth 4 35073.68 35378.5
10 Age + Age2 + region of birth 5 34999.92 35421.98
4 Region of birth 4 35166.19 35439.74
6 Age + region of birth 5 35066.84 35449.81
12 Age + Age2 + region of birth + SHA 4 34957.44 35449.84
10 Age + Age2 + region of birth 3 35205.02 35455.12
9 Age + region of birth + SHA 4 35023.94 35485.07
6 Age + region of birth 3 35266.34 35493
4 Region of birth 5 35160.18 35504.08
12 Age + Age2 + region of birth + SHA 3 35149.41 35516.75
8 SHA + region of birth 4 35112.13 35542
9 Age + region of birth + SHA 3 35212.68 35556.58
13 Age * region of birth 4 35067.81 35560.21
4 Region of birth 3 35360.68 35563.89
12 Age + Age2 + region of birth + SHA 5 34955.41 35572.87
9 Age + region of birth + SHA 5 35026.39 35604.76
3 Age + age2 4 35464.22 35612.72
8 SHA + region of birth 3 35298.57 35619.02
2 Age 4 35507.34 35624.58
13 Age * region of birth 3 35260.85 35628.19
3 Age + age2 5 35442.85 35630.43
2 Age 5 35488.93 35637.43
8 SHA + region of birth 5 35112.11 35651.4
17 Region of birth + age * SHA 4 35036.03 35653.48
16 SHA + age * region of birth 4 35020.13 35668.85
17 Region of birth + age * SHA 3 35217.42 35678.56
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11 Age + Age2 + SHA 4 35375.44 35680.26
1 None 4 35597.64 35683.61
1 None 5 35574.68 35684.1
13 Age * region of birth 5 35069.19 35686.64
16 SHA + age * region of birth 3 35208.15 35692.73
7 Age + SHA 4 35419.83 35693.39
20 (Age + age2) * region of birth 4 35022.19 35733.43
20 (Age + age2) * region of birth 3 35206.86 35738.34
5 SHA 4 35504.9 35747.2
11 Age + Age2 + SHA 5 35366.43 35749.41
7 Age + SHA 5 35419.59 35763.49
22 Region of birth + (Age + age2) * SHA 3 35167.41 35769.23
22 Region of birth + (Age + age2) * SHA 4 34981.79 35786.83
11 Age + Age2 + SHA 3 35567.23 35793.89
5 SHA 5 35495.19 35800.01
23 SHA + (Age + age2) * region of birth 3 35151.32 35800.04
7 Age + SHA 3 35610.53 35813.75
3 Age + age2 3 35704.46 35813.88
17 Region of birth + age * SHA 5 35044.25 35818.02
16 SHA + age * region of birth 5 35016.79 35829.64
2 Age 3 35744.87 35830.84
14 Age * SHA 4 35425.77 35855.64
23 SHA + (Age + age2) * region of birth 4 34994.67 35862.23
5 SHA 3 35700.81 35880.57
1 None 3 35842.59 35905.11
14 Age * SHA 3 35616.81 35937.26
20 (Age + age2) * region of birth 5 35057.94 35948.95
22 Region of birth + (Age + age2) * SHA 5 34945.5 35953.74
14 Age * SHA 5 35435.77 35975.06
21 (Age + age2) * SHA 4 35384.51 36001.96
21 (Age + age2) * SHA 3 35582.24 36043.38
23 SHA + (Age + age2) * region of birth 5 34976.34 36062.75
21 (Age + age2) * SHA 5 35391.26 36165.03
24 Age + age2+ region of birth * SHA 3 35193.54 36264.32
10 Age + Age2 + region of birth 2 36122.3 36286.44
18 Age + region of birth * SHA 3 35246.73 36294.05
12 Age + Age2 + region of birth + SHA 2 36068.49 36310.78
6 Age + region of birth 2 36184.27 36332.77
9 Age + region of birth + SHA 2 36131.88 36358.54
15 SHA * region of birth 3 35335.23 36359.1
4 Region of birth 2 36278.53 36411.4
13 Age * region of birth 2 36184.85 36427.14
8 SHA + region of birth 2 36216.45 36427.48
17 Region of birth + age * SHA 2 36131.99 36436.81
16 SHA + age * region of birth 2 36130.49 36450.94
20 (Age + age2) * region of birth 2 36114.64 36466.35
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22 Region of birth + (Age + age2) * SHA 2 36073.95 36472.56
24 Age + age2+ region of birth * SHA 4 35054.78 36485.08
23 SHA + (Age + age2) * region of birth 2 36058.4 36488.27
18 Age + region of birth * SHA 4 35137.33 36536.36
15 SHA * region of birth 4 35180.57 36548.34
11 Age + Age2 + SHA 2 36516.27 36664.78
7 Age + SHA 2 36562.8 36695.67
3 Age + age2 2 36657.96 36728.3
2 Age 2 36699.45 36754.16
5 SHA 2 36648.14 36765.38
14 Age * SHA 2 36564.36 36775.39
24 Age + age2+ region of birth * SHA 2 36115.46 36826.7
21 (Age + age2) * SHA 2 36523.13 36827.95
1 None 2 36793.34 36832.42
18 Age + region of birth * SHA 2 36149.39 36845
24 Age + age2+ region of birth * SHA 5 35076.59 36866.42
18 Age + region of birth * SHA 5 35133.63 36884.38
15 SHA * region of birth 5 35184.05 36895.72
15 SHA * region of birth 2 36235.57 36915.55
19 Age * region of birth * SHA 3 35392.21 37400.88
19 Age * region of birth * SHA 2 36242.3 37578.81
19 Age * region of birth * SHA 4 35244.07 37924.91
25 (Age + age2) * SHA * region of birth 2 36206.35 38199.4
25 (Age + age^) * SHA * region of birth 3 35468.69 38462.16
19 Age * region of birth * SHA 5 35297.35 38650.35
25 (Age + age2) * SHA * region of birth 4 35382.56 39376.46
25 (Age + age2) * SHA * region of birth 5 35492.19 40486.52
Table A.2C. Results of latent class mixture models with covariates for the component standard 
deviations (a)
Note: Models are ordered by BIC._________________________________ ______________ ________ ____ _ _______
Model
number
Covariates Number of 
components
AIC BIC
20 (Age + age2) * region of birth 5 35573.2 35682.7
3 Age + age2 5 35573.5 35683
19 Age * region of birth * SHA 5 35574.8 35684.2
5 SHA 5 35575 35684.4
17 Region of birth + age * SHA 5 35575.3 35684.7
10 Age + Age2 + region of birth 5 35576.2 35685.6
11 Age + Age2 + SHA 5 35576.2 35685.6
4 Region of birth 5 35576.6 35686
15 SHA * region of birth 5 35576.6 35686
24 Age + age2 + region of birth * SHA 5 35576.6 35686.1
9 Age + region of birth + SHA 4 35600.3 35686.3
8 SHA + region of birth 5 35577.7 35687.1
2 Age 5 35577.8 35687.2
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7 Age + SHA 4 35601.3 35687.3
12 Age + Age2 + region of birth + SHA 5 35577.9 35687.3
1 None 5 35578.2 35687.6
15 SHA * region of birth 4 35601.7 35687.7
19 Age * region of birth * SHA 4 35601.7 35687.7
25 (Age + age2) * SHA * region of birth 4 35601.8 35687.8
10 Age + Age2 + region of birth 4 35602.2 35688.2
5 SHA 4 35602.3 35688.3
14 Age * SHA 5 35579.2 35688.6
17 Region of birth + age * SHA 4 35602.9 35688.9
23 SHA + (Age + age2) * region of birth 5 35579.5 35689
1 None 4 35603.6 35689.5
4 Region of birth 4 35603.6 35689.5
6 Age + region of birth 5 35580.3 35689.7
24 Age + age2 + region of birth * SHA 4 35603.7 35689.7
6 Age + region of birth 4 35603.9 35689.8
8 SHA + region of birth 4 35603.9 35689.9
20 (Age + age2) * region of birth 4 35604 35690
21 (Age + age2) * SHA 5 35580.7 35690.1
7 Age + SHA 5 35580.8 35690.2
18 Age + region of birth * SHA 4 35604.2 35690.2
2 Age 4 35604.3 35690.3
13 Age * region of birth 4 35604.4 35690.4
12 Age + Age2 + region of birth + SHA 4 35605 35690.9
14 Age * SHA 4 35605.1 35691.1
16 SHA + age * region of birth 4 35605.2 35691.2
21 (Age + age2) * SHA 4 35605.2 35691.2
22 Region of birth + (Age + age2) * SHA 4 35605.4 35691.4
11 Age + Age2 + SHA 4 35606.1 35692.1
3 Age + age2 4 35606.5 35692.5
16 SHA + age * region of birth 5 35583.4 35692.8
18 Age + region of birth * SHA 5 35583.3 35692.8
25 (Age + age2) * SHA * region of birth 5 35583.4 35692.9
23 SHA + (Age + age2) * region of birth 4 35607.3 35693.3
13 Age * region of birth 5 35587 35696.4
9 Age + region of birth + SHA 5 35590.2 35699.6
22 Region of birth + (Age + age2) * SHA 5 35602.3 35711.7
2 Age 3 35841.7 35904.2
8 SHA + region of birth 3 35841.7 35904.2
9 Age + region of birth + SHA 3 35841.7 35904.2
10 Age + Age2 + region of birth 3 35841.7 35904.2
11 Age + Age2 + SHA 3 35841.7 35904.2
12 Age + Age2 + region of birth + SHA 3 35841.7 35904.2
15 SHA * region of birth 3 35841.7 35904.2
16 SHA + age * region of birth 3 35841.7 35904.2
17 Region of birth + age * SHA 3 35841.7 35904.2
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18 Age + region of birth * SHA 3 35841.7 35904.2
19 Age * region of birth * SHA 3 35841.7 35904.2
20 (Age + age2) * region of birth 3 35841.7 35904.2
21 (Age + age"2) * SHA 3 35841.7 35904.2
22 Region of birth + (Age + age2) * SHA 3 35841.7 35904.2
23 SHA + (Age + age2) * region of birth 3 35841.7 35904.2
25 (Age + age2) * SHA * region of birth 3 35841.7 35904.2
1 None 3 35841.7 35904.3
3 Age + age2 3 35841.7 35904.3
4 Region of birth 3 35841.8 35904.3
5 SHA 3 35841.7 35904.3
6 Age + region of birth 3 35841.7 35904.3
7 Age + SHA 3 35841.8 35904.3
14 Age * SHA 3 35841.7 35904.3
24 Age + age2 + region of birth * SHA 3 35841.7 35904.3
13 Age * region of birth 3 35841.8 35904.4
1 None 2 36792.8 36831.9
2 Age 2 36792.8 36831.9
3 Age + age2 2 36792.8 36831.9
4 Region of birth 2 36792.8 36831.9
5 SHA 2 36792.8 36831.9
6 Age + region of birth 2 36792.8 36831.9
7 Age + SHA 2 36792.8 36831.9
8 SHA + region of birth 2 36792.8 36831.9
9 Age + region of birth + SHA 2 36792.8 36831.9
10 Age + Age2 + region of birth 2 36792.8 36831.9
11 Age + Age2 + SHA 2 36792.8 36831.9
12 Age + Age2 + region of birth + SHA 2 36792.8 36831.9
13 Age * region of birth 2 36792.8 36831.9
14 Age * SHA 2 36792.8 36831.9
15 SHA * region of birth 2 36792.8 36831.9
16 SHA + age * region of birth 2 36792.8 36831.9
17 Region of birth + age * SHA 2 36792.8 36831.9
18 Age + region of birth * SHA 2 36792.8 36831.9
19 Age * region of birth * SHA 2 36792.8 36831.9
20 (Age + age2) * region of birth 2 36792.8 36831.9
21 (Age + age2) * SHA 2 36792.8 36831.9
22 Region of birth + (Age + age2) * SHA 2 36792.8 36831.9
23 SHA + (Age + age2) * region of birth 2 36792.8 36831.9
24 Age + age2 + region of birth * SHA 2 36792.8 36831.9
25 (Age + age2) * SHA * region of birth 2 36792.8 36831.9
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